var title_f19_18_19744="Partial thickness burn PI";
var content_f19_18_19744=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F65552&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F65552&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Superficial partial-thickness burn",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 367px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Superficial partial-thickness burns can form blisters, and they turn white when you press them. They might feel moist and leak fluid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eric D Morgan and William F Miser, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_18_19744=[""].join("\n");
var outline_f19_18_19744=null;
var title_f19_18_19745="Meconium ascites";
var content_f19_18_19745=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F59852&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F59852&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Meconium ascites",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 316px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this 20 week fetus, fetal ascites is noted in the lower abdomen, adjacent to what appeared to be a markedly echogenic loop of bowel.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen T Chasen, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_18_19745=[""].join("\n");
var outline_f19_18_19745=null;
var title_f19_18_19746="MRI Chiari III malformation";
var content_f19_18_19746=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F74322&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F74322&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    MRI demonstrating a Chiari III malformation with cervico-occipital encephalocele",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 404px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGUAa4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDx8lWXdtHT0otiiXELPGCisCwA6ijGFA6/Wg8HNAE+ovDNeySQxIiOeFA6CqzKnHyr+VKCCT3IpCfmwRQAqouceWoH0oaNcjCr+VKDkgdKUMC/zHHOKACMLGflUc+1MkAbkIvJ9KkJx0oBAjyRwTQBHsQjBUc+1ARepUHHtTwAw4p23CEhgDwMHvQBFtjPAQevSpFRSudqj8KV1Ix0/CpkjYHB6YzQBAYwAPkXB9qlWJpMEIoKjggdBWlp2lzXLKFBJ3dCK7rR/B0hAeVAiYwe9AHnttp0jkho1IYdTWra+G3nkBOFDdscV6HJpOn6epJIOO5qpNfxKhMCgkdKAMa08FQMpWUjJHftW5Y+A9MO0yOmQOelZtzezzLlMgAclagjlvyy7ZJORxQB1p8HaPGADKuB1oPhLRgFYSLXNmHUHAbzX5PIJpyw3e4hpZMigDel8J6SiMY5UAPt3qNvD+nbFXC46EjvWIVvV3EO+B1pY/tpPDt70AbLaDpyQFo0V/qKjTRLRo2/dKAazg1782GbZjBpzz3iK4LkgUAaL6Dp+SCi4IGeKI/D2l78hUBPYCslLy55JLMMVCL+VXBkBQCgDUvPDVgxCpsC55bFY974Tti/yRpzxyO1TJfuxIEhAPOM1HPdXUm3Y+1lJ5J6igCsngfJZ0hRgRjpxWfqHgy4iJPk+4wOBXVafq17DEFZ/MHXFX4vFD9LiMFR7daAPKrjQZ4N2+2I98VkyW4QkNGFI6LjrX0Jba1pF4qJdwogPdhUl14K0HWUeS2CbyMgg0AfORiR2BKDPrih0GR8owe2K9L8SfDe8tGL2Y3LnjbXA6jp93YSlLiNlI9RQBntEOBhcemKTylH8I/KpflxuwfrSBuMGgCLYvTav5U3YAMFFJ7ZWpDkDrmlDAjkYoAjEacHYN3fim+WAeQuPpTwOevU0pPHHXOKAImCA4ZR19KUxKeiqM+1PZducd/Wg/e684oAYqIo+ZAfwoWMOPur9QKlHoOe9IOBjHNADdiYxtU/hQqoDwq/lTlP4YpR0OG5JoAasaMei8e1NMadQoGPanKuGAJ6d6AOSM0AJtQrkqPypu1B0UHPtTuTnb0FDYGAaAGqE67VyeOlKQhbkDP0pRj8qaD/AProAdhfvFBk8UbFbso/CgEhOe1SZBUEjNAExORgD6U1TweDkU/Hyg+o4pgUB2NAAQMEY5x1pFI9DRyS36ULznJ5HagBfdeaeowMnqKQDaD70q59aAFTgHrmkZRjIBPNPAO7mpAh2ZbgngUAQrwR0xUqpv4JBYHAJ/lV6w06W7wkaEnscV6B4c8DyXHlyyR4XqcigDgbDSbi4UERkD3FdpoHhCaXDSoAp5LGvQrPQ7DSF3ync3oaz9W1nyyqWygL0A9KAGW2m2OmIDLtLgcCq13rvSK3GSeODWVdCeYPJIWY545p2g2Re5Dthl/WgCf7DNdD98TgnpU0OjNCu7bkZroSFjXAXAxUSXORxgfWgDLfT4Y0AwMmnw2w8wYXGBx7U28dt/uTxirCzLs64boTQAjhI2OVBz2pp8t2yRioLksybVIqGIshUH05oAtTBFyMADPWjZEEyAMkdaoXrysxGfkAyR0psUzgRqQxDDgmgCwAfNYKPlx1p6KGjIdevrU8SBlG786WRVCkDr2FAFVbWIgBQM4qveaWrx7tvNW7WGTcWDYUdB6VfiZWQgnLUAcZ/Z0nnNtBIXrjtUsNnI7bfm46HFdJFa7p2QMAD3q0bEqucjIHagDmo7SSMq3PTHFRSW6tA/lAsScEY6GttxuygzmqCWskcwVGJXOST3oAyzZTSR/OG4P6VLY6hf6bgwsyp0HNdfHBHLb/ADda56/tfKMgj5B7GgDoNF8bquI9QAORxmte90XR/E1o7gRF2HUdRXl00KBiGDAgZXPerOn6pd2EmYHO30oAo+Kvh1daexktY90Sg4I5Fef3dpJbvskQhs85FfROg+LYLxFt79QXPHsab4l8D6frSPLaqiuRnigD5wIA5HU03Hb0rrfEng690W4OY2aIfxCuVkU+2e49KAI+E4I98mlHz46eoNKQSOxFJtzj2oAbyzAHJGTS9unPoaUAr/FQ+duerUANDdu5o3HAIJx3peh6UAcGgBQGZBzxSZOeQMe1AyWJY4B/SnBemDQAzcT2penXqaQ8SAdzQ6/OQ4PFACkcEYxnvSHb60ZBB60nPegBoPPBoAyppSCwyOlMzhgDwKAHo2D04qToBiokBP4U8FiaALRBCgdOKQDPGfrQMdCcgjinHg/LxQAwE5JIBApwzu3cdMUBAD6ZqQrjAGDQBGAf4qkGAcYzml6gqVOSRg1Zs7WSeUIicnj1oAZDFvb5Vz+tdV4c8J3OqXMSeWx3DkY4FdR4E8BXFzIsk8ZEfuK9YQ6b4btdo2eYPzoAwvDXgu00WISXYXcOoIqxrPiC3tQ0NlGowMgisDWvE8+pzMkWQingDvWXbRSTzgvyKAC7ury8myvzgnOCelWbLS1XMlxy3pW5awW1tBuKqXPXio5F8x+Bj09KAMq4t1eZY4+AetOtLNrWXKHAHUVoYWGUHA3juaZJJ8rHnntQBVupXdiAcY6VFFvUEsQfSp441kBbo3pUMsht5MsOPpQBHLGZAeMnr1qmjESLnmM+3etIT+Zkjgj2qOUB4iETBHPFAEUkRCFox8xNVAGiDM3zZPStOzctgOASO1WXtVkjZxxg0AZcqiSPAUc9c0kcaNJGAdoHGKsTFgS6gYHGKriUs/KEc8GgC46FW2g4BpsgMbgHPIq0qkxKQDuHNLMhcA4w3vQAsSI8J2Zz3qJ4Nqkqee2KlgARcFs96YzEuSM7qAKy5WUNjpV1XMzhckHFVGJbLkY5xT43OC4bG3pQBYmswoLGskENKwyQRWyJzIf3npyKp3CxM3ygBuxFAE1u52gk9Kp6iVEw2nGRjJFIA0eMMSD1qJw7sSOf1FAFK904XCGRDhxwKw7u0e3b5wQO3vXSWkhEzJklh+VLqkJuFAVB69O1AHLRDy/3iv8AMCMc9K67w94rmsZEjmbKEY5rmry2MXVCGPb1FROEYgDjHQ5oA9rH9m6/ZbJAjl1546V5R48+GTQB7nTl3DrtWmWOpXOnzAxsx74HevT/AAv4jg1K3EM4G8jBzQB8sXFs9tI0UilXU4IqGvob4i/D6HUbaS801F80AkqBXgepWMlndNBOpWRDyDQBTADHtilIXIGTTsY6dKODlsZxQA04ycjFJjuKcQSx96TaBj1FACY3L83JpgOGzn8KkGW+7196COeBz6UAI2GAoY85z9aAh6nJFKMYzwKAGhMZIPPWmvycdKfjLZFNcHPUUARndtIPAphBVVyc+hxUrbeh6/yqJuckHpzQA9WYgg9Cc05TxkDJ9aYp5+fFOBY9DgdiKALhACDb1xS5Jxnt6U4EdD6Ckx2FACow355OO1O/i28/SkwflC4HY1csrWSe4EaDn1oAdp9jJezqsakkHHA6V7b8PvAKRol3fqQByA3epfhl4IS0hF5fx/NwRmt/xl4qisIjaWZXzcYOO1AFvxB4js9KtWhs9vmgYAFedz3c+oXDSXDMv171WffOxnnbczdiKnSCS7iATcpBoAmtYgXAReBxn1rYtkMOF20thZiGEA5LetXWCmMEH5+1AFcIzMc5PfFSxyOmQy/SnyFyV7MOvvTWfafm/KgCtdRSysXA4NRMTHsVslsdK0t4MYAwOOlUpoizg4+VelAFeZnQgAfKeuKdMilQx6VZiXAYHn0okjzETjOKAIBB5kPycGmRRlVIOM9M01Z/nAyR2OKvxeWVOT8uKAMplVJQW/StCN0mjUKxBHWqF1l5GRPug96db5hX5upoAknjXDBjgZqrAytIq8AdqtxkyZ3rxVS6URuoHHNAGsFMagjnNUrp/wB8N3QDHFWLaQNEQ5JNMuY1f/V5B680ARJNG65jYkAd6hM5MnpUBVg5BbAx0FPjjIXqTg9aALRAlUenWmpEAWZT9Rip7VRGgB6mk3bS+cc9MUAQlv3fI6is1piswB6d6nu5mXC7OaoKSzEMCPQ0ATl5J/MAJGOmKcrNENrEj+tLaxuIiwGST1z0ouF2R7id2fzoAW0wpLD8KseZz8/HasRHLSZdTgHAya1FVnwaAJbuzW5tWAwT2Nczd2RtzzyexFdVC7dwAtJfW8bwjKDB596AOOLNsIPXjr1q5ZXDWrK8EjBhycHgfWrdxpRk3NGwFZc1vLbEiTO08GgD07wR4m+2yfZbsYfkAnvWN8V/BUV3ZNqNkgDjlgB1rj7WaW0uUeF8N2xXr/hTVU1zTXt7ggy7djLQB8oyxGOUr0KnpiowCDkfw84rvvij4a/sbWWePiBySOK4PAJ4PJoAa30x9O9ITzyABTiO4HNG31oAQ4VuKZyDknkU8cHg8HjpS7cg/wB4d+1ADWOMk5xSBMDIOQaeoI5JGSKADjAoAZyM/pSE884p/wB8deRSFQCcDn1oAjJyCc1Gw2jB5JOTUjZHOV560xyTk0ARlQfl5z2NScYwxOBSLzgknAp5J5yMigDQQhlQ4HI54pR128Y9aM7kG4ZOMZ9Keibj8oJ5x9aAHRRNI4EYy2a9h+FPgozzLf3kf7sc8jrXO/DXwlNq9+srRsIFILNivdtWvLbw/owWIKhC7QB60AZfjLXo9MtfstnhJSOPavMos3d75k4DMW5Oamv72XULtpLhGc54qaC0c3CGIYB7YoAka1KzjA4PGa6HTbYQx5UDJ7+lRizYBWyM+hq+i7IxgEH0FADZxhDxn6VFGEBIKk46Z7VYCLGVMgJyajmUFyVbA9KACVsEHPA6VEihyd5w2aeYHaIMD+dRyliqqOSOuOtADVi3uOSccUkisikHJHpU3mYQBQcio9xcEEYNAEIcNkKDwMUNJsQqwNNMZhl7+vHenznC5I5POaAM1htmyV4NXYUwwCZ5/KqZlQuQOWzWpany4gSBQBGIVYnI5pXtjxuX5QelPNxty5UZFRy3bSRgrwOxoAZLGFkyM4x0NZ90okccnf2A9astNvkw2TxnNJGqm4Uk4PYUAS2ykJyDnvTZgVdj2xV4fLxkVTvHY4HcUAUGbLEFRz3qe3dACuc1UZS56nJ605jEg8tX/eAcigCxNMjAhWw4HSoYZCcg5JzxVQoZLjcvCjr71o2YxkgBv6UAQyqXf5vvd81FIiqScDnsa2AFbcXXJqlKsXnZI60AEGwwHjAzWdqORGVTII6VoOfLAxggHkVCyB3LgA57UAZun5njbeowvWtO2z0BBB6VaggSOFtqgE8kVCxKYOAD2FAA3C7DjIPWlYmSNdvaopCSpZhzTbGQoSXI+lACSN5bcHn0qteWa3iNk8EVfaNZJC6heepNDKE24IxQByYtpbSYu5wB0zXVeBrsWusKdw/edT71Dfwrc8D7w55FZ1u/2W4MjDDDkHpigDuvipoqav4ekkVP3qcggdq+aLiDyGbccOG2ha+utNk/tDw8Aed8eG79q+YPGWnvYazcK6hcynFAHOkeo59qQA78dql2kMP1xTSjDuCaAGdDwCAOvNNAwOCfpmpQozls9KFAHO2gBo4UfyoI7fjSkEnPXHQUjDcMgYY9aAEzxnHJ9KQ5xgAACncAnA4PemdWzQA1wOlRuQo64p7EgnIzSEgL0596AGqR60/cfQ0zaG5OBSvyByKANRcoPqOAK6bwdoFxq2oRQwozZPLY4FYlrbPcSJFGOWA6V9KfCzw0uk6THcTDMsi56UAbmi6bB4c0ZU4BRfmPrXmHizV2vr2WN2fygcpnpXonj67eHTGSNcbhzXkN0/nFOc+gPWgDd0a3VoPOdeWHUVfSAxKd3DdjT9Gi8uwjyD06VbkQykMtAEcZcxgnLFetXo5WMYIzg+tKihVVTj3NErRKhXcTgZUAdTQBG0yf8tBgdBVZcu5Xac1JIFP8PX1qwpKoOm79aAK0pk8vYTioIzIo/dkNzzmrpIJJYZz1JqE7cnkqKAI5ph8oIyw7VUkkkwWwc571bMYIL8bulNuIwFHPJoAhRpDlmPy+lEpMgHJFP+VFUqc+1OGxxl8oe3FAFdbYKXJA5qSJWDFQuVI65pWkHlkY6DtUcDSOMHge1ADrlWLBMZXHJFVXRvMKjIQdKvOBGeMnIoG3/loMZHFAFRYm8rOeRUmxYtvzq7ON2V52+1SMRuIBGVFVCjg5bBGc8UAWw+5uDzSSRghix7dqqvJs27etLHKzFmzgDqKAKwXy5gRkqT0qK+RjqMEka8HgrirgZSwbsDk06WdGIKjazHAzQBD5YEe5QCehFCSGLhQAParVvDlw+RjuPWmXAVpBtXvQBPG5wDjiovsiyTcDcx9KfASvUcZ6VatzsJZeG9aAMiWAiTa4wM45q1BAsbZXvUt0xduQob3pI2wvAyVoAe8eweYzDHTFZ93LuU7R0/OrV1IJFGfl5/Wq0yiOHpuY0AUWnL7Y2B5ogJBAI5HGfWgyAHOAG7Co35cFDgdetAGmIgYxzyaU25Qde3fvVGC5ZJFBwwHXnkVpvJvjG3kjrQBRQHzCxOT0IqDWbbdb7ogCavqoCg8BieKZcICvJOT0HpQBv/DDU2nhktHzlBgA1xvxt0NfPN7EhA6HineGNROleIwSzKkjY5r0Xx9YJq3hibYRuC7hxQB8pHh/QfWmjAPQ9etWr6BoLmRJFxtOKqgdTQAjnJPcj0pQCep69qaCSS3QelODcDHNACMSQCKTJBJ7CpCCeeMAUzaCn/16AEAxz29KbtwDxwe/pTh7mkyVBGcrQBGRtzzxiouQfbvUkjfPkY5qPI65+UnmgByspGSOe1OVD2496Z8pJ2Z4PelAO3BJFAHonwx046n4ht1dT5fBxX1VBCsFvHEnCKMAV4Z8ErRVvlkZSCFr3g89BxQBwfxIl2WigV5hpVs9/fqSCI1OOldt8VbktOkAGG7HNVvC9mEs2kcLvxQBrrbpFZLHH071BBIYjgr+QqUuSvzrwPemiRQQVoAtLLG6HIyfpVR2TO7nJ4INSxzIJAGK81JLbtNJvAAA6e9AEVtCXYMT93nmpJSGIJXn1qRo2jwDgcfnUbPtDEY5PagCrcOVjBVe/Smq28At1PSp3zKBuHAqtLIVkCMuR2oAq3TbR124/WmrcGRQCuSOKdeld+9hkY6VPaNEkLOy/mOaAIZkVIssCCOeaqmZpVOxuR61Yml+0EgcrTAigcDB+lAEsceSjA8EYNSsqxBihzjnFZ0l4YzgHgVHdTkxFw3XgigCxczloWZThl96zpL/AMuLdPIpb+VYt/qrDcPuqPTvWPLfNJ82TjPagDo/7TZmLAEA9Kcur7CoY4BPSucF9JuAyBx1FMlvRLg/KD6+tAHXf2kjMQSC3pUhvE8pguA7DjnFcet64YOp+YcZFO/tCQqPNYD3PagDqo3DHJOSRU0bK6rkYxWBbX5RVAAJA+8a04WS6UbWPrgHvQBuW7Bh8pwveglUdh94Gs2NpIpQEOBV5WaRhuODjtQA7GJAV4U1ahBW4zx/jVeCJi+c49jU1wyouVGSKAG3q+ZICnQcH61VBaN3AYdM1CJmZ3L8g9MGprdWkJJFADQd5J/i6ilRPMQ+Y3Xv6VP5PzY24FRzDYjZJAWgDKuVG8oDwO5qEIqjO5ivtVuIfaCxA6nAzUj2LcB14HTFAFfYFYOvzD1rTtWBiJAAPeqOCiHcN2OgAqaEkgFvl9hQBJcKCqv/AMtB2qGcNsDE/nSzuUlADAj3pt/MEtWY9NtAHL3sjR3kcobBDZHevavDF2NT0FFkKu23BArxC5UyKZCQCea7b4Z60sF59kdsRv8AdHvQB5v8UdLk03XJQUIRmJFcQu48nr2r6Q+MXh5NS0oXcEeZY85x3r5zlRomdZFIYZ4oAhYnHHWlA7j8aCSMA45GaRSeeQD7UAOPPANNwO1J+VIAN3LED2oAcQOg600jA980LkAucAimknJPY0ARj5l5ApVG0dAPrSjKgknHtTdpDdSc0AIvTr34qTkoChGe9MIzkcZNOVQBgjpQB9HfA63xvYpztA5r2cZAJH5V5p8FrRE0ky878bcZr00qQvtQB4r8UHD6/EmM475ra01FWziOOq8+lcp8SZceLJFBK8DNdPpLs1lCM8baANFogYgCAWPYVRmjCRHaDx6etWWcghUPI70rkLGSPSgDITcfvpnnr6Vt2bFoj7dKqwQhpCz8L1AqzuWMBY270ADOpfDYzn1qCWMFiADVe6I84FATjrSS3YQqQCSeMUAWzIIkI28HjJrNnYmU4OfSnXE/mcrkAGoN2HBoAR1Jb5hk+lLLJgqiqfy61KAu4MT17GpbzZGgdQN2OlAFW3iCEkjn0olyQcjg9KsWh84FnGM9qbcQNgEfcFAGAV/eEMuMmszxJPJDCscXIbr7V0r2zEMVQ+tYerWRubf5sjbzigDkrgEuAxIBXBquqGIkxnGeADWjLAQ37xRjOMA0j2bFlKg4I4B4oAoBSQeme7VUliDzqNrbexHStRrZouMA81O1nuRCMdOlAGIq4YqpLDOcjtUrlB9/cSSB0rWTTZN+AD69O1V7m0kW5+UALjvQAkYOVDHAA61dtblldVU7V7kVVa2YyBSSMgEVYigJDYBBPT0oA6O0l3InJz6mrgYlxjJIrD0wNFKEdyQR3rp7dEyhBHXnHJxQBLDJkqpHOOtMuSQjDH41PI8cU8nlZaIH5WYYJFU5A8zlsHHpQBTjDBiQNymtK2O1D/SqU5nht3WAoJSRt3DIFWo3bZuKjcw5A6fhQBPKfMTKg59az55wXCMwB9KvQMRx+lVJ4FlkdvXpQA61h8yUGLJAHarMwXKgZ3dKZZo8SEDIB4yKeyGKNifmPqaAKrou9QAQO5qFm5OOQKRpXDn9Kkgx5gOeT1oArIheQmYYB6VX1MZtmQZOOK22CE44+tU7y3QRNjPPSgDjS7eW0ZPPYUlnO1ndRSpklTnHoas6tatBCspXp3rLjkDjdknHXFAHvvh2/g13R9smCcbWBrxL4qeDZNJ1F7mBf9Hf5q3vBuuyaVKNpBjbhhmvU9V0y38TaEdwDMyEigD5ClUBiAe/FIMjAwM9/at7xdo0ujatJBLGVUNwawj1wPTrQBG4w2PxpAMggnae1OBGBtzzxz2oHA5wfrQA1ssm0k/Wkxg4J6UowzentQwG7JABPTFAEcm05J6n0pikgDP6VKQR6VFj5iM5zzQA4MQeCuf1p6gtnOKjB9QAfWn4DLjNAH1r8HkI8Pq2AN3Ir0En5SM4ri/hNGP+EcjJODXbMOKAPBPGwWXxy0co4DAZPeu1eJLaOEIAFZRjFcd8QSIvGgcnGcc4rst/n2kB9FAoAIV3E5HNVrrCqRng/pUxk8nAY1SuG3nuAfWgB8T/ACbiQFAxj1qJZyeBwOvNNkjMYzgH19qgj3TTBeOKAJEkY7y+TzSMwCBmBx6VNJGwICc/SoZtxwjjGOetACRSgIyNx6U07N4PUHtUXyPMcN8w7etTRRvuBdTjPAFAEbs28beg6ZqefDoFf72KkkCggbOneopgQclfl9aAIw3lqAT9Kf5wK4Y5welRvGZYvkGCPWqh3pkMGI9qANOGZCc/j9KrXdusjM4IwTyKLaXzUYBQD0qzEoC5745oAxLnTIJW3ovz1WTSmEmXbI9MdK6GyCGfEhA9Kt3VujAsg/IUAcbeWMZZYx1HPFVo4xK7RFQHHAOa29QjMIEioc4PNN0vTBdIZi33upoAradpj+aJDKdp4q3PYRN0VWI9qvvCIFCpyB6UsceFYnkGgDDuNPR5Y2UhRjkVmz2jW0x4JXHArqxAHYnI+lQzQ/8APTt2oA53TpEaQxTLiQ9DW5ADDGDyT71j6jFFbTefGCWzge1a9ldLc2iNnAHFADxOwbDDI9PSpEk+YkZBpqx+YxZQTUh2pgcZ9qAIZQZDkDgU+3cbSpQ560/Yd5zxnpVkQmNI5M5B4PtQBCm5ZeAOnpT44ijc9KlC4cM1ML7iTnHtQBJ8rcNgkHtVXU5fKXacCpDOsSFgMmqbO87fNjb70AUUcM5LD8xU8UqxtuwMdKUoS2ewqKZSpyvOT6UAW2dZCpHGRxxUaBpA/wA3TpT7VWlTOMelS+WIZVOSBQBz+tRubKTngDjNchAVgDEncR6V6Fr6hrGTbjbg4rgrfAz8vByOKAJbaQfK20r3Br1/4Yaq0ySW8jE7eme9eQW0DuV+8WzjHWvYvhtoM9rELmcbc9BQBifGzw9Hc6ab9VG5OuBXztJuV+ByO1fWPxUmji8MXKyOAxHFfKVzgSyNnK56igCLlid2M+1NYAMAecilADtlevcih14ycUAKvHGOlI5B5p46gY5I61Dxu5JyaAGkgk4/OmMx4wMMefoPSnuAcgAjilgfybiORkEqAdCOKAGDJA6Z7mpMg47YpqgbicYyc8UoCg4IBoA+xfhUu3w9H64rs3Uk+3vXJfC8A+HIiBgkc117nA96APF/ivbLFfxyhQWzzWp4elNzoyunVR0NP+IcIuJZCUztGaxvh/ebYZbaQcsTgelAGyzhGzJ1qux3MT146DrVjUtnmMM8ryaq25UZJPJoAlK4hA24Le/SoI0xKNh2+pqRctIApyM96kkjb+ADA60APDCI4z77qZKyvJllwT3NPgi3MG/MVa8obOMZoAqmyjIDKM46YqeDCsEIOAPTpUkR2MQRx7daiuZli4C9e/egBHVd+RgHr70ojWRwTgfWqTzAYZlJ7daeLpTgAECgAuYkU/IuSepqnJFI0W4YDDpV9ZQ5HYD9aHcSJsQAEGgDGQmEhn6nqRWhGwaLcrfMR0pbiBcKvU1Vi3RzgA49qAJ1VBMjMOAOc+tX4YpHU7T8hGTUUUQJHmAY9K1oIxGoI6HtQBROl+eoTPyjnmozALaIxKoAPf1rZabcTFHgEc8VTv8AI560AYMisDgAdaYM4I5zV8Ak7iFqOVgCcr8xPagCkylHGOaUqHznIY0ksjI37td+T0pZGOwE8HNAGTcwZcjPApNObZvjIGCeB6VbePd/rCdtVd0cM4IOQTz70AbMYXyxnIYDAxUKxliSATzTklBXdg4PQUjTgfKow2fzoAcwIAY84NWFiLxgg8d/eoPM3plhznpViKVBCyEYoAY0yKwjXkiqxiG/JOM96ZLIqShRk5705ASxL/d7UARvASCobgdMVIAiR4z81PkcRj5eS1UZJSrZXk+hoAmV0RTubJPNNADo2WBHb2qtn92QefamQu+eV5FAE0Ksrq+4hRkUt1IcbuvtSTXIVeF/CoFlMr7X70AN1CJm0uZi2BsJ5rjtCsJrxkigXe7MeQOK7fxA4TThbrkmRcDArqfhn4Yi0jSUurvBdxnntQBJ4W8CQ2gjnujulAziuuv7y30u1zI4RVrnPFHjS10pTHDiWXGABXlGu+Kb7U/MMzlI8HC9c0ATfFLxYuos9vAcqDge9eQuzFx75ya39SV5x5u1gG7HtWYNOmIZljb5RyTQBQ28E8Gmg89iB1FXHtiduAVX1qu0bKDkdPagBmWOCcgUyQc59KeFzywyBTGyRgnr+NAETHc2aaR+WOlSBCAeeDxxTDn7q547mgB+wYJxS7enHakKkHg9P1qRTlVzgDFAH2Z8NVC+HIQPTmurkGBzXJ/Dh1/4R6A4OMYFda2CuaAOK8V6a87M0aZyOa81sf8AiTeJDG24Ke9e9vGrrhhkd68q+KOmpaTQ3UKgMaALd4kcqhkyfMHJqqbVVjB9KlsZVl063bGCByalfCA4yfrQBVig3SAhicdAO1aUMYKkN1PWqcD7X+YDOOKnE6qcLwSOaAHGJSD5fDDrT0jGwAnB9KjiAk3HODmmXMigY70AE8yQuxI+Y8VmTzNIevWnTlpcljn6VXBeM8AYoAliRmByw/GniIrGDjPNEWJGbIKn1p6kqrKW+XNAEbrIrfK1RySkHC8N1zUpLH7pOKhkQtJkDn1oAfFc53FuWFLcnfGNo+YdcU23UKTvzVkgHO08UAGnsWGGyK3rYZxu6AViQswA4GK3rRl8gluMj8qAGzxbFaU9TxVViGOT3q7curIASSMZ4qrtWVBsPFAGTM+GYqvBOKqO5JKjr61rPbnzSGAwO9Z90Nr7vLxz1oAqIGVt2KcQXlyeRUzkBcZ61Xcyq67BhT1oAWXbsI9+TWLeBWvowgwAccVdunILKHBkHRKjjQF9xX6/WgC+DhFUjOBRJCmQx4NOhXK5bJpswcpgYwOlABJzjaMCmSOY1bbgn3pUkwCrDDHpUFyMZyeRQAtud84kkxwMbake4C7ug7Yqm05SPIPsalUb4wx57+9AGfc3MhwCpwTjIqGNJNx+Yvz37VqpCVbAXg89KbJG0bZ25ye1AEMZUREEfN25q1CFKcqCe+aT7I7FSg+tSbRFJtAyaAKF5AwTcvU9vSpdOibzPn5NaHlB2Bbg4xj1qWxsnM+FGQfyoAsaVpJ1PUEaZSsUDbgcdaseNPEgitzY6eVVjwSP4aNW1aLS7BooXCyuNpOa87unAO5n3Fmz1zQAmoBZHRpmLSMDn2NZs0QKgcelSTytLIUwSR1PpUUkbfdcEHtQAkNp5j7AMj0q29mgJ+UKMY5qKGF9wO7aAM8dafcSDKqmDjr70AV5dPhmRYtmCD1rKvtBDuFRiNpzjHWujUOsQlBB/GossXXJ6nJBGaAOMvNDlVmOGIxxWLdWksA+ZSBjkEV6a8RKAsuV56jpWPqOmi5Y4B5HynsKAPPB8qfLluM038z71oX1pNFcTxSxBQvQg9azzkKCBQA5Rls9cVKDhdp249RUI3HBzx6VIuFPoKAPrv4d6gsWiRRYwAoGBXbJcr5G9s4ryn4ezqunQszHkZxXoMcontsZO3PagDXguYZMgMNx7VyPxO0yW60R5LfBePkA96khVhdhomfINdLPbG901oZeCwxkigDzvwXbG7siso5XA57Vrz6Y6syjpjir9tokumM5g5GMnHetISLJFmRNr45oA5STTZFQlgc1WntyDjB4HGK27+5zOVXkAc1XgAMuWHHvQBnQ27Ki7shiM0z7FK8vzcg11MMUU4GVwVp0dtuckIwwccj9aAOXOkuN2wkE9BVaW38jcmOepzXfRxKsmNgHvT7jSoJo2O0Z+lAHm8QCvz9004MgbyyuGPOa0tfsRaFmXIA5xWNaX8MpwwHmDgA0AXlRE3DrkcVWWWMyAEYx1qUzo23KjinIIGcuNuO4NAFY4inbJBB7VI025WAAA9qfLLCWBGAPWs67mMMbYySehAoAt208SR4kPU/iKu2M5uCyhiExwK5y1R5bcyP3OAB1xXQ6TavDayyk8npk0AXWJi+VWzkVatUAhIOPesy1jeVt5bIPbFasEZGUAIz2oArTIwBAHA6VnXMTSD5q3pU4wVrHuX8mXkZzxQBQZdrbWzTMSYb5cDtmpJx5b7mBwf0prybYHyWIP6UAc/cMDeHBBlHUirMyyK8YOMEckVmW7A6o0nO1u/pWw6EXKbu9AF1F/cYUlqcgO4AAYxjmliJQE9qbC+ZcZ+XOaAFuFB+7gMO5rA1i78gEED6iuiu2QumRkdDzg1xepgNeuDnyxzknvQBYsbgzZ38p2NbkJVtqrmsbRoyhLuAyHnNadtIftBAxtzwKANNIjGzdyR36Uk0akjJGcU5Z8DGM5FUZLlTJgnGOlAE8JO4gVGUcS/NjinW7JyxYk5p7xm4ybdt2Oue1AFZZna6AxlOla638NjBtXPnEZFZW9rd9uAWFVpC91JukAG3oaAKl9G088k8h3bucHpWPLADKfL6k85rW1CYRphPmx1FYU0rEueRn7vNAEkcSg5cjcDwuev1qG8Zvu/Jg9MckVSlu3+4owD1bPJNRxzNHLiQ5B9TQBK28Aseh9O1V8ukgyCTV9J0k4IAUnk+lWvsUM0YJcLk4B7/SgDPWcBCCwA7ZFWbYtIw2sMnoabfaRNb4EZLr1yB0rMjleFyGOADkY60AdBPOBbmBsFuhOKphmUAHlc4UEVFbzGck7iTjv6VYeUHaqMcL0oAydYsVu4XITDAdRXBX8DQSujZ+U16YC6zMHGVIrmfE9hvUSpgMB8wFAHIryMsMH0pVYgkpzTRHhu+fU09cKuW9aAPc/AGpJJBHCGAPpXqNvdNFCEZcehFfMei6jLYzxtE4QLgAivcvC/iqG7tY47nlwANx70AehaTGrNuIGetbnmIvGecVx1rrUUfJztz2qSTWoppSIJMMO1AHVvIoHzEVzOu38cBOzAqPUL+T7LgP0HWuD1bU2UkSsWHP4UAaNzqQRmOck+9EOrMcHPArlklZ2G1gec4NL5zqx2djnHpQB6DpWtJ52XHHpXZWVzFcoMCvIdLvF3nziu/sfWu+8O3ULphXwSe9AHWCOMkjA4604gdAABVWPnBHPtVknAyOmKAMHxNaRz2sgIG4rivFLuzvLLVC43YBJ69q9g1zeblArH5j69K5nXNMkJztyp7kUAcoNSVIx5j8noayptWmE5CHCbvXg1tz6DIxG4YUdKxdUshbKFVQeefegDcsb+KWMK4wTV2OaF28rIIzk+tcrCsq4G3auOoPWoLG6nW+24P3up9KAPVdH0pLhAqqNh71uyaMFg2AYOOaz/BNyjWa+YQGHbNdJd6jDApbcCfSgDkjE1tKUxgVOJpFnRQMqe4p2s3ltqFoxhbbKB24rJ8NNL5TLcE78nGaANy4kVAqvk7zxgVl3UCSHd3B61rclTuAwKoyg8hcEUAYlxls7STjrmmXqKLRjjGRyKnvMRygZ60jjzIiDgDFAHJ6dCovnfJxjjNb9my3BKgjg1kXUX2aVyinYetVUu2jmBiOM9qAOvSxRX3b+tQXEaw8oN3vWBc608EKq7YZveqS67K0RU7iVPHuKANa/vcIw24YdKxLmFpgcjqc59KcLiS5kZscY9Ku2rgIBKuOeT7UAV9OidYdqFtp9avWysjljye3FaFkkZJSPHPb0qwttumATG0UAVFDkHK+496oGFmkZyenauuFqnlYIGcda57VysCbUO6VjjAoA4/4TXl5qekvDe3D3F1b3c1u7yHcTtcn+RFezQW1vZWOVVfMYYNeSfC6a30TVvHFnKB9oh1EXMYz0EqBv6Vq6j4lmeUOGI4Jx60AXdXg2SPMXCn3rn7m8WB8NI2DzxVK+1yS6Qh3JHt2rBuLh5zncxQdKALd1qLNNJ5ZYAno1UXlmdh8x69R2qNSq8t95qRtwyyqcY7UAK7tn5SRjrkZowzKMMckHGRUTOyyrvztPPApJZm3PhyOOOeooAYjyRKFySxPXoKuQ3k0ZQqdoHGTVBJN7jcQ393jpU8rhMtuJTrzQB1Gk62GbyrnhenNM1zTUmR5rYlk/wBntXLxh1+cYO49u1bulavJFEY5FJVutAGXbyNGQnIHTd61ZRirDJyO3tWhcWaXEatEBuJzgdh61lStJG/lMucHqKANCJstjcSasTWcdzAVfG8qeazIZMuDu5B6dq3LeM3P7yNhwc9etAHlmrWzWt2UI4J4NUASCTx+Ndt44sDGVlMYVyeSDXGKAetAHQ6db+fMiYHUZIr17wZ4feUKccDoa4rwTpT3NyiqMkcNgda+i/Cmki1tI96jO30oA5m40ia1jPB21T0+3UXLSMePSvRby0DKynGD6iuM1iykhkP2ccZ7UAQ6stw0GbfGPeuG1RJTkv1x613LMwt8sTkDpmuX1i1kkcMFyD2oA5UXMsXzcfj2p8d08pO447/L3rRnsRHDudVYEdCKSC0i2fu+GHpQAtiskiKygnPT2r0nwjYFkjc53Y5ritKU286s2CnXBrv9N1KOGNWQhT6DvQB2cEapGBjmn7QR83euWk8SJGpLkZHSsy68e28Xy4AYe9AHV39hHKM9+xrIu5I7ddkuG7ZJrHsvFsmottjjP4VPLot3qchYytGp74oApXri5k8qFSSTxiuP1bTp4borcRkpnIPpXrNvpdvYqGYcgda4nx1qlsxZYnAZepFAHHvPBbsQeR29jWFqUpSVZLcYbOSRTryY3EiGM5PUnFUWmKy7Suc9RQBs2Hia7tFIiOSB61fl8VyS2ypcOVZjwDWNaRQyqAoG4HPFaMMMRIIRSw6e1AGvZX8qp8zk8ck962tHuWWQMzYU9KxdPhVw+Tn29KtafJsuNjHoaAOzWXdED+BqrcSYUjbtNMtZgVVf4OtLqCJjMYPPqaAMw5aQhj7UyZ9qqmD1/OrnlBAGC1FMu8qxIJHegDDv5WRthIUseAe4rBuImW63hs/QVu3Nmof5mLHOcsckZ/pWZeQMgYIcjPWgDn9XYGVTkgdSTTrR02pI3Iz0rO1ppFuSiuduccmotJact+9AAB4HrQB2tkFYK6ABR1BrWhCSKPkBrI0ydZLYiX5GB7dxWpaHy9xzlPWgCSDbFKdn3j1rYs9igc/MfWsZWDZcHC560k995akrz70AdBdXa+S2eCvBxXE6hqItr24uWRpEhjMm1OWbAzgD1puq6pIsPqW96raIvn/vJWwOmWoA8juPifZxeMtZ1izsriSC/jhXZIVQ74125OCRjFdvc37zLvIUHHPtXj/ivQl034gvYQofs810rQrj+Bm6fgcj8K9ant5kwfL2g8lcUAVHmHTJB7U4SgD5WBJ6ioJhFzwy4/iPb6VF5uFBAw3Tk9aALTPtAP3mPbHSm7nADEH5RjFQ/aAm5VJJxyPQ0i3QMZx99hz9KAJ/tCuAdxCjih3Gx8oDleTjtVBX2kgkbc8VO05UeXw2Oee3tQAKqjavY9OeRRNjd5aksCOp7U3Jl3scqwPAqusjo8YUk565oAurK7bQuFA4zU0ZZnQOGPuKhTkH5RknnNTwBgTgfKOc0AaVtPJCwZeVHqatSrHcpuQbWAOcVWiVXTJ5HUinQ5V2ZThB1UUAUpIzExAOQeMe9aGl3LRs/lnnpRcSxSIyrGA/XNQwFY9hB456UAS+I4WurBmZckDnPWvNpMIe47cCvUgwurORUUuCuOTyDXmmpwvbXjxygg56YoA94+EFgJ7hWC8CveIk8uMKBjAxXlHwUs2FtJLyAOK9bwQvrQBUvP8AUv2NcxfI/llyyk11c670IPQiud1G2Ko4HTrmgDlYUPmOJmBXPSrVy1mIowGUk9faud1W7nincJwAcGudkuZ2lBDkKScigDvrqxs7iEKAoGOtctf6W1vLugOVJ6DvTLS6mMAG47e9Sw3EynIO4A96AJLEKmTcjbjpV64iVFMlvJgDnk1i3t9vJBU7gewqrHPINwy3J6GgDZmkaSP94cn2rKutKFwMoCWHeqz3txBL8inGMZPSmxeI5o2wV5HHSgDtPh5brDO8c+OOg716cXWGEEDC14zouuRR3yyyOFya79PE1mYM+aCMcUAbeo3kIs5PNZRkHrXhPiKIvqEzh3KZ49Otdnq+snV5fKs2GQcDmuS1ayvoCwliOG460Ac7N5scp2BQR/nNVZYXR/Mds98etX7qF4FzMcY4qEXaquCA2R0oAmsoCTv3bGHOBW5paFmPnLhs8EdKq6bNAwXzVCt6E9q2TfWsVthAB6NQAk14LR+NqgetZ02oyi9BjQfNznsaztRuxcEuJOrYwaZpEm+52yNjsBmgDv8ATr0SRgAjNbEJ82IhuCK4eGVra5RBnYa6awuMI20gk9M0AX3Zd3Gc+lU7pw6FVBX3FPMj7CSQW9qqNMA6qX6/pQBRQ+ZNiXORVXV4hApkQ8d/arNxmOVpBkn2qPUn87S3LKA2O9AHmmq75rglTkZ6f1otCQ4DkAd6W4kDXJXGD0ye9SQoWbO3pyTQBp2yvvAV2UAdfWupsdssYMTFmxzXIpI6xg5J+bkegrovDdzFDcGN3Tew3bM8lemcelF7DUXLZGpMhW3UqpHPSoCrGBsL90Z6c1smWGdtqEZPQURwFCzgjgdKBGBDpovYhK4ZM8YYYNWho5jixCwweeK21dSpQDB6N71OYwsICnr+lAHmPibwgmq+IND1JQPMsrnM2f4o8E/owX8zXQ3NnFI+51Izx+Fb0sZQlj0HeqsixyEA8mgDz3xVpeIjJbn5PSuTjVTJhwdwOOler+IEjNtsVBx0rzO6UJM5jHBIz7UAQ72WQ7lGBwMU+BQk5KkDPHNRtFiVgvQEbjT2VUdmX5s8Y9KAE8pcZyCynp2olEOz99hcc5zUYDvHwQwXqtKYEfeJlGwjkevtQBMhScK0MiSL2KNnFSxxDdvkU4HBxWLa6TbWt8lxbPJGMZMe7gVrKH2gHO0nt0oAtnaoG0jaTnHelRkUZXJGcfSq7OPLGw5Knk461ZgQsAwAB6nHegDasYFEDOhUjHQnmq13hVJVtpI6VZsU/dluAPeqF/KhkKAkkjBOOBQBQnuehicluhPrVm3cyAZK7s8n0rPjXbMUYFR1/wD11aVG4C4G7nK0Abli0cd3gEFSMYHeuU8XQoNTcn8B6V01ud0kO0YI71heLUlW8DyKrBumaAPon4Nqw0IsRweleigVx/wwg8rw7F8oXPtXY46c0AMA5IPQ1QuLQTM4Y9uK0D940YB60AcFrWkIkUhkUc8g4rims4nMo/LFeu68i/ZH4HTrXjV3My3sqRNtUnFADbdPs4Kv39DUiKCflJz2pUKo4BIY4ppkjab5SF29c0AKYYw3zkEn171M1muwP7ZxVWedQVOzeOg9qZcSyNgxk59B2oAdPbeZHwQSOtVGtYzICUUk9xVWaa7NzsQyHdwTjirtvb3DMqlGzmgCjfWQjjzHgYOcVSkuJVhCK7IM8ZrtLrRmKRkDIZeRism90vbIFIIxQBjWj3NnIr27sWA3etb9pr7zHbeo0gXnpU8MFqti7DhxxmsO4utjbU2nHegDcv8AWNHnQQTW4Vz0PasK40WzumMtrcIi/wB3PNZN/HbTWbTNM4nL4WPHAHrmsB9Ra2yIWZSpweaAO0h0hjkbs8YyBUk2k3DQO8TsUAxj1rmNM8TzQn5mLY4IJ611+ieIElQxtjB7UAcpPBLHIwkVgV7GoYZvLZJckDOSO9dxqEMVwpIXk965fV7Eo5CcKV7CgDpxcWup6eJIn/exgcDrV/SLlTiKRhvHGa810+9k024DHcYsc8VtpqDMyXMTYyRkdsUAekIqkFB/Oql1AVOThRnGarWFys9sjhufUVbdg21Rh/rQBFLEUC7jvJ9Kj1AJJZshHy4xgVccOYgMjP06Vn3TswCkAsOpoA8+1Kw8udlHJ+8Pas/TZitxOjt0YEZPrXoV1YRzqSMZPX1riNWtFtdaMaKQJIs4I7g/4VjV0cX5/melgEp069N7uF16xaf5XNaw8qRmilPB6Ed6tXsC2uv6Q6ghJVkhY/hkfrWJpdwsF2N24gH8BW34lvoZLGxnUgvbXUch+mcH+dGI0hftZ/cx5R72KVP+dSj/AOBRaX4tHQW1uVl3K/ArVE8YjX5vm75rHFyqPgY65rOvtSIkKqCV9a2PMOrVo5mUuQD04qeWRIflU5BrF0ycTRLt+bA61bEhc4YYPYmgB92+YcHqarxRBlBJwfSnTjZgsc96q3V7FHDywye3pQBi+I5DbxF8KwPqa8+mcTs7Y29mxW14m1CSZykbfJ145xWArsJM7c+o6A0ALsCoMHKMPWmOhL78kDHX1pbiRpUXyQML1qVp0MYXIGB+tAFJZERtqg5J4NSyfLk7hgDkVE37sgBeh5HXNKI8hiCMseAf50AMkLEAtyo6sOtWI5CYyI8AnjB71BGrOrBiAOlWCcMAmMjAyaAHMroFU/KeM1rWKlSu4qVPQ1m7Xllh+bO6tK2DQRHcMleQKALss37o4ADHtWXIV80sW5x2PFQ3Ny8ilTtznv1qIwKQu0nPXrkUAO8z97gkfQipo5P3TqxKnoOOKrSPJuAZFGf4qfEcxlQQVU/xUAa9oxYKWYfKOw5rK8UsWMJAP41r6SqysNxA44PasfxY6mdEBBx3FAH1h4Lj8rQLbBH3R0+lbiscY71j+EMf2Fbf7orZOBzQAjZNNzkZpwHPPFGMAigDl/GeoJbWEi4IJGBivGPLY3MsgJwxJAzmvTPiQ262Kj72eK4K2VVX5x060AUxI7IPMOHB6etWERDwWy2M1LMsJPyHL9eR0qnBOZVkwVXacc9TQBpwLBs2s/Qda0LCK0BxIcHHXsa5TNwZdoAIHp3q3PcOm0FtoI5zQB1srafCN/ygAZq3aahYvHvjEZb0rzufUHHAAPY88VFbagIQdq8j0oA9Oi1KJyQduB2p2qRW9zDvQAEjtXmcGrzmbqFUnGT6V1Wma1ELbZI3bjPegCrPC2fLxtU9q5jWoDA+UOQOMV3W5Z49wIJxXPa/YtIm7b1POO9AHCXsoW3Ry53g/c9jWHOR5jsvAAIJNauublushG2oNoX1rCaTG4AMB/ED3oAjEhLbcAZO7PcGtLSL97a4Uuz57VmLgg7hx0+tPRhkEE8UAeuabcfbIAFbOBk4q1HGst0I5xhWHcVwnhnVmgdQXI9c969BjaKeISxt8xx1oAzdd8KMYGe2+ZT6VyEVnNZSmF2YrnGCelew6NqdvFG0N4c5HftXKa5p8c1+ZLUo6O3JoAi0gtaRAPk5wetdAZh5iOACPasq5hW3jVXHKjotN0q7zL5b7Rnpk0Ab6Op3ZJBNY1/KIpwc5+vetSNTJkkDrxiqep23mDC8cdaAK0dwyx7uOua4TxLriTa2kn2di1uXRgzY3ZGP/r1vXk72jrGnKAY2muO8SLF9qSRDh3HzA9/euLH86pc0Oh9NwmsNPHqliVdSTS1tq1Zr5q69bGzZ2z3mnreKApIJ2A+5FYWo3MvltGBiJvlI68g1t+HdWiW2jiPMca7Gx61L4jt4JLFpYEznBGO3vVVITq4eyetv6+8ywWIw+Czn2kor2am/kr6P/t3R/Im8G3d3qP2o3UzSYKKu7t1z/SujNgCTkA449a4bws88cczRNsVTkn19q1zr00MwXOO/Peqwd3Ri5bmXEipxzOtGkkoppWWi0SR1US/YE/d9COlZl1r4WURsMFT61mXGus8Pzudx6ADNYctx5rlm+bP4V0nhnWS+IAYxyQAOvWsbUtW85QQSAOeKxZXUjaxI4yKbFtfIXIGM5PegB8g84Fmbl+hFV44B8wkJK9jUUkirLiM8Y5zQC5jO+Tgc4FADZUUEtEF2DqM1BMWVnbC7COw5FSSTDYmFUDH51HxKh4xjoeuaAFkdfLRQFJbnng0Y8na2Rj86g5YKJF3AdwKVNr4SMtjqR/jQBMHZmOB8oHII609HVxjAU9OTUEqA7PLJbPcdqu2durqrOME8cCgBtqmJAwBBzxmr1zdmPgg5ApkrfZYdoUknoRVJ5xgAv8xxQAwyK8wGxjz36VKmV3DHBPHNShgY18tVLDk/Smb/ADMhDsZe3UUARK771QAbicZI6CtVYf3YDjPHIFVIkEjJJHge9aMRDnyyTv6ZoAXTYmMqmFiFHXPQVy3iibGpSbSetdxCn2awmnJIx1rzzVZftV47nvQB9qeEIzHodqDj7gra2jrWT4WXGiW3PG0VrY4JNADWHSg5xjIoBDrlfpQgJBL4B7UAcr42077VZuwUZxXjt5K9ndiHnJ67vSvoW8gWeBkYZrynxv4f2TrKg4oA44lpgSoK8YqvZxSJK5lwQ1aKr5eQ2cilt3ilm2chvpQBDJcJFIqbckiqdypnfIYnHatK5RTMVUHjgU22tsOR1oAwjayDJOS3YCktraSYt5gKr2Arp3gj2k8fL1qpMYlIyMAcUAY09i0gEO7ZuUqCpoFrPbxRfOTs4BY5NbTQKDuJBI6E0FFdCSPmFAFbTtUkhyszd8H3rdWcXMe0kHjgVz03EnzqTxgccVYtZioLrwRxxQBieItPCSSYOAeg9PeuIdSsrj0GCT3r0fWo3uVzuIY/yriNUs2ZiMHHcetAGJL6E5AwB7GgFlzU/l5YtMAOO9MdOGZSODjGaAL9lKd0e9Rj1Bya9I8N3iyWZRuoBxzXlkYZFCgc4zwa7DwtfAy7ZOCy7aANwx3N9cukZIOcED0pbN5LSV452bIOBk9K3PDqwpMFkYcnqai8WRRQI7x4J6/hQALcrKAJmHIwPpXMXebLUt6vhT8w5/SqEmoyGUkZAAAHtSTSmWNixyRzk96APQtHukngjIPJHJzWlNBuULu47e9cBpV79niQLklTg11tlqqSIQW+YHAoAzfEOkAxl0JJ7iuRvdDlu4sJHumXlSe3tXppu4JSFdR+NKkUKuSqAg0pJSVmXSqSpTVSDs07r1R59pXhR4bdBID5h5P1Na8fhyZIwCSQeCD0NdjmFY/lxv8A0p4cCIsxGCKErKyFObnJye7OEttAm09ZVjBMbsSVIrPvdMLyNui2IBgt616UJY7mJFVeakn0aGW3L4JBHQ+tCSSsgnOVSXNJ3Z43NYLGfkJfB9etVyjK/lujDuMHpXb6vozRM8iDgfwjvXNzbUnYSIQcDANMkx5FfzCrjgDg1BPOsSK4B9ODWpIkMmWViD3Bqu9mpiUnHHOPWgDM27w7ptAJ5Hp9Kc77du4ZX1XvVn7PkYwNjHGBTjZFFCp068nNAFHJCkLggdMjpSRlkDbflHU5q9JasYw5Azg9KrpabdhkOQeTQBAgVgx9WyMHmkWJRcEIxUn+daKrA0EmUGV7nvUDKiKAmQcZFAEVviOba6rlO/8A9arZmCRAR7vn457GqdxcEnaNu3oCB3+tQ4Ktg857k5oA6TwvpE/iTVm0uKdI71o2eBWOBKw5K57HGfyrO1LTp9KvZbbUIJIriI7SHXGDSaReTaVqtrqNm2J7WZZlA6fKc4Psa+pfE/hrTPH/AIbiuoGSG5uIFkgugoYrkZAYdx+ooA+VwjIC+SDjioUZl7HPJ471v+KdBv8Aw1qLafrEJSRBuUhsrKvQMp7jislQ4RjHHlRjkUANhYhB2GeB6VuabD5u0rgMOee9UtNszdzBWUlc+mMV0V55OnRZO35RxxQBheKb4wWRgGAzd8158SxcknnvWnr+pC9uX25wDwCen0rKB6BgQfWgD7Z8AXj3fh62Mgw4XBArpVGO1eS/BzXhJafZJmxjpk161kbc9e4oAbgnPYUDpjvSgfJz1po9hQAH3rI1nTPtkZAAJNa/JU5NIepx1oA8w1TwlMXby4wCByR3rm5oDaSlWj2svB4r3CZA64xjNeeeM7JIwXAyx70AcYiqXDZwfSrMlt8qlXOT3FZ0EiLcYkHStqzuoMYcDA7UAVRbvznkdziqM0SbmU43eldEt1EVkBQbD0xWXexL5gljGR0NAGTPkIBt9qgR2EhGTgVrSspYAAY+lZ0rp5hCn68UANGJY2BUlz+lPSAqqhVH1NER2gkHB7E1YR1wd/LfpQAGMOm1wGNYes6VtQssXAzyK6K2OWJIAqS6i85MZBU9RQB4/qamCYZiLLjnjpWaDnkAemK9C1vT4kd0AJGM8iuHu7V4JDlDjtQBWWRU65BHHBrT0S7EF0Gl3cnA5rM8pWjcNwSOtNjby8EEg8Y4zQB6/Y3EUlussYIYDrVLV7mW4cJuBU1k+DL8OrJIeB1yOK23hV7ppeuDkYoA5qe2kLA7flY54rSh02R7R2CYPb3Fb3lRm187HRuRStqNoiGNSCMUAYMAXbLGTsIHcUlu7WxVw+cdTSXJxO8ikbX+XAPSqFxJ5R2sx2fzoA6Wzv8Ad8pPI7k0o1mT7QIoyetcwbzzIsR5Izg+ua63wxpq3EUcsoBz3NAGsonbacHBGa29JtFuV8uX7zVn6lcLbRqg4KnH1qaxuzZvDKynDfxUAZ/iG5fQr4Iv3f5V03hrztZtgVfgjtWR43tEvraO5hIYng1d8AC5spUjjTMJHzUAXtV0GWOM5UsBnNeb67p8gZsx429Djk19C4Dr8yg56Cue8S+GINUgYRAI5HBHrQB8ySLIkrk4wegqGKaTeMnJBx1rsPFnhW80u4cSRts/vdhXKzQNG4KsqjHfvQBGt1KruyrlAepFQSXM6Rlc7iTke1MuHMUgVJQ4A5xSllIR4xuBPzZNACi4njCFy2P89afLcPLHhdu4dPQ1XuGMowoZAvP1FTWRjQB/LSUIwba2cH2NAEAZ1kMcp4YflSXiSRfMqsVxjcB3qa/eIksybS2SB6VtaJqayCy0241STT7CZm86SOEFlbHygHB4Jxz2zQByygy8BXUADO5SB7/jzmryRIGySGGPlArsPGt9c6pptlqMU8KWnlrDJZpKsnlzgYLDgHkAfSuKgdu24uM8Y70APLrknHAOM5r1TwP8WH8MeEE0wWjXlxDcfujI21VhJBI9c53Y7c+2D5lHamcIec5446VpQWI6FuSOSRQB1vxL0d7nVIfEtjdTXmlaqfMjllYs0L94m9Mdh6DHasG0tU3KGxuPSup8EaraWCXGia0+/RL8gSE/8sJP4ZV9McZ/+tisPxhay+GNWmsL8jdGN0UijiRT0cexoAilnj00hi+P73vXJeIdf+0yskH3Ohwe1U9X1Oa7clmACjgVhBtzjHH1oAczb3zuI56GnpwTuPFRnHrmjGeTwaAPSfButHTbmFomI5x1r6Q8KeJrfVbZAXAkAxj1r5GiYRYOPmPB7AV13h3xLLYsoSQqRgrg0AfWBOV9aM46V5h4Y+IazbIr305YV6JYXsF7EJbeRXXHY0AWjwOelJ707gjkmhlGOpxQA0jOa5PxTZyzgiNSy11oIApGVXHIBoA8H1XTZbeUSSIygVmSTYYcgL7177f6Xa3MWyWIEGvJ/HfhB7BXubSNpIv7o7UAYNveYAQsOe2etWnuNo2ggVxMk0gnG4FGX045rSW+cxgtliepoA3pB5s6hDgVWkt8NIQQWP5VBpFwZyyEEMT1PpWk0IhkAJJye9AGesb7cSAjmrEJwwGTj1rYe3jltwpXB659ayLq28lyB3oAnUiEklvlI60kTAsNjnJ6iqVxuEe0gkUsLHkMmF6e9AFi9tkLluSSMGuJ8R2YEDSKCoHODya74KfKHPA4HNZGr2ayAqQDxQB5fPbywlVkiZdw3LnuPWoWGwfNW1rFp5czFpHwOACensKx5TiMDmgC9oOo/Z7kAt9K9OtFE0CSxkM7AdOleNgHflWI+ld/4K1ZgnlS/d+6e9AG8khEjRduc7Tx+NZV5ZSQsrhi3OcVs3E0Vtcl2IAxmlV4JyGZlbdzyelAGFcoFiSR1bHv61kaoCYQ4HyA102ozQNHJCxOV+7joTXLyLL9kaF2LhTnigCvbNm6AUnYw7V6doOI7KIB8BBXmlnGqXULqx2DsRXotiwa13KcD6YoAr6tet9vByWXuooOrSXG2EK2wdzWfqCySXgVHP0A6VrppwiSFgw9yPSgC2bqQ2iwljxyBXb/AA5JktyHX5uucVwb3K26MVC5A6sa6X4b6q9xdmKQnjoKAPUgnUnFMd0RcucfSnAVS1SJ57R1h4lx8tAFXW7Oy1KzkhuAH3DvXhfjXw9HpcjPEoZQSVHWui1671yzldX8xcHGRmsa81Wee1aG+TOcYLdTQB5wVIlfMapv5IA6VWgKGVlK8YOCfWui1i3WNy+1RnlCPSswW6s44A4zlaAKEhdlbKj0BHalUBRlWIBxwK0Xh3J0yDxwO1EdqI2VQoOOmaAKJjaSTY/OejHtUn2MkgqPmHfPetEWZYDau5uuG7VczDDAhmKI2cDPrQBl22nTEEng5zn1rXsdGG7eeGHP51F/aEMIwGAfrjNVbvxEIlYQuA/p2oA2lWGBXSRcEdCKyLzUI0ZvnBA6DFYUF1qOrXUqWatLKFaQqnUKBlj+A5rKuZ5Hcsjk+oJ70rpuwGrqOsSFyEY+wNQaz4m1XWbDTbO/uTLBp8bRQbkG5VJzjd1IGABnoBxWJcSOmSy9+aTcSnAHNMBXZyxyRg+tNQqH+cbh7UqqxJbIpHAUcAZNACnaV7gDgCnnkAn86agIGSOaenzZ3E0AbMfKnd84xkZ4qRHZHyigK3P4019pjwiYKjk5oChYWG3Jx680AacWoSRSDc54IxtPFem+APFslvMu+XMfQjNePRM2QU+hAGcVoWF55d3G+SEU8LjBzQB9i6ZeRX1qksTbgwz9KtkHoe9eXfCnxClxF9mMgL+9epds9TQAmATgU4Dg9s0gGKTODg0AKw7dTUF1BHdQNFIu7Iwc1PnjJ602gDxXxx4QksZ3ubeLzI2JPTpXIrDHEgWYKD7V9J3NtHcQlJFBU+teZ+MfAKEy3VgMP1K0AeXCYW0oki4C+p612mn+TqFkrZ+bHWuKuYXjnkikQK68Nmug8Fy7HaOXkZxzQBoeeLWYwO28DvUl/aNcQ+ZEdvHBpNYtlS7L7hnvViC9T7OU42gUAc0kMqyFX+YZ6mppFw2Cc8etagWCZ/vjbVS/hWBCUIbPegDMiuHPmIwBweATUzxNcRlW/DFVIIDK7Fmxzxit+0ESRYJ+btQBwPiO0aGNmA7fxVxtwS8adMf7Neg+LUlYOQuBg4IrjI4VfkOQVwcUAZh4AwDwPSr+jXLQXKkE4PUVZNoZnGMDecf4VBc6fPZ3DRMrRzp1U8UAd1fzLdafCRgyAZOBUdosZsWl+bcpx04rE0i7eS2wWJbuO9bdldRi1khxk98igDOfznlAHIBou4zESzLtyOg71owwI3mFpQtZepSbSfL3Oo6EnrQBnM7QSKFBweQK7jSZ2ls4w/O0c1wrM7XSlwGXtzXW6OGEO7GOOAKALF/cGO8BUAZXr61NFqx8mPIGTxWbrUMrRh+mOcE8mqtgxYqrHA9+1AG4GS5ODncedvatDwxejSPEELTMSrcYqtbWnlhHByD/ABHuKh1Zzbujqq56Bs0AfQdpMLi3jkUjDCpG3Z+UVxvw61iO+08Rb8unBJrtcjjigCpc2kFwdskasT6iuW8TeDrW/t2MCBJhyCK7Lg59KjYY6cigD528R6Pcae3lTIMJ3AxXKEbHBPY4r3H4pwrFZ+dtBJGM18+3+oeXcyBVzjgZNAGjJIFJLA7TxinmVI9rEjA5rnp9UkZBzVW41BygG4kZxwetAHVXOupFbgKFZT1OOTXOX2rm4chR8noece9Z8kjOpAyuD931pmV3dMNigAaaUzOHcFf4G7n61E7MTh+eeDTy+ABjDHr6UrsSE3Y9qAOh+F12bL4iaHMPlVpvLf8A3WG05/A123xn+Ho0WaTXdFjC2Er5niA4hYnqPQE/4eleT208tvcpNC5jljIZGHUHPWvry78Q6RdaBM87RXofTzeS2URV5HhKgn5CemD3r43iHGYjLMdQxdBcyknGS7pNNfm7P9DopRU4uLPkGT7oXg/yqL7vHGParuqvaSalPJp0MkNmzkxRyPuZVzwCe9U2J3EYBHWvsIvmSdrHONkJBwvpSgs2DnH4U3hsb+OalJABGM+lUABjuBA6GnHDkkgj6UgI6DGKf8qE96ANtkHlqHB3YwcdMetRoQCWQh1xx2NPjuPLBDjdngGo+OpX5E+UgetADoZGII2AAnPBqZiYlV1GAWznOc1XjKxEENlW7ntTlDbPMdSwB4IoA77wJqb2GpRuACCRnBr6S0e/ivrOOVCOR618g6dcPbzK4f5SckdxXqngjxa9lMFkk/c+hPSgD3aSRVBOelU3vAehBrl38U200LOkqnPbPSotM1VZ5SquCOtAHcQyF0BNPzzVGwctHndV0DPTrQA7jbUM20xNuGRipTnoahuOY2HqKAPAfiK0EPiBnQbV7gd6z9GnBuRLGdq5Ga6Xxj4ekudZabYSjHBFZtzpHkwBLdCjAckUAWNTnWU/K2WqvYRSTI4VTnp9a1dF0Fn/AHs5GwjoTXSxRWVjaSHCeZjigDh5baWFhtGMdc96p3ME08RUN8xPc10eoyi5IMagduBRp2n7nG7JB60Ac7bW0qLgnIXrTLqcRXAO/aCMZ967ybRC0ZKjBIri9f02SBCSuADn3oAxtenjFhJyGce/SuDEaTP8p5OMmun1CF7uNiBlRxgetYLWpV22ZB4wKALMKoBtHUdTW2IYr6Jpbh2afABduSawTKyRF5MA1raJcKVbzG4PQAUAV1tmtrosMAEYwB1qKC6K3s6tkdO1dFe2wW3ErHr1HtWNNbhpNyjk9CaALU7bFBPIcck1RM8bnbjOO1aNzAgtkweo4yc81miIICVI5ODmgCncRh1UkFcHgrXTeHbwRAJJ8wxzmuWkBikMWSc81c0SVTOVLEqOxHNAHaXirLEcbCQMjNYdrOlvK4wM9q15EM8aCPgj9BXP3KiK6KEE46EUAa39pTN+7GAAM0Avex7252DJ9zUdvb71Qs2CQMA+ldJbWcMVkSPTigBPBGrnSNQ2SgBJDnIPSvbbGdLqFZYyCjCvmy7kWG6JyVYdD1r2P4ca3Fe6YkbN86cUAdz0HtTWOcYHFOU57UxvvD1FAHGfEq18/SXJ7DNfLOqIVvJlfsxxX1p48Yf2NKG9K+U/E6x/bnZT79aAMcthsgfL0x61EM8YAAHb0py7CCWzj1oIAGRkr29aAJIixcMefegrgkcZ+tHm7VwQNuKiV8gnAPORmgBT5pdAqIYu5J5/CnSqMqxzjpjFPDfPkYAI4FOnJEYOc89KAISo27gOM45ra8Ha3L4b8R2WpwgskTYljX+OM8Mv5Z/HFZBLEHpntih2ARNvDkcms61KFanKlUV4yVn6MadndHQ/EbQI9B8TSrZ4bTrpRdWbqPlMT8gD6dPwrl+pz0NegpcReJfhpLbXDoNU8Pt50BZsF7ZzhkGeu04P5AVwBbavC5zXHltSbpOlV+OD5W+9tn81Z+t10Kmle66jNhDZKgqfWnDCjAXil65zTGJ27SPpXoEChOM044L568elICQevOKaTu4B5HrQBtlQ4jcgAADA9abKu0nJITG7b70IWEZTgYOSD1/ClmUnJJ5J4z6UAMBAcckk84PTFK8r44O5T2HSmxg+YNpUj3qQxfvccAHuO1AADtCOrEMTjnpWhDqPlqWDBiOD2rOySxjyCy9yKUxq3+tI9ivrQB0Npq8ixArIw3dia6HQPEMsFz95sdhXAu7oAxACgfjV3TrvMoBHTowNAH0x4W1oTQrvIz9a7GKZWwwI/Cvm/wAP69LblMPkKeea9J0TxhC0al2GcdKAPS9wPWmAqx4NconiiGZfkcA+mau6ZqJnkG3oaAJ9a01bqFsDB9a4m8t4rSKQE7nPY16cwBTJrC1PRIbjLnAYnNAHl2o3tx5ShcrxgEcZqrYxajeMDIH57A16EPC3mOfMcMmemOlaVno8VmDtAwOlAHNaBorspM6njpmtSW0jgkC8D8a312QIeAM1x3iu4lgBeM9u1AHS2ao6KVIJ6Vn+INEW9tXKqC9cR4X8USi9RJCShfbivW7d0lt9ygcjmgD5+1OxeyWVdnJYgmuWu7VhIFkXg85Br23xhp0QmBYDaTXnGuWSIcIMknGMUAcJdKADtUA+pp9ldbZUO1+OParGsWojDBlJA4AHY1npIsP7vlTnhu1AHarciayTft2jPWs6VlZRtz060ywkDRKOGB6c8VHL+7kUAH5jhvagBokK7VVi4z09KS6ljhVDIWXJxinRqBMoU4H0puoRb4tq8t3JoAp3hEjBwD8vQiorWUC6DhGVz3PQ1OkBWM9T71Gjq28dTH2FAHZWN0SAwUBcdO9ZWtxsLpWHGTn6UuizxyxlC7DPFWL+DCgHO49cnqPagCjBfvHkAcj+dTya1dPEF34VuMCsl5dksgYlRnAOKngiXaMZPHU0ASCQzDLEkk967X4YytBqgXlVbj2rnEshFCJCDu64/rWh4Wv1ttXRwSqEgYPY+tAH0TBIGiBzzinkA4I6Vm6dIZIoyO4zWovYGgDj/iCg/sx+pBHOK+WvEcKJfyc5GSR7V9deK7YTaZJnoRXyt4xtlhv5SchtxoA5MnIx90+lSOihRt6d6awOckArTBzwPu9x3oAMDjvTiygYHPNAYcZxwcUrkZwwHPTFAAAcEA543UgBYHOTjn6U0jnjFKMhsZxQA+PG4DoGpsmWO3sBijJzg9ulIzDORx/jQApwoG48VGSMlgSe1PIBbBGc/lQQdpxgYoAiZirYww96exzimRBwzGQ9+1PIDDaOpoAibcfmWpBgjk0i4yfSlIYcLg0AaqKm0ZBLMOuaXPPzDzD02ntSgN+7ZT25GOlDKYgecknOfSgBhXDrtIx3WlDshLFmDDpx1FG0sXCqf94CiYkqqt0X060AN3hzkgjI5Occ1IhCqCBkHvmk8p5BgDMZ/WkVFTKMeAchc0AD7w67yd3TrkU+IS5JDhTnBBqEKokONwA5qZ3HkhY8uxOST1oA0bW9MSOpYMAeorTg1B9isD9ADzXNwvu8wHAb+6aR2IY7M5X0NAHa22r3COpaXAr1r4YaoLolZSNw9TzXzxHdyKMM+RjPPeu++G2sfZL9HDABjzk0AfTWVx7VT1BtkLMDyBmodOvUuLRXDg5FFywZDuIxQBzVvr1w85iCHI6kVftbi4uLkNIQsQHIxzSBIIZSwQc9wKLq9iht2ZCOBQBZvGjKFmYACuF8Q3nnSNHGVYdKg1rXpZnCxkqCcVDo1jJdThny2TnNAEXhbS/O1LeyALu9O9eu2cCxW4QelYejaelodxVQTWxJMcYHagDlPGETecMHpXmOpOyXDKXOc8DtXpXiqdyoyv4mvOtQTfeRv8pGeQe9AGJrmksYTKXHrj1rj5Sm5lJO4dFPSvSbpTKhV3+70rgNbg8ubcTjkjIoASzlxMFRgB14NbBbJVnwwA6+hrjbeQxTAqzDJwSK6F5ZZUCkBEPXHcUAX5E2sJAB045qP92wxklz1GeKrq6LGQn3R2NJHGxcsDwKAJZZNrqAOPU1RuCPOO0Lh+oHeq+ouwwvOM9fSkj3PAW3MSO1AF/TpzBcxr/Ca37y68yNMj69/wBa5ZZvlG4YHUdq17OYzQKJHwBQBDcMjS7cHHvUkM6qw7DGM1DqkSsGCtnB6VVUM1qQCvt2oA6BNR81Cm7cAMAEdapQzmOYSAAEHJxVO03BV3fKwGOuasshDEsxzQB7p8P9eTUbBF8wGRcKRmu7hfIA6187eAdSaz1pACAjdVr3i0uNwVlOVYZzQBb1BfMtHVgOa+a/idpLR30zrwSSeehr6a3Bkx1zXlXxO0Xz0dymQeKAPm5kIJzhh9aaqhgSCB7Ve1KFra7aIYCg4wfSqIBBwCMg8YoAEUFCen1FEinGQc4/WnFBtOTljzScKoOef5UANBI3L5fQZ6UyWHeQXbB6gelTD7h6n1NMcAsNuenegBWVANxjGe+DTZNpUAcA80buABz7UAAk9ePSgBpJDAZ+X1pT1PNLxuO0n6EU1lwBtY+tADQSSMUqYXBHzc9aaU3cnv0x3pWBJ8sDBzQAAnPA+oqQ4Jz39KSNdr7W7frT1IG7G3OaANhHLA7jtUryaiZ3RFSMhR1JzmnDiFyyq49RTWVGGIt2SOTjigCJ3csTvbHfbxTRKwZSfun16mrQjcFFUZGPmJqORGjBAyeeOKAFjCyYBcq/XHbFRTIq4LKWU88fpUsfmRgSFWyRzmn7ZGKhhljyPpQBWKneDJzuHHvT0tzITjKkDIqw9ttBBJwehJ6VLDCyYY/NngHNAFALIgB6bjxmiXCjod5HOK0J4HlRsIMr90561WuIn+UoDvIwR2oArxruZeSQePpV/Sbp7W5RVfgNkYqqEaLhh908GnQySBn2hcA/jQB7P4T8ZNCFSYkqB2PSu1h8TWt3D+6kX35r5wstQZJCC5XH3q0odVkibbDI4OPwNAHtt7r1tDuLTDPoD0rmLvX5b5mht2JBPavPHvWkYbpuSfWtfw9c+Xcgs3PcUAelaJoMtxCjzDII711umacloigL7VkeHtUU2IBOCBwK10u1dMhwD6UAXrmRIQeRwOKy5tUVX2gnd7Vm3s8jykM+F7YrMuZTb4P3vegCTxDcmW1YuT0NeYTSiW5bczj0rrdcvvNg+Xp0rg2ci43bjnNAHQWsLyoGckFR371g69YBw+x2J68V0tncI0alXy23JqLUbVLm1Z1I3DnB70AeXuuwjdlQpxj1rYsJklAUHOe/pUetWaxRHcoyeRiq+msYpNqrhMZ5oA2WjUj5ecdeKRMAlQPenQTfKfQ9eKJgFJI5z3oAqXduspLDOP5VLFGFXam08YqHcRgIcEnp1qve3HlycKeByaAB4tyuW6jgA96XS7gKzRncGAwA1VxLJJGDyO2T0pVykisG3EfePrQBrTPvJIOTjqBVIqsi7Hy0Z59MVOuDGvJUYyB6VVKBJUbB47DoaALtmqRuEyVBPAPeurtrG3ubINJgSr1FcZJMGQsQQwOPcU+01G5U7Sr7WOOtAG/EYbTUUlQ4RT0HXOa9r8O6jHc2MJV+g9a8Akl3dWwByciu7+Hmsxg+TIT7EigD2aG4CEB2x6VW1+wTUbdkPOR1qOwmjkQE8t29qvI6kgA5z1oA+bPiB4cksbhwygqDkHHWvPWQI77e5zX1P8QNIS+0+RtuXCnGBXzdrdibS4kXaVweRQBkxyKWUkEHBFMUbn296e4CjgHr2obawDJnPfPagCJDtBUgnnrT2IfnJJxzSZYqQuDgZIpDjHUZ6YFAAsgaLYR7Zpny5+UEnPWnsrEqqqPx71JsJOCFB6CgCNAPNKnIGKQoNpw3OelOUbTtkGG6A0kigvu70ANIyyjr6ZoRQGBAycmpCA0WCxyDkcUR5yRjBoAgbcHyueDnipQAxyTijaWB4wB6daFIUY2k/wBKANqRRiMdAxwQKm8pU2hcgenaiigBsbEnb25pioJVG8k4biiigCe4hTYU5wwyat2kKZAx0HFFFAEF388ojb7uOlMPEYTAK+9FFACLGEu1Vc7WGSM0s64L4JG0ZFFFAFQHzEKvyAaSJR5xGTjBoooAdJEnlbgoDKvWq0Mzq/B7d6KKAJFkfcnznlq6DSmYOp3HOaKKAPVtAc+Sg/2a07KRnuvmNFFAGlNGghztFc1qczgAcdcUUUAc3q8zRTgJjDA5BFctfkpvZeDRRQBJZ3Egtyc8lau21zI0TIT8vtRRQBz+r/MpZuo6VRVi0Sgk8UUUAadl91Cec9c1JdqPJJ96KKAKoUKNwHOcVm6hGC7ZJ496KKAHWfMSZ9ajlcqrqvAzmiigC/aZZSWJJCjFRXiDfuyfp2oooAfCxLYPI96tLErR4xjBzxxRRQBJHErRNnJ28irejTSRXkbIxBLUUUAe5aFK8llGzHlhzW9ZEleeeaKKAJb5FaIgjIIrwH4n2EEd07opBPXFFFAHmKthm9qc6KEBA+9yaKKAK65D8E02b746daKKAFdiZAen0p852orDrvAoooAUsfNKHG2pCq7egzRRQAkygRKBxUUXMiZP3uDRRQBPtGT7VC6gngkd+DRRQB//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A sagittal MRI scan shows the bony defect involving the inferior occiput, foramen magnum, and posterior elements of C1 and C2 with herniation of the cerebellum (black arrow), dilated posterior aspect of the fourth ventricle (white arrow), brainstem, upper cervical cord (red arrows), and meninges (yellow arrow) into the posterior sac.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Eisenberg RL. An atlas of differential diagnosis. Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_18_19746=[""].join("\n");
var outline_f19_18_19746=null;
var title_f19_18_19747="Ferric subsulfate: Drug information";
var content_f19_18_19747=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"12\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ferric subsulfate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F14228099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      AstrinGyn&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F14080410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Hemostatic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F14080424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hemostasis:",
"     </b>",
"     Topical: Apply evenly to wound",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F14080425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15881416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15881417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F242404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical:  (8 mL, 59 mL) [Monsel's Solution]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AstrinGyn&reg;:  (8 g) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F14080426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: For external use only. Apply to wound using cotton applicator/swab. Avoid contact with eyes.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F242405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hemostatic in minor surgical procedures",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F14080415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dermatologic: Hyperpigmentation (application site)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F14080411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F14080412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hyperpigmentation: May cause heavy pigmentation at application sites, which may result in histologic artifacts (upon rebiopsy) or in radiographic artifacts.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: For external use only. If inadvertent ocular administration occurs wash eye(s) immediately with large amounts of water or normal saline for approximately 15-20 minutes or until no evidence of solution remains.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13929253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F13929251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14207655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ferric subsulfate is used as a hemostatic agent following cervical biopsies (Manca, 1997; Tam, 2005). May cause vaginal pain if leakage of solution occurs (Tam, 2005). A case report also describes use following a miscarriage; fertility was not impaired and a successful pregnancy occurred 7 months later (Disu, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Astringyn External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     259 mg/g (8 g): $14.85",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F14080428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hemostasis at site of application.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F14080418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Causes agglutination of surface proteins resulting in hemostasis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F14080420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset: Hemostasis: &le;20 seconds",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Disu S, Rebello L, and Atalla R, \"The Use of Intrauterine Monsel's Solution in Severe Hemorrhage After Evacuation of Retained Products of Conception: A Case Report,\"",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 2007, 196(2):6-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/18/19747/abstract-text/17306641/pubmed\" id=\"17306641\" target=\"_blank\">",
"        17306641",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jetmore AB, Heryer JW, and Conner WE, \"Monsel's Solution: A Kinder, Gentler Hemostatic,\"",
"      <i>",
"       Dis Colon Rectum",
"      </i>",
"      , 1993, 36(9):866-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/18/19747/abstract-text/8375230/pubmed\" id=\"8375230\" target=\"_blank\">",
"        8375230",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Manca DP, \"Stopping Cervical Bleeding,\"",
"      <i>",
"       Can Fam Physician",
"      </i>",
"      , 1997, 43:2121.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/18/19747/abstract-text/9426929/pubmed\" id=\"9426929\" target=\"_blank\">",
"        9426929",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Olmstead PM, Lund HZ, and Leonard DD, \"Monsel's Solution: A Histologic Nuisance,\"",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 1980, 3(5):492-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/18/19747/abstract-text/7217377/pubmed\" id=\"7217377\" target=\"_blank\">",
"        7217377",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tam KF, Lee TP, and Ngan HY, \"Hemostasis Following Cervical Punch Biopsy Using Monsel's Solution,\"",
"      <i>",
"       Int J Gynaecol Obstet",
"      </i>",
"      , 2005, 88(2):160-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/18/19747/abstract-text/15694100/pubmed\" id=\"15694100\" target=\"_blank\">",
"        15694100",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83319 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-AEB5EC0217-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_18_19747=[""].join("\n");
var outline_f19_18_19747=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14228099\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14080410\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14080424\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14080425\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15881416\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15881417\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F242404\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14080426\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F242405\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14080415\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14080411\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14080412\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13929253\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13929251\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14207655\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322893\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14080428\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14080418\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14080420\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/83319\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/83319|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_18_19748="Peripheral chemical mediators of pain and hyperalgesia";
var content_f19_18_19748=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F53674&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F53674&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    Peripheral chemical mediators of pain and hyperalgesia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 418px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bear MF, Connors BW, and Parasido MA. Neuroscience - Exploring the Brain, 2nd ed. Philadelphia: Lippincott Williams &amp; Wilkins, 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_18_19748=[""].join("\n");
var outline_f19_18_19748=null;
var title_f19_18_19749="Thyrotropin alfa (recombinant human thyrotropin): Drug information";
var content_f19_18_19749=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Thyrotropin alfa (recombinant human thyrotropin): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?28/43/29363?source=see_link\">",
"    see \"Thyrotropin alfa (recombinant human thyrotropin): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F227397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Thyrogen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F227398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Thyrogen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F227410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Diagnostic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F227399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Radioiodine imaging or ablation:",
"     </b>",
"     I.M.: 0.9 mg, followed 24 hours later by a second 0.9 mg dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     For radioiodine imaging or remnant ablation, radioiodine administration should be given 24 hours following the second thyrotropin injection. Diagnostic scanning should be performed 48 hours after radioiodine administration (72 hours after the second thyrotropin injection). Post-therapy scanning may be delayed (additional days) to allow decline of background activity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     For serum Tg testing, serum Tg should be obtained 72 hours after final injection of thyrotropin.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F227405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Diagnostic aid:",
"     </b>",
"     Children &gt;16 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F227400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15159240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Although thyrotropin alfa elimination is significantly reduced in dialysis-dependent end-stage renal impairment, no dosage adjustment provided in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F227385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thyrogen&reg;: 1.1 mg [DSC] [derived from or manufactured using Chinese hamster ovary cells]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thyrogen&reg;: 1.1 mg [derived from or manufactured using Chinese hamster ovary cells; supplied with diluent]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F227373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F227387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer I.M. into the buttock.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F227386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An adjunctive diagnostic tool for serum thyroglobulin (Tg) testing (with or without radioiodine imaging) in patients with well-differentiated thyroid cancer; adjunctive treatment for radioiodine ablation of thyroid tissue remnants after total or near-total thyroidectomy in patients with well-differentiated thyroid cancer without evidence of metastatic disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Potential clinical uses include: Patients with an undetectable Tg on thyroid hormone suppressive therapy to exclude the diagnosis of residual or recurrent thyroid cancer, patients requiring serum Tg testing and radioiodine imaging who are unwilling to undergo thyroid hormone withdrawal testing and whose treating physician believes that use of a less sensitive test is justified, patients who are either unable to mount an adequate endogenous TSH response to thyroid hormone withdrawal or in whom withdrawal is medically contraindicated, and patients without evidence of metastatic disease to ablate thyroid remnants (in combination with radioiodine [I",
"     <sup>",
"      131",
"     </sup>",
"     ]) following near-total thyroidectomy.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F227416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Thyrogen&reg; may be confused with Thyrolar&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F227408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Gastrointestinal: Nausea (3% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (1% to 7%), dizziness (&le;3%), fatigue (1% to 3%), insomnia (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypercholesterolemia (&le;3%), cholesterol abnormal (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Vomiting (1% to 3%), diarrhea (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (&le;2%), weakness (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Nasopharyngitis (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adverse reactions which may be related to local edema or hemorrhage at metastatic sites:  Acute visual loss, enlargement of locally-recurring papillary carcinoma (accompanied by dyspnea, stridor, or dysphonia), hemiplegia, hemiparesis, laryngeal edema with respiratory distress, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Atrial arrhythmia, flu-like syndrome (arthralgia, chills, fever, myalgia, shivering); hypersensitivity reactions (eg, flushing, pruritus, rash, respiratory difficulty, urticaria); hyperthyroidism, MI, pain, stroke, taste loss, thyrotropin alfa antibody formation, unilateral weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F227390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F227377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bovine TSH hypersensitivity: Caution should be exercised when administered to patients who have been previously treated with bovine TSH and, in particular, to those patients who have experienced hypersensitivity reactions to bovine TSH.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Mortality: Deaths within 24 hours of thyrotropin administration have been reported. Thyrotropin-induced hyperthyroidism may result in serious complications in patients with certain risk factors (heart disease, extensive metastatic disease or with underlying serious illness); consider hospitalization for administration and subsequent observation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neurologic events: Acute hemiplegia or hemiparesis have been reported in patients with CNS metastases; may be associated with sudden/rapid tumor growth and occur 1-3 days after administration. Postmarketing reports of stroke or unilateral weakness within 3 days of administration have been reported in women (without known CNS metastases). Patients should be advised to seek immediate care for any neurologic symptoms following thyrotropin alfa administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tumor growth: Sudden, rapid, and painful locally recurring papillary carcinoma growth has been reported within 12-48 hours of administration; may be associated with dyspnea, stridor, or dysphonia. Prompt improvement has occurred with glucocorticoids. Consider glucocorticoid premedication in patients where local tumor enlargement may compromise vital structures (trachea, CNS, or extensive macroscopic lung metastases).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with known history of heart disease in the presence of significant residual thyroid tissue; thyrotropin-induced hyperthyroidism may lead to serious cardiovascular complications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Thyrotropin alfa elimination is significantly reduced in dialysis-dependent end-stage renal impairment, leading to prolonged elevation of TSH levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Residual thyroid tissue: Use with caution in patients with significant residual thyroid tissue; will cause significant increases in thyroid hormone levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Underlying illness: Use with caution in patients with serious underlying illness in the presence of significant residual thyroid tissue; thyrotropin-induced hyperthyroidism may lead to serious complications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Thyrotropin use in elderly (with functioning thyroid tumors) may result in palpitations or cardiac rhythm disorders; arrhythmia has been reported in elderly patients with pre-existing cardiac disease; carefully evaluate risk versus benefit.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration:",
"     <b>",
"      For I.M. use only;",
"     </b>",
"     NOT for I.V. administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Considerations in the use of thyrotropin alfa:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1. There remains a meaningful risk of missing the diagnosis of thyroid cancer or of underestimating the extent of disease when thyrotropin-stimulated Tg testing is performed even in combination with radioiodine imaging. Thyroid hormone withdrawal Tg testing with radioiodine imaging is the standard diagnostic to assess presence, location and extent of thyroid cancer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     2. Thyrotropin Tg levels are generally lower than, and do not correlate with, Tg levels after thyroid hormone withdrawal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     3. Newly detectable Tg level or a Tg level rising over time after thyrotropin or a high index of suspicion of metastatic disease, even in the setting of a negative or low-stage thyrotropin radioiodine scan, should prompt further evaluation such as thyroid hormone withdrawal to definitively establish the location and extent of thyroid cancer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     4. Decision to perform a thyrotropin radioiodine scan in conjunction with a thyrotropin serum Tg test and whether or when to withdraw a patient from thyroid hormones are complex. Pertinent factors in this decision include the sensitivity of the Tg assay used, the thyrotropin Tg level obtained, and the index of suspicion of recurrent or persistent local or metastatic disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     5. The signs and symptoms of hypothyroidism which accompany thyroid hormone withdrawal are avoided with thyrotropin use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     6. Clinical experience in thyroid remnant ablation with thyrotropin is limited; long-term outcome data have not been established compared to withholding thyroid hormone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     7. Thyrotropin studies for thyroid remnant ablation used I",
"     <sup>",
"      131",
"     </sup>",
"     activity of 100 mCi &plusmn; 10%; activity of I",
"     <sup>",
"      131",
"     </sup>",
"     used in clinical practice may vary; lower radioiodine doses may not be as effective.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6223312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F227383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2738770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Animal reproduction studies have not been conducted. Effects on the fetus or pregnant woman are unknown.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F2757286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F17917300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if thyrotropin alfa is excreted in breast milk. The manufacturer recommends that caution be exercised when administering thyrotropin alfa to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Thyrogen Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.1 mg (1): $1196.40",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F15159242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Neurologic adverse events (hemiplegia, hemiparesis, stroke, weakness); dyspnea, dysphonia, stridor or other symptoms of local tumor growth",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F227391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Thyrogen (AT, AU, BE, CH, CZ, DE, DK, EE, FI, FR, GR, HK, HN, IE, IL, IT, KP, MY, NL, NO, PE, PL, PT, SE, SG, TH, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F227376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Thyrotropin alfa, derived from a recombinant DNA source, has the identical amino acid sequence as endogenous human thyroid stimulating hormone (TSH). As a diagnostic tool in conjunction with serum thyroglobulin (Tg) testing, thyrotropin alfa stimulates the secretion of Tg from any remaining thyroid tissues (remnants). Under conditions of successful thyroidectomy and complete ablation, very little serum Tg should be detected under TSH stimulatory conditions; conversely, elevated Tg levels suggest the presence of remnant thyroid tissues. Since the source of TSH is exogenous, stimulation of Tg synthesis can be achieved in euthyroid patients, avoiding the need for thyroid hormone withdrawal.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     As an adjunctive agent for radioiodine ablation treatment of thyroid cancer tissue remnants, thyrotropin alfa binds to TSH receptors on these tissues, stimulating the uptake and organification of iodine, including radiolabeled iodine (I",
"     <sup>",
"      131",
"     </sup>",
"     ). Cancerous tissue is destroyed via gamma emission from the radioiodine concentrated in these tissues.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F227389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 25 &plusmn; 10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Median: 10 hours (range: 3-24 hours)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Haugen BR, Pacini F, Reiners C, et al, &ldquo;A Comparison of Recombinant Human Thyrotropin and Thyroid Hormone Withdrawal for the Detection of Thyroid Remnant or Cancer,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 1999, 94(11):3877-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/18/19749/abstract-text/10566623/pubmed\" id=\"10566623\" target=\"_blank\">",
"        10566623",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mallick U, Harmer C, Yap B, et al, &ldquo;Ablation With Low-Dose Radioiodine and Thyrotropin Alfa in Thyroid Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 366(18):1674-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/18/19749/abstract-text/22551128/pubmed\" id=\"22551128\" target=\"_blank\">",
"        22551128",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pacini F, Ladenson PW, Schlumberger M, et al, &ldquo;Radioiodine Ablation of Thyroid Remnants After Preparation With Recombinant Human Thyrotropin in Differentiated Thyroid Carcinoma: Results of an International, Randomized, Controlled Study,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2006, 91(3):926-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/18/19749/abstract-text/16384850/pubmed\" id=\"16384850\" target=\"_blank\">",
"        16384850",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schlumberger M, Catargi B, Borget I, et a, &ldquo;Strategies of Radioiodine Ablation In Patients With Low-Risk Thyroid Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 366(18):1663-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/18/19749/abstract-text/22551127/pubmed\" id=\"22551127\" target=\"_blank\">",
"        22551127",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schroeder PR, Haugen BR, Pacini F, et al, &ldquo;A Comparison of Short-Term Changes in Health-Related Quality of Life in Thyroid Carcinoma Patients Undergoing Diagnostic Evaluation With Recombinant Human Thyrotropin Compared With Thyroid Hormone Withdrawal,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2006, 91(3):878-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/18/19749/abstract-text/16394083/pubmed\" id=\"16394083\" target=\"_blank\">",
"        16394083",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10286 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-A392849A5D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_18_19749=[""].join("\n");
var outline_f19_18_19749=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227397\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227398\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227410\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227399\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227405\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227400\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15159240\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227385\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227373\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227387\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227386\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227416\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227408\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227390\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227377\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300137\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6223312\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227383\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2738770\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2757286\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F17917300\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323966\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15159242\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227391\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227376\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227389\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10286\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10286|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/43/29363?source=related_link\">",
"      Thyrotropin alfa (recombinant human thyrotropin): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_18_19750="Cortisone acetate: Patient drug information";
var content_f19_18_19750=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Cortisone acetate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39174?source=see_link\">",
"     see \"Cortisone acetate: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/33/16918?source=see_link\">",
"     see \"Cortisone acetate: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10022312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691277",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to add adrenal hormone to the body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat Addison's disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691733",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat arthritis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691735",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat asthma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691762",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat brain swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691790",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat COPD (chronic obstructive pulmonary disease).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat swelling from autoimmune diseases.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691910",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat swelling in parts of the body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691928",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat leukemia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691947",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat lymphoma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691999",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat organ transplant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat sarcoidosis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin rashes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692097",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat spinal cord injuries.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat ulcerative colitis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701866",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to cortisone acetate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701378",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a bad infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696833",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696653",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid being near anyone with chickenpox or measles.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697204",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor. This drug may raise blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your blood sugar as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697224",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma or cataracts, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are being treated for any infection, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have soft, brittle bones (osteoporosis), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697342",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have stomach ulcers, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697345",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have TB (tuberculosis), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698139",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood sugar. This most often goes back to normal when drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698236",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mood changes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697937",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in body fat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698390",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weak bones with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698255",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698341",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin changes (pimples, stretch marks, slow healing, hair growth).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697932",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cataracts or glaucoma with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698659",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired, weak, or touchy; trembling; having a fast heartbeat, confusion, sweating, or dizziness if you missed a dose or recently stopped this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698688",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been exposed to chickenpox and have not had chickenpox or had a chickenpox vaccine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695878",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take in the morning if taking once a day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with food to stop an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695745",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take calcium and vitamin D as you were told by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12341 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-65E6C3AFCD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_18_19750=[""].join("\n");
var outline_f19_18_19750=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022312\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022314\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022313\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022318\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022319\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022321\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022316\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022317\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022322\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022323\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39174?source=related_link\">",
"      Cortisone acetate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/33/16918?source=related_link\">",
"      Cortisone acetate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_18_19751="Abacavir: Pediatric drug information";
var content_f19_18_19751=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Abacavir: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"    see \"Abacavir: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?17/53/18261?source=see_link\">",
"    see \"Abacavir: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5696175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F128749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ziagen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F128750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ziagen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1050695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiretroviral Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       HIV Agents (Anti-HIV Agents)",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nucleoside Reverse Transcriptase Inhibitor (NRTI)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1050687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"      see \"Abacavir: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children, and Adolescents:",
"     <b>",
"      HIV infection, treatment:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Use in combination with other antiretroviral agents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants &lt;3 months: Not approved for use; safety, efficacy, and dosage not established",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants &ge;3 months, Children, and Adolescents &le;16 years: 8 mg/kg/dose twice daily (maximum: 300 mg twice daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Alternate dosing for patients &ge;14 kg who are able to swallow tablets (scored 300 mg tablets):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     14-21 kg: 150 mg (",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     tablet) twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &gt;21 to &lt;30 kg: 150 mg (",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     tablet) in the morning and 300 mg (1 tablet) in the evening",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ge;30 kg: 300 mg (1 tablet) twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Once-daily dosing: Not recommended in manufacturer&rsquo;s labeling; limited data exists; not recommended as",
"     <b>",
"      initial",
"     </b>",
"     dosing in pediatric patients: 16-20 mg/kg/dose once daily (maximum dose: 600 mg) has been used in clinically stable children with undetectable viral loads and stable CD4 counts while previously receiving twice-daily abacavir. Monitor viral load, CD4 counts, and clinical symptoms after switching from twice-daily to once-daily dosing (DHHS [pediatric], 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adolescents &gt;16 years: 300 mg twice daily or 600 mg once daily (DHHS [pediatric], 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"     <b>",
"      HIV infection, treatment:",
"     </b>",
"     Oral: Use in combination with other antiretroviral agents: 300 mg twice daily or 600 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, renal is a minor route of elimination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild hepatic impairment (Child-Pugh score 5-6): Adults: 200 mg twice daily (using oral solution)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderate to severe hepatic impairment (Child-Pugh score &gt;6): Use is contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F128722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ziagen&reg;: 20 mg/mL (240 mL) [contains propylene glycol; strawberry-banana flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ziagen&reg;: 300 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F128708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Tablet",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM224556.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM224556.pdf",
"     </a>",
"     , must be dispensed with this medication. A Warning Card (summarizing symptoms of hypersensitivity), which is available with the product information, must also be dispensed with this medication for each new outpatient prescription and refill.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1050699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May be administered without regard to food",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1050690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store tablets and oral solution at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Oral solution may be refrigerated; do not freeze.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1050698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of HIV-1 infection in combination with other antiretroviral agents (FDA approved in ages &ge;3 months and adults);",
"     <b>",
"      Note:",
"     </b>",
"     HIV regimens consisting of",
"     <b>",
"      three",
"     </b>",
"     antiretroviral agents are strongly recommended.",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F128781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity reactions (which may be fatal) occur in ~5% of patients. Symptoms may include abdominal pain, anaphylaxis, arthralgia, conjunctivitis, diarrhea, edema, fatigue, fever, headache, hepatic failure, lethargy, lymphadenopathy, malaise, mouth ulcerations, myalgia, myolysis, nausea, paresthesia, rash (including erythema multiforme), renal failure, respiratory symptoms (eg, adult respiratory distress syndrome, cough, dyspnea, pharyngitis, respiratory failure), vomiting.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Rates of adverse reactions were defined during combination therapy with other antiretrovirals (lamivudine and efavirenz",
"     <b>",
"      or",
"     </b>",
"     lamivudine and zidovudine). Only reactions which occurred at a higher frequency in adults (except where noted) than in the comparator group are noted. Adverse reaction rates attributable to abacavir alone are not available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Abnormal dreams, anxiety, depression, dizziness, fatigue, fever/chills, headache, malaise",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: AST increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Musculoskeletal pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity reactions, infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Erythema multiforme, hepatotoxicity, immune reconstitution syndrome, lactic acidosis, MI, pancreatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1050702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to abacavir or any component [",
"     <b>",
"      do not rechallenge",
"     </b>",
"     patients who have experienced hypersensitivity reactions to abacavir (regardless of",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     status), potentially fatal hypersensitivity reactions may occur]; moderate or severe hepatic dysfunction",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1050686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and decrease the dose in patients with mild hepatic dysfunction; use in moderate to severe hepatic dysfunction is contraindicated. Fat redistribution and accumulation [ie, central obesity, peripheral wasting, facial wasting, breast enlargement, dorsocervical fat enlargement (buffalo hump), and cushingoid appearance] have been observed in patients receiving antiretroviral agents (causal relationship not established). Always use abacavir in combination with other antiretroviral agents; do not add abacavir as a single agent to antiretroviral regimens that are failing; resistance to abacavir develops relatively slowly, but cross resistance between abacavir and other nucleoside reverse transcriptase inhibitors (NRTIs) may occur; limited response may be seen in patients with HIV isolates containing multiple mutations conferring resistance to NRTIs or in patients with a prolonged prior NRTI exposure. Use with caution in patients with plasma HIV RNA levels &ge;100,000 copies/mL as earlier virologic failure has been observed in one study (DHHS [adult], 2013).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Immune  reconstitution syndrome (an acute inflammatory response to residual or indolent opportunistic infections) may occur in HIV patients during initial treatment with combination antiretroviral agents, including abacavir; this syndrome may require further patient assessment and therapy. Autoimmune disorders (eg. Grave&rsquo;s disease, Guillain-Barr&eacute; syndrome, and polymyositis) have been reported in patients experiencing immune reconstitution; time to onset is variable and may occur many months after antiretroviral treatment is initiated.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Use has been associated with an increased risk of myocardial infarction (MI) in observational studies; however, based on a meta-analysis of 26 randomized trials, the FDA has concluded there is not an increased risk. Consider using with caution in patients with risks for coronary heart disease and minimizing modifiable risk factors (eg, hypertension, hyperlipidemia, diabetes mellitus, and smoking) prior to use.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     May cause mild hyperglycemia; more common in pediatric patients. May cause diarrhea; severe diarrhea may occur at a higher incidence in patients receiving once daily dosing.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1050685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serious and sometimes fatal hypersensitivity reactions may occur",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Patients testing positive for the presence of the",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     allele are at a significantly increased risk for hypersensitivity reactions",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Screening for",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     allele status is recommended prior to initiating therapy or reinitiating therapy in patients of unknown genotype status, including patients who previously tolerated therapy. Patients who test positive for the",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     allele should have an abacavir allergy recorded in their medical record and should",
"     <b>",
"      not",
"     </b>",
"     receive abacavir. If a suspected abacavir hypersensitivity reaction occurs during therapy, regardless of",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     status, abacavir should be discontinued immediately and permanently. Hypersensitivity reactions may also occur in patients who test negative for the",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     allele, but at a significantly lower rate.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Abacavir hypersensitivity is a multiorgan clinical syndrome",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Discontinue therapy immediately in patients who show signs or symptoms of 2 or more of the following: Fever, skin rash, respiratory symptoms (including cough, dyspnea, or pharyngitis), GI symptoms (including nausea, vomiting, diarrhea, or abdominal pain), and constitutional symptoms (including fatigue, malaise, or achiness). Carefully consider the diagnosis of hypersensitivity reaction in patients who present with acute onset respiratory symptoms, even if other diagnoses, such as bronchitis, flu-like illness, pharyngitis, or pneumonia, are possible. Permanently discontinue abacavir if hypersensitivity reaction cannot be ruled out, even when other diagnoses are possible (regardless of",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     status)",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Skin rash may be maculopapular or urticarial, but can be variable in appearance; erythema multiforme has been reported; hypersensitivity reaction may occur without a rash. Other symptoms may include edema, lethargy, myolysis, paresthesia, shortness of breath, mouth ulcerations, conjunctivitis, lymphadenopathy, and abnormal findings on chest x-ray (ie, infiltrates that can be localized). Anaphylaxis, renal failure, hepatic failure, respiratory failure, ARDS, hypotension, and death may also occur in association with hypersensitivity reactions. Laboratory abnormalities include increases in liver function tests, elevated CPK or serum creatinine, and lymphopenia.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Do not restart",
"     </b>",
"     abacavir or any other abacavir-containing product after a hypersensitivity reaction occurs",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; more severe symptoms can recur within hours and may include life-threatening hypotension and death. Fatal hypersensitivity reactions have occurred following the reintroduction of abacavir in patients whose therapy was interrupted for other reasons",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . These patients had no identified history or had unrecognized symptoms of abacavir hypersensitivity. Reactions occurred within hours. In some cases, signs of a hypersensitivity reaction may have been previously present, but attributed to other medical conditions (acute onset respiratory diseases, gastroenteritis, reactions to other medications). If abacavir or any other abacavir-containing product is to be restarted following an interruption in therapy, the patient must first be evaluated for previously unsuspected symptoms of hypersensitivity.",
"     <b>",
"      Do not restart",
"     </b>",
"     abacavir or any other abacavir-containing product, if hypersensitivity is suspected or cannot be ruled out (regardless of",
"     <i>",
"      HLA-B*570",
"     </i>",
"     1 status). Hypersensitivity reactions occur in 5% to 8% of adult and pediatric patients (actual incidence varies by race/ethnicity); most hypersensitivity reactions occur within the first 6 weeks of therapy, but can occur at any time; one study reported a higher incidence of severe hypersensitivity reactions with once daily dosing compared with twice daily dosing (see product information).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Cases of lactic acidosis, severe hepatomegaly with steatosis and death have been reported with the use of abacavir and other NRTIs",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; most of these cases have been in women; prolonged nucleoside use, obesity, and prior liver disease may be risk factors; use with extreme caution in patients with other risk factors for liver disease; discontinue abacavir in patients who develop laboratory or clinical evidence of lactic acidosis or pronounced hepatotoxicity",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F128716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ganciclovir-Valganciclovir: May enhance the adverse/toxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Hematologic toxicity is of specific concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the serum concentration of Abacavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ribavirin: May enhance the hepatotoxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Lactic acidosis may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F128718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F128732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in some animal reproduction studies. Abacavir crosses the human placenta. No increased risk of overall birth defects has been observed following first trimester exposure according to data collected by the antiretroviral pregnancy registry. Cases of lactic acidosis/hepatic steatosis syndrome related to mitochondrial toxicity have been reported in pregnant women with prolonged use of nucleoside analogues. It is not known if pregnancy itself potentiates this known side effect; however, women may be at increased risk of lactic acidosis and liver damage. In addition, these adverse events are similar to other rare but life-threatening syndromes which occur during pregnancy (eg, HELLP syndrome). Hepatic enzymes and electrolytes should be monitored in women receiving nucleoside analogues and clinicians should watch for early signs of the syndrome. In addition, mitochondrial dysfunction may develop in infants following",
"     <i>",
"      in utero",
"     </i>",
"     exposure. The pharmacokinetics of abacavir are not significantly changed by pregnancy and dose adjustment is not needed for pregnant women. The DHHS Perinatal HIV Guidelines consider abacavir to be an alternative NRTI in dual nucleoside combination regimens.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Regardless of CD4 count or HIV RNA copy number, all HIV-infected pregnant women should receive a combination antepartum antiretroviral (ARV) drug regimen; this includes women who require therapy for their own health, as well as women who do not yet require therapy for their own health. ARV therapy should be started as soon as possible if required for the woman&rsquo;s health. Although earlier initiation may be more effective in reducing the perinatal transmission of HIV, also consider maternal conditions (eg, nausea and vomiting) and the potential risks of first trimester fetal exposure for specific agents. Plasma HIV RNA levels should be assessed at ~34-36 weeks gestation in order to help determine mode of delivery. If ARV therapy must be interrupted for &lt;24 hours during the peripartum period, stop then restart all medications simultaneously in order to decrease the chance of developing resistance. Long-term follow-up is recommended for all infants exposed to ARV medications.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to enroll pregnant women exposed to antiretroviral medications in the Antiretroviral Pregnancy Registry (1-800-258-4263 or www.APRegistry.com). Healthcare providers caring for HIV-infected women and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1050694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     genotype status prior to initiating therapy or resuming therapy in patients of unknown",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     status (including patients previously tolerating therapy); signs and symptoms of hypersensitivity reaction (in all patients, but especially in those untested for the",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     allele)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Monitor CD4 percentage (if &lt;5 years of age) or CD4 count (if &ge;5 years of age) at least every 3-4 months (DHHS [pediatric], 2012).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Prior to initiation of therapy: Genotypic resistance testing, CD4, viral load, CBC with differential, LFTs, BUN, creatinine. At initiation and with any change in treatment regimen: CBC with differential, electrolytes, calcium, phosphate, glucose, LFTs, bilirubin, BUN, creatinine, albumin, total protein, lipid panel, CD4, and viral load. After 4-8 weeks of therapy: CBC with differential, viral load; then every 3-4 months: CBC with differential, electrolytes, glucose, LFTs, bilirubin, BUN, creatinine, CD4, and viral load. Albumin, total protein, calcium, phosphate, lipid panel, and urinalysis every 6-12 months (DHHS [pediatric], 2012).  Monitor for signs of opportunistic infections or lactic acidosis; serum creatine kinase.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1050684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A carbocyclic analogue that is converted within cells to the active metabolite carbovir triphosphate; carbovir triphosphate serves as an alternative substrate to deoxyguanosine-5'-triphosphate (dGTP), a natural substrate for cellular DNA polymerase and reverse transcriptase; carbovir triphosphate inhibits HIV viral reverse transcriptase by competing with natural dGTP and by becoming incorporated into viral DNA causing chain termination. Abacavir is also a weak inhibitor of cellular DNA polymerases (alpha, beta, and gamma).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1050701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and extensive",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Apparent V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.86 &plusmn; 0.15 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CSF to plasma AUC ratio: 27% to 33%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via alcohol dehydrogenase and glucuronyl transferase to inactive carboxylate and glucuronide metabolites; not significantly metabolized by cytochrome P450 enzymes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Tablet: 83%; solution and tablet provide comparable AUCs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, elimination (serum):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pediatric patients &ge;3 months to &le;13 years: 1-1.5 hours (Hughes, 1999; Kline, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 1.54 &plusmn; 0.63 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic impairment (mild): Increases half-life by 58%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, intracellular: 12-26 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration (Hughes, 1999):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pediatric patients &ge;3 months to &le;13 years: Within 1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 1-1.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine: &sim;83% (1.2% as unchanged drug, 30% as 5'-carboxylic acid metabolite, 36% as the glucuronide, and 15% as other metabolites); feces (16% total dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance (apparent): Single dose 8 mg/kg (Hughes, 1999):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pediatric patients &ge;3 months to &le;13 years: 17.84 mL/minute/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 10.14 mL/minute/kg",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1050692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/53/18261?source=see_link\">",
"      see \"Abacavir: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Abacavir is not a cure for HIV. Take abacavir everyday as prescribed; do not change dose or discontinue without physician's advice. If abacavir is stopped for any reason, notify physician before restarting therapy. If a dose is missed, take it as soon as possible, then return to normal dosing schedule; if a dose is skipped, do",
"     <b>",
"      not",
"     </b>",
"     double the next dose",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Serious and sometimes fatal allergic reactions may occur. Read the patient Medication Guide received with each prescription and refill of abacavir; carry the Warning Card. Stop taking abacavir and notify physician immediately if 2 or more of the following sets of symptoms occur: Fever, rash, GI symptoms (nausea, vomiting, diarrhea or abdominal pain), flu-like symptoms (severe tiredness, achiness, or generally ill feeling), or respiratory symptoms (sore throat, shortness of breath, cough). If an allergic (hypersensitivity) reaction to abacavir (or Ziagen&reg;, Trizivir&reg;, or Epzicom&reg;) is experienced,",
"     <b>",
"      never",
"     </b>",
"     take abacavir, Ziagen&reg;, Trizivir&reg;, or Epzicom&reg; again. Taking an abacavir-containing medication after having an allergic reaction, may result in life-threatening symptoms including very low blood pressure or death within hours.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     HIV medications may cause changes in body fat, including an increase in fat in the upper back and neck, breasts, and trunk; a loss of fat from the face, arms, and legs may also occur. Some HIV medications (including abacavir) may cause a serious, but rare, condition called lactic acidosis with an increase in liver size (hepatomegaly). Before starting abacavir, review medical conditions, including any liver or heart problems, smoking status, diabetes, high cholesterol, or high blood pressure. Do not take Ziagen&reg; with other abacavir-containing medications (eg, Epzicom&reg; or Trizivir&reg;).",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1050703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The patient Medication Guide, which includes written manufacturer information, should be dispensed to the patient with each new prescription and refill; the Warning Card describing the hypersensitivity reaction should be given to the patient to carry with them.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The development of the abacavir hypersensitivity reaction has been associated with certain HLA genotypes (eg,",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     ,",
"     <i>",
"      HLA-DR7",
"     </i>",
"     ,",
"     <i>",
"      HLA-DQ3",
"     </i>",
"     ) which may help predict which patients are at risk for developing the abacavir hypersensitivity reaction (Hetherington, 2002; Lucas, 2007; Mallal, 2002). Patients who test positive for the",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     allele should have an abacavir allergy recorded in their medical record and should",
"     <b>",
"      not",
"     </b>",
"     receive abacavir. All patients who receive abacavir (and their caregivers) should be educated about the risk of abacavir hypersensitivity reactions (including patients who test negative for the",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     allele, as the risk for the reaction is not completely eliminated). Approximately 4% of patients who test negative for the",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     allele will experience a clinically suspected abacavir hypersensitivity reaction compared to 61% of those who test positive for the",
"     <i>",
"      HLA-B*570",
"     </i>",
"     1 allele.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     The prevalence of",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     in the United States has been estimated to be 8% in Caucasians, 2.5% in African-Americans, 2% in Hispanics, 1% in Asians; in the sub-Saharan Africa it is &lt;1%. Pretherapy identification of",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     -positive patients and subsequent avoidance of abacavir therapy in these patients has been shown to significantly reduce the occurrence of abacavir-associated hypersensitivity reactions. A skin patch test is in development for clinical screening purposes; however, only PCR-mediated genotyping methods are currently in clinical practice use for documentation of this susceptibility marker. A familial predisposition to the abacavir hypersensitivity reaction has also been reported; use abacavir with great caution in children of parents who experience a hypersensitivity reaction to abacavir (Peyri&eacute;re, 2001).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Reverse transcriptase mutations of K65R, L74V, Y115F, and M184V have been associated with abacavir resistance; at least 2-3 mutations are needed to decrease HIV susceptibility by 10-fold. The presence of a multiple number of these abacavir resistance-associated mutations, may confer cross-resistance for other nucleoside or nucleotide reverse transcriptase inhibitors (eg, didanosine, emtricitabine, lamivudine, zalcitabine, or tenofovir). A progressive decrease in abacavir susceptibility is associated with an increasing number of thymidine analogue mutations (TAMs; M41L, D67N, K70R, L210W, T215Y/F, K219E/R/H/Q/N).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     A high rate of early virologic failure in therapy-naive adult HIV patients has been observed with the once daily three-drug combination therapy of abacavir, lamivudine, and tenofovir. This combination should not be used as a new treatment regimen for naive or pretreated patients. Any patient currently receiving this regimen should be closely monitored and considered for regimen modification (DHHS [adult], 2013).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aberg JA, Kaplan JE, Libman H, et al, \"Primary Care Guidelines for the Management of Persons Infected With Human Immunodeficiency Virus: 2009 Update by the HIV Medicine Association of the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2009, 49(5):651-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/18/19751/abstract-text/19640227/pubmed\" id=\"19640227\" target=\"_blank\">",
"        19640227",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, \"Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents,\" February 12, 2013. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children, \"Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection,\" November 5, 2012. Available at",
"      <a href=\"file://aidsinfo.nih.gov\" target=\"_blank\">",
"       file://aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, \"Recommendations for the Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States,\" July 31, 2012. Available at",
"      <a href=\"file://aidsinfo.nih.gov\" target=\"_blank\">",
"       file://aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Foster RH and Faulds D, \"Abacavir,\"",
"      <i>",
"       Drugs,",
"      </i>",
"      1998, 55(5):729-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/18/19751/abstract-text/9585869/pubmed\" id=\"9585869\" target=\"_blank\">",
"        9585869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hetherington S, Hughes AR, Mosteller M, et al, \"Genetic Variations in HLA-B Region and Hypersensitivity Reactions to Abacavir,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 359(9312):1121-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/18/19751/abstract-text/11943262 /pubmed\" id=\"11943262 \" target=\"_blank\">",
"        11943262",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hughes W, McDowell JA, Shenep J, et al, \"Safety and Single-Dose Pharmacokinetics of Abacavir (1592U89) in Human Immunodeficiency Virus Type 1-Infected Children,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1999, 43(3):609-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/18/19751/abstract-text/10049275/pubmed\" id=\"10049275\" target=\"_blank\">",
"        10049275",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kline MW, Blanchard S, Fletcher CV, et al, \"A Phase I Study of Abacavir (1592U89) Alone and in Combination With Other Antiretroviral Agents in Infants and Children With Human Immunodeficiency Virus Infection,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1999, 103(4):e47. Available at file://www.pediatrics.org/cgi/content/full/103/4/e47",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/18/19751/abstract-text/10103339/pubmed\" id=\"10103339\" target=\"_blank\">",
"        10103339",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lucas A, Nolan D, and Mallal S, \"HLA-B*5701 Screening for Susceptibility to Abacavir Hypersensitivity,\"",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 2007, 59(4):591-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/18/19751/abstract-text/17317695/pubmed\" id=\"17317695\" target=\"_blank\">",
"        17317695",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mallal S, Nolan D, Witt C, et al, \"Association Between Presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and Hypersensitivity to HIV-1 Reverse-Transcriptase Inhibitor Abacavir,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 359(9308):727-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/18/19751/abstract-text/11888582/pubmed\" id=\"11888582\" target=\"_blank\">",
"        11888582",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Paediatric European Network for Treatment of AIDS (PENTA), \"Comparison of Dual Nucleoside-Analogue Reverse-Transcriptase Inhibitor Regimens With and Without Nelfinavir in Children with HIV-1 Who Have Not Previously Been Treated: The PENTA 5 Randomised Trial,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 359(9308):733-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/18/19751/abstract-text/11888583 /pubmed\" id=\"11888583 \" target=\"_blank\">",
"        11888583",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Peyri&eacute;re H, Nicolas J, Siffert M, et al, \"Hypersensitivity Related to Abacavir in Two Members of a Family,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2001, 35(10):1291-2.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13176 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-AD134220F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_18_19751=[""].join("\n");
var outline_f19_18_19751=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5696175\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128749\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128750\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050695\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050687\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128722\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128708\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874271\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050699\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050690\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050698\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128781\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050702\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050686\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050685\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298624\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128716\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128718\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128732\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050694\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050684\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050701\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050692\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050703\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13176\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13176|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=related_link\">",
"      Abacavir: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/53/18261?source=related_link\">",
"      Abacavir: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_18_19752="Venlafaxine: Pediatric drug information";
var content_f19_18_19752=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Venlafaxine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"    see \"Venlafaxine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?19/43/20150?source=see_link\">",
"    see \"Venlafaxine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5710003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F233762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Effexor XR&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F233763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      CO Venlafaxine XR;",
"     </li>",
"     <li>",
"      Effexor XR&reg;;",
"     </li>",
"     <li>",
"      GD-Venlafaxine XR;",
"     </li>",
"     <li>",
"      Mylan-Venlafaxine XR;",
"     </li>",
"     <li>",
"      PMS-Venlafaxine XR;",
"     </li>",
"     <li>",
"      Ran-Venlafaxine XR;",
"     </li>",
"     <li>",
"      ratio-Venlafaxine XR;",
"     </li>",
"     <li>",
"      Riva-Venlafaxine XR;",
"     </li>",
"     <li>",
"      Sandoz-Venlafaxine XR;",
"     </li>",
"     <li>",
"      Teva-Venlafaxine XR;",
"     </li>",
"     <li>",
"      Venlafaxine XR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1055989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidepressant, Serotonin/Norepinephrine Reuptake Inhibitor",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1055981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"      see \"Venlafaxine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children and Adolescents: Note: Not FDA approved. Limited information is available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ADHD: One open-label clinical trial and one case report are available; 16 children and adolescents (8-16 years of age; mean: 11.6 &plusmn; 2.3 years) were enrolled in a 5-week open trial of venlafaxine; doses were initiated at 12.5 mg/day for the first week; for children &lt;40 kg, the daily dose was increased (if tolerated) by 12.5 mg each week to a maximum of 50 mg/day divided in 2 doses; for patients &ge;40 kg, the daily dose was increased (if tolerated) by 25 mg each week to a maximum of 75 mg/day divided in 3 doses; mean dose: 60 mg/day (1.4 mg/kg/day) in 2-3 divided doses; 10 patients completed the study [2 were lost to follow-up; 5 discontinued therapy due to adverse effects (4 had an increase in hyperactivity; 1 had severe nausea)]; venlafaxine decreased behavioral symptoms (but not cognitive symptoms) in 7 of 16 subjects (44%) (Olvera, 1996). An initial dose of 37.5 mg given 3 times/day was used in an 11-year-old female with ADHD; the dose was slowly titrated to 100 mg given 3 times/day; after 6 weeks the patient showed moderate to marked improvement in symptoms, but developed hypertension; the dose was then decreased to 75 mg given 3 times/day with normalization of blood pressure (Pleak, 1995). Further studies are needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Autism: One retrospective report is available; 10 patients (3-21 years of age; mean 10.5 &plusmn; 5.6 years) with autism spectrum disorders (autism, Asperger's syndrome, and pervasive developmental disorders not otherwise specified) received initial doses of 12.5 mg/day administered once daily at breakfast; doses were gradually titrated based on clinical response and side effects; mean final dose: 24.4 mg/day; range: 6.25-50 mg/day; 6 of the 10 patients were sustained-treatment responders (Hollander, 2000). Further studies are needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Depression:",
"     <b>",
"      Note:",
"     </b>",
"     Due to the lack of demonstrated efficacy and concerns about an increased risk for suicidal behavior, venlafaxine should be reserved for pediatric patients with major depression who do not respond to fluoxetine or sertraline (Dopheide, 2006).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     One double-blind, placebo-controlled, 6-week study is available; 33 children and adolescents (8-17 years of age) with major depression completed the trial (16 received venlafaxine;",
"     <b>",
"      Note:",
"     </b>",
"     One patient who did not complete the study, discontinued venlafaxine due to development of a manic episode requiring hospitalization and lithium therapy); immediate release venlafaxine was used; for children 8-12 years, doses were initiated at 12.5 mg once daily for 3 days, then increased to 12.5 mg twice daily for 3 days, then increased to 12.5 mg given 3 times/day for the rest of the study; for adolescents 13-17 years, doses were initiated at 25 mg once daily for 3 days, then increased to 25 mg twice daily for 3 days, then increased to 25 mg given 3 times/day for the rest of the study; both venlafaxine and placebo patients improved over time; however, no significant difference in symptoms was noted between groups (ie, venlafaxine did not have a significant effect on symptoms or specific behaviors); the authors suggest this lack of efficacy may be due to the low doses used and short duration of treatment (Mandoki, 1997).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     A large multicenter double-blind, placebo-controlled study of venlafaxine-ER in children and adolescents 7-17 years of age with major depression is ongoing; this study is using higher doses; initial: 37.5 mg/day for 1 week; with increases to 75 mg/day for weeks 2-8; results are not yet available (Weller, 2000). One report of two 16-year-old patients used higher doses of venlafaxine (final doses: 112.5 mg/day and 150 mg/day) in combination with lithium to successfully treat major depression (Walter, 1998). Further studies are needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release: Depression: Initial: 75 mg/day in 2-3 divided doses; dose may be increased (if needed) by increments of up to 75 mg/day at intervals of &ge;4 days as tolerated, up to 225 mg/day.",
"     <b>",
"      Note:",
"     </b>",
"     Doses &gt;225 mg/day for outpatients (moderately depressed patients) were not more effective; more severely depressed patients may require 350 mg/day; maximum: 375 mg/day in 3 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Depression: Initial: Usual: 75 mg/day; may start with 37.5 mg/day for 4-7 days to allow patient to adjust to medication, then increase to 75 mg/day; dose may be increased (if needed) by increments of up to 75 mg/day at intervals of &ge;4 days as tolerated, up to a maximum of 225 mg/day.",
"     <b>",
"      Note:",
"     </b>",
"     Although higher doses of the immediate release tablets have been used in more severely depressed inpatients (see above), experience with extended release capsule in doses &gt;225 mg/day is very limited.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Generalized anxiety disorder and social anxiety disorder: 75 mg/day; may start with 37.5 mg/day for 4-7 days to allow patient to adjust to medication, then increase to 75 mg/day.",
"     <b>",
"      Note:",
"     </b>",
"     Although a dose-response relationship has not been clearly established, certain patients may benefit from doses &gt;75 mg/day; dose may be increased (if needed) by increments of up to 75 mg/day at intervals of &ge;4 days as tolerated, up to a maximum of 225 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Panic disorder: Initial: 37.5 mg once daily for 7 days; may increase to 75 mg daily; dose may be increased further (if needed) by increments of up to75 mg/day at intervals of &ge;7 days; maximum dose: 225 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Adults: GFR 10-70 mL/minute: Decrease total daily dose by 25% to 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in patients on dialysis:",
"     </b>",
"     Decrease total daily dose by 50%; withhold dose until completion of dialysis treatment; further individualization of dose may be needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Moderate hepatic impairment: Decrease total daily dose by 50%; further individualization of dose may be needed",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F233734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, oral: 37.5 mg, 75 mg, 150 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Effexor XR&reg;: 37.5 mg, 75 mg, 150 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 25 mg, 37.5 mg, 50 mg, 75 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral: 37.5 mg, 75 mg, 150 mg, 225 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F233719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088586.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088586.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1055993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Immediate release tablet: Administer with food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Extended release capsule: Administer with food once daily at about the same time each day; swallow whole with fluid; do not crush, chew, divide, or place in water; capsule may be opened and entire contents sprinkled on spoonful of applesauce; swallow drug/food mixture immediately. Do not store for future use; do not chew contents (ie, pellets) of capsule; follow drug/food mixture with water to ensure complete swallowing of pellets.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1055984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tablets and capsules: Store at controlled room temperature, 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); Effexor XR&reg; 37.5 mg capsules: Protect from light and dispense in light resistant container",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1055992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of major depressive disorder, generalized anxiety disorder, social anxiety disorder (social phobia), and panic disorder (all indications: FDA approved in adults); has also been used to treat ADHD and autism in children and obsessive-compulsive disorder and chronic fatigue syndrome in adults",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7914389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Effexor&reg; may be confused with Effexor XR&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F233808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain, edema, hypertension, orthostatic hypotension, tachycardia, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Abnormal dreams, abnormal thinking, agitation, amnesia, anxiety, chills, confusion, depression, depersonalization, dizziness, fever, headache, hypoesthesia, insomnia, migraine, nervousness, somnolence, vertigo, yawning",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Bruising, pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Libido decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, appetite increased, belching, constipation, diarrhea, dyspepsia, flatulence, nausea, taste perversion, weight gain/loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Abnormal ejaculation/orgasm, impotence, metrorrhagia, prostatic disorder, urinary frequency, urinary impairment, urinary retention, vaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, hypertonia, neck pain, paresthesia, tremor, trismus, twitching, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Abnormal or blurred vision, accommodation abnormal, mydriasis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Albuminuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchitis, cough increased, dyspnea, pharyngitis, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, flu-like syndrome, infection, trauma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Agranulocytosis, anaphylaxis, anemia, aneurysm, angina pectoris, angioedema, anuria, aplastic anemia, appendicitis, arrhythmia (including atrial and ventricular tachycardia, fibrillation, and torsade de pointes), arteritis, asthma, ataxia, atelectasis, atrioventricular block, bacteremia, balance/coordination impaired, basophilia, bigeminy, biliary pain, bilirubinemia, bleeding time increased, bradycardia, bradykinesia, BUN increased, bundle branch block, carcinoma, cardiac arrest, cardiovascular disorder (mitral valve and circulatory disturbance), cataract, catatonia, cellulitis, cerebral ischemia, cholelithiasis, congestive heart failure, coronary artery disease, CPK increased, creatinine increased, crystalluria, cyanosis, deafness, DVT, dehydration, delusions, dementia, diabetes mellitus, dystonia, ECG abnormalities (including QT prolongation), embolus, eosinophilia, erythema multiforme, exfoliative dermatitis, extrapyramidal symptoms, extrasystoles, facial paralysis, fasciitis, fatty liver, gastrointestinal ulcer, glaucoma, glycosuria, granuloma, Guillain-Barr&eacute; syndrome, hematemesis, hematoma, hemorrhage (eye, GI, mucocutaneous, rectal), hepatic necrosis, hepatic failure, hepatitis, homicidal ideation, hostility, hyperacusis, hypercalcinuria, hyperchlorhydria, hyper-/hypoglycemia, hyper-/hypokalemia, hyper-/hypophosphatemia, hyper-/hypothyroidism, hyperuricemia, hypocholesteremia, hyponatremia, hypoproteinemia, hypotension, interstitial lung disease (including eosinophilic pneumonia), intestinal obstruction, jaundice, kidney function abnormal, larynx edema, leukocytosis, leukoderma, leukopenia, liver enzymes increased, loss of consciousness, lymphadenopathy, lymphocytosis, maculopapular rash, menstrual abnormalities, MI, miliaria, moniliasis, multiple myeloma, myasthenia, myoclonus, myopathy, neck rigidity, neuroleptic malignant-like syndrome, neuropathy, neutropenia, osteoporosis, pancreatitis, pancytopenia, peripheral vascular disorder, pleurisy, pneumonia, pyelonephritis, pyuria, renal failure, rhabdomyolysis, rheumatoid arthritis, seizure, serotonin syndrome, SIADH, skin atrophy, Stevens-Johnson syndrome, suicidal ideation, suicide attempt, syncope, tendon rupture, thrombocythemia, thrombocytopenia, tongue edema, toxic epidermal necrolysis, withdrawal syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1055996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to venlafaxine or any component; use of MAO inhibitors within 14 days (potentially fatal reactions may occur); do not initiate MAO inhibitor within 7 days of discontinuing venlafaxine",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1055980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution; decrease the dose in patients with renal or hepatic impairment or concomitant diseases that may affect hepatic metabolism. Use with caution in patients with seizure disorders; seizures have been reported; discontinue if seizures occur. Use with caution in patients receiving diuretics or those who are volume-depleted; may cause hyponatremia or SIADH. May cause mydriasis; use with caution and closely monitor patients with increased IOP or those at risk of acute narrow-angle glaucoma. May cause anxiety, nervousness, and insomnia. In children treated for ADHD, an increase in hyperactivity (behavioral activation) was reported (Olvera, 1996). Use with caution in patients with a history of mania; may activate mania or hypomania.  Use with caution  in suicidal patients, children, or during breast-feeding in lactating women.  Use with caution during late third trimester of pregnancy; newborns may experience adverse effects or venlafaxine withdrawal symptoms; consider risks and benefits.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause anorexia and significant, dose-related weight loss; use with caution in patients where weight loss is undesirable; may adversely affect weight and height in children; monitor closely in pediatric patients; weight loss in pediatric patients was not limited to those with venlafaxine-associated anorexia; reduction in growth rate, as assessed by height, was greater in children &lt;12 years of age than in adolescents.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution in patients with diseases that may affect hemodynamic responses (eg, unstable cardiac disease, recent MI); dose-related increases in systolic and diastolic blood pressure have been documented; monitor blood pressure regularly, and if sustained increases noted, consider dose reduction or discontinuation. May cause abnormal bleeding (eg, ecchymosis); use with caution in patients with abnormal platelet function. A case of priapism has been reported in an adolescent patient (Samuel, 2000). May cause tachycardia; mean increases of 4 bpm and 8.5 bpm have been reported; use with caution in patients with underlying medical conditions (eg, recent MI, heart failure, hyperthyroidism) that may worsen with tachycardia, especially at doses &gt;200 mg/day in adults. In adult studies of depression, Effexor XR&reg; was associated with an increase in QT",
"     <sub>",
"      c",
"     </sub>",
"     interval of 4.7 msec from baseline (versus a 1.9 msec decrease for placebo); clinical significance of this effect is not known.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1055979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clinical worsening of depression or suicidal ideation and behavior may occur in children and adults with major depressive disorder",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . In clinical trials, antidepressants increased the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (18-24 years of age) with major depressive disorder and other psychiatric disorders. This risk must be considered before prescribing antidepressants for any clinical use. Short-term studies did",
"     <b>",
"      not",
"     </b>",
"     show an increased risk of suicidality with antidepressant use in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients of all ages who are treated with antidepressants for any indication require appropriate monitoring and close observation for clinical worsening of depression, suicidality, and unusual changes in behavior, especially during the first few months after antidepressant initiation or when the dose is adjusted. Family members and caregivers should be instructed to closely observe the patient (ie, daily) and communicate condition with healthcare provider. Patients should also be monitored for associated behaviors (eg, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, mania) which may increase the risk for worsening depression or suicidality. Worsening depression or emergence of suicidality (or associated behaviors listed above) that is abrupt in onset, severe, or not part of the presenting symptoms, may require discontinuation or modification of drug therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Avoid abrupt discontinuation; discontinuation symptoms (including agitation, dysphoria, anxiety, confusion, dizziness, hypomania, nightmares, and other symptoms) may occur if therapy is abruptly discontinued or dose reduced; risk of discontinuation symptoms may be increased at higher doses and with longer duration of therapy; to discontinue therapy in patients receiving venlafaxine for &gt;1 week, taper the dose to minimize risks of discontinuation symptoms; to discontinue therapy in patients receiving venlafaxine for &ge;6 weeks, taper the dose gradually over at least 2 weeks;",
"     <b>",
"      Note:",
"     </b>",
"     Clinical trials of Effexor XR&reg; tapered the daily dose slowly at 1 week intervals by increments of 75 mg; if intolerable symptoms occur following a decrease in dosage or upon discontinuation of therapy, consider resuming the previous dose with a more gradual taper. To reduce risk of intentional overdose, write prescriptions for the smallest quantity consistent with good patient care.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Screen individuals for bipolar disorder prior to treatment (using antidepressants alone may induce manic episodes in patients with this condition). Venlafaxine may cause sustained increase in blood pressure (dose dependent; monitor blood pressure; dose reduction or discontinuation may be needed). Serotonin syndrome or other serious adverse reactions may occur when venlafaxine is used in combination with serotonergic drugs (eg, triptans) or drugs that impair the metabolism of serotonin (eg, MAO inhibitors).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F233795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (major), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2B6 (weak), CYP2D6 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F233728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the adverse/toxic effect of Serotonin/Norepinephrine Reuptake Inhibitors. Specifically, risks of psychomotor impairment may be enhanced. Alcohol (Ethyl) may enhance the hepatotoxic effect of Serotonin/Norepinephrine Reuptake Inhibitors. Particularly duloxetine and milnacipran. Management: Patients receiving serotonin/norepinephrine reuptake inhibitors (SNRIs) should be advised to avoid alcohol.  Monitor for increased psychomotor impairment and hepatotoxicity in patients who consume alcohol during treatment with SNRIs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Serotonin/Norepinephrine Reuptake Inhibitors may enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: Serotonin/Norepinephrine Reuptake Inhibitors may diminish the antihypertensive effect of Alpha2-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aspirin: Serotonin/Norepinephrine Reuptake Inhibitors may enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: Venlafaxine may decrease the serum concentration of Indinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Serotonin/Norepinephrine Reuptake Inhibitors may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ioflupane I 123: Serotonin/Norepinephrine Reuptake Inhibitors may diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: Serotonin/Norepinephrine Reuptake Inhibitors may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Venlafaxine. Specifically, the risk of serotonin syndrome may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Serotonin/Norepinephrine Reuptake Inhibitors may enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of Venlafaxine. Management: Monitor for increased venlafaxine levels/adverse effects (e.g., hallucinations, agitation, confusion) with propafenone initiation/dose increase. Conversely, monitor for decreased venlafaxine levels with profapenone discontinuation/dose decrease.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraZODone: Venlafaxine may enhance the serotonergic effect of TraZODone. This could result in serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Venlafaxine may enhance the adverse/toxic effect of Vitamin K Antagonists. Specifically, the risk for bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May enhance the adverse/toxic effect of Venlafaxine. Voriconazole may increase the serum concentration of Venlafaxine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1055999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food does not affect bioavailability of venlafaxine or ODV (active metabolite); tryptophan supplements may increase serious side effects; its use is",
"     <b>",
"      not recommended",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F233729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F233745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in some animal reproduction studies. Venlafaxine and its active metabolite ODV cross the human placenta. An increased risk of teratogenic effects following venlafaxine exposure during pregnancy has not been observed, based on available data. The risk of spontaneous abortion may be increased. Neonatal seizures and neonatal abstinence syndrome have been noted in case reports following maternal use of venlafaxine during pregnancy. Nonteratogenic effects in the newborn following SSRI/SNRI exposure late in the third trimester include respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hyper- or hypotonia, hyper-reflexia, jitteriness, irritability, constant crying, and tremor. Symptoms may be due to the toxicity of the SNRI or a discontinuation syndrome and may be consistent with serotonin syndrome associated with treatment. The long-term effects of",
"     <i>",
"      in utero",
"     </i>",
"     SNRI/SSRI exposure on infant development and behavior are not known.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Due to pregnancy-induced physiologic changes, some pharmacokinetic parameters of venlafaxine may be altered. Women should be monitored for decreased efficacy. The ACOG recommends that therapy with SSRIs or SNRIs during pregnancy be individualized; treatment of depression during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary healthcare provider, and pediatrician. According to the American Psychiatric Association (APA), the risks of medication treatment should be weighed against other treatment options and untreated depression. For women who discontinue antidepressant medications during pregnancy and who may be at high risk for postpartum depression, the medications can be restarted following delivery. Treatment algorithms have been developed by the ACOG and the APA for the management of depression in women prior to conception and during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1055988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor blood pressure regularly, especially in patients with high baseline blood pressure; monitor renal and hepatic function (for possible dose reductions), heart rate, weight, height, serum cholesterol and sodium. Monitor patient periodically for symptom resolution; monitor for worsening depression, suicidality, and associated behaviors (especially at the beginning of therapy or when doses are increased or decreased)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1055978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Venlafaxine and o-desmethylvenlafaxine (ODV) are potent inhibitors of CNS neuronal serotonin and norepinephrine reuptake and weak inhibitors of dopamine reuptake; venlafaxine and ODV do not significantly bind to alpha-adrenergic, histamine, or muscarinic cholinergic receptors (may therefore be useful in patients at risk from sedation, hypotension and anticholinergic effects of tricyclic antidepressants); venlafaxine and ODV do not inhibit monoamine oxidase",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1055995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: &ge;92%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Distributes into breast milk; breast milk to plasma ratio: Venlafaxine: 2.8-4.8 (mean: 4.1); ODV: 2.8-3.8 (mean: 3.1) (Ilett, 1998)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mean V",
"     <sub>",
"      d",
"     </sub>",
"     (apparent): Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Venlafaxine: 7.5 &plusmn; 3.7 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     ODV: 5.7 &plusmn; 1.8 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Venlafaxine: 27%; ODV: 30%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive in the liver, primarily via cytochrome P450 CYP2D6 to o-desmethylvenlafaxine (ODV; active metabolite); also metabolized to N-desmethylvenlafaxine, N,O-desmethylvenlafaxine, and other minor metabolites.",
"     <b>",
"      Note:",
"     </b>",
"     Clinically important differences between CYP2D6 poor and extensive metabolizers is not expected (sum of venlafaxine and ODV serum concentrations is similar in poor and extensive metabolizers; ODV is approximately equal in activity and potency to venlafaxine)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 45%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Venlafaxine: 5 &plusmn; 2 hours; ODV: 11 &plusmn; 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults with cirrhosis: Venlafaxine: Half-life prolonged by &sim;30%; ODV: Half-life prolonged by &sim;60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults with renal impairment (GFR: 10-70 mL/minute): Venlafaxine: Half-life prolonged by &sim;50%; ODV: Half-life prolonged by &sim;40%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults on dialysis: Venlafaxine: Half-life prolonged by &sim;180%; ODV: Half-life prolonged by 142%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release: Venlafaxine: 2 hours; ODV: 3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release: Venlafaxine: 5.5 hours; ODV: 9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: &sim;87% of dose is excreted in urine within 48 hours; 5% as unchanged drug, 29% as unconjugated ODV, 26% as conjugated ODV, and 27% as other minor metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults with cirrhosis: Venlafaxine: Clearance is decreased by &sim;50%; ODV: Clearance is decreased by &sim;30%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults with more severe cirrhosis: Venlafaxine: Clearance is decreased by &sim;90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults with renal impairment (GFR: 10-70 mL/minute): Venlafaxine: Clearance is decreased by &sim;24%; ODV: Clearance unchanged versus normal subjects",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults on dialysis: Venlafaxine: Clearance decreased by &sim;57%; ODV: Clearance decreased by &sim;56%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not likely to significantly remove drug due to large volume of distribution",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1055986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/43/20150?source=see_link\">",
"      see \"Venlafaxine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Read the Patient Medication Guide that you receive with each prescription and refill of venlafaxine. An increased risk of suicidal thinking and behavior has been reported with the use of antidepressants in children, adolescents, and young adults (18-24 years of age). Notify physician if you feel more depressed, have thoughts of suicide, or become more agitated or irritable. May cause dizziness or drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth; report the use of other medications, nonprescription medications, and herbal or natural products to your physician and pharmacist; avoid alcohol, tryptophan supplements, and the herbal medicine, St John's wort; report skin rashes, hives, or allergic reactions to your physician. Take as directed; do not alter dose or frequency without consulting prescriber, avoid abrupt discontinuation.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1055997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Drug release from extended release capsules is not pH dependent (it is controlled by diffusion through the coating membrane on the spheroids); patients with depression who are receiving immediate release tablets may be switched to Effexor XR&reg; using the nearest mg/day equivalent dose (dosing may need further individualization)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Long-term usefulness of venlafaxine should be periodically re-evaluated in patients receiving the drug for extended periods of time. Neonates born to women receiving venlafaxine, other SNRIs (serotonin and norepinephrine reuptake inhibitors), and SSRIs late during the third trimester may experience respiratory distress, apnea, cyanosis, temperature instability, vomiting, feeding difficulty, hypoglycemia, constant crying, irritability, hypotonia, hypertonia, hyper-reflexia, tremor, jitteriness, and seizures; these symptoms may be due to a direct toxic effect, withdrawal syndrome, or (in some cases) serotonin syndrome. Withdrawal symptoms occur in 30% of neonates exposed to SSRIs and SNRIs",
"     <i>",
"      in utero",
"     </i>",
"     ; monitor newborns for at least 48 hours after birth; long-term effects of",
"     <i>",
"      in utero",
"     </i>",
"     exposure to SSRIs and SNRIs are unknown (Levinson-Castiel, 2006).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Dopheide JA, \"Recognizing and Treating Depression in Children and Adolescents,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2006, 63(3):233-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/18/19752/abstract-text/16434782/pubmed\" id=\"16434782\" target=\"_blank\">",
"        16434782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Emslie GJ, Yeung PP, and Kunz NR, \"Long-Term, Open-Label Venlafaxine Extended-Release Treatment in Children and Adolescents With Major Depressive Disorder,\"",
"      <i>",
"       CNS Spectr",
"      </i>",
"      , 2007, 12(3):223-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/18/19752/abstract-text/17329983/pubmed\" id=\"17329983\" target=\"_blank\">",
"        17329983",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hollander E, Kaplan A, Cartwright C, et al, &ldquo;Venlafaxine in Children, Adolescents, and Young Adults With Autism Spectrum Disorders: An Open Retrospective Clinical Report,&rdquo;",
"      <i>",
"       J Child Neurol",
"      </i>",
"      , 2000, 15(2):132-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/18/19752/abstract-text/10695900 /pubmed\" id=\"10695900 \" target=\"_blank\">",
"        10695900",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ilett KF, Hackett LP, Dusci LJ, et al, &ldquo;Distribution and Excretion of Venlafaxine and O-Desmethylvenlafaxine in Human Milk,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1998, 45(5):459-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/18/19752/abstract-text/9643618 /pubmed\" id=\"9643618 \" target=\"_blank\">",
"        9643618",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lessard E, Yessine MA, Hamelin BA, et al, &ldquo;Diphenhydramine Alters the Disposition of Venlafaxine Through Inhibition of CYP2D6 Activity in Humans,&rdquo;",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 2001, 21(2):175-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/18/19752/abstract-text/11270914/pubmed\" id=\"11270914\" target=\"_blank\">",
"        11270914",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levinson-Castiel R, Merlob P, Linder N, et al, \"Neonatal Abstinence Syndrome After",
"      <i>",
"       in utero",
"      </i>",
"      Exposure to Selective Serotonin Reuptake Inhibitors in Term Infants,\"",
"      <i>",
"       Arch Pediatr Adolesc Med",
"      </i>",
"      , 2006, 160(2):173-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/18/19752/abstract-text/16461873/pubmed\" id=\"16461873\" target=\"_blank\">",
"        16461873",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mandoki MW, Tapia MR, Tapia MA, et al, &ldquo;Venlafaxine in the Treatment of Children and Adolescents With Major Depression,&rdquo;",
"      <i>",
"       Psychopharmacol Bull",
"      </i>",
"      , 1997, 33(1):149-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/18/19752/abstract-text/9133767/pubmed\" id=\"9133767\" target=\"_blank\">",
"        9133767",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Olvera RL, Pliszka SR, Luh J, et al, &ldquo;An Open Trial of Venlafaxine in the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents,&rdquo;",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 1996, 6(4):241-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/18/19752/abstract-text/9231317 /pubmed\" id=\"9231317 \" target=\"_blank\">",
"        9231317",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pleak RR and Gormly LJ, &ldquo;Effects of Venlafaxine Treatment for ADHD in a Child,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 1995, 152(7):1099.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/18/19752/abstract-text/7793453/pubmed\" id=\"7793453\" target=\"_blank\">",
"        7793453",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Samuel RZ, &ldquo;Priapism Associated With Venlafaxine Use,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2000, 39(1):16-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/18/19752/abstract-text/10638063/pubmed\" id=\"10638063\" target=\"_blank\">",
"        10638063",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walter G, Lyndon B, and Kubb R, &ldquo;Lithium Augmentation of Venlafaxine in Adolescent Major Depression,&rdquo;",
"      <i>",
"       Aust N Z J Psychiatry",
"      </i>",
"      1998, 32(3):457-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/18/19752/abstract-text/9672738/pubmed\" id=\"9672738\" target=\"_blank\">",
"        9672738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weller EB, Weller RA, and Davis GP, &ldquo;Use of Venlafaxine in Children and Adolescents: A Review of Current Literature,&rdquo;",
"      <i>",
"       Depress Anxiety",
"      </i>",
"      , 2000, 12(Suppl 1):85-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/18/19752/abstract-text/11098420/pubmed\" id=\"11098420\" target=\"_blank\">",
"        11098420",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12878 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-D40D2B0C78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_18_19752=[""].join("\n");
var outline_f19_18_19752=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5710003\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233762\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233763\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055989\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055981\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233734\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233719\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874929\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055993\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055984\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055992\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7914389\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233808\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055996\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055980\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055979\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233795\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233728\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055999\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233729\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233745\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055988\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055978\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055995\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055986\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055997\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12878\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12878|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=related_link\">",
"      Venlafaxine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/43/20150?source=related_link\">",
"      Venlafaxine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_18_19753="Pelvic floor disorders associated with pregnancy and childbirth";
var content_f19_18_19753=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pelvic floor disorders associated with pregnancy and childbirth",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/18/19753/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/18/19753/contributors\">",
"     Victoria L Handa, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/18/19753/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/18/19753/contributors\">",
"     Linda Brubaker, MD, FACS, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/18/19753/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/18/19753/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/18/19753/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic floor disorders (PFDs) include urinary and fecal incontinence, as well as pelvic organ prolapse. These disorders affect one-third of adult women in the United States, with substantial impact on their quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. One study of 149,554 adult women reported an 11 percent risk of undergoing a single operation for pelvic floor disorders or incontinence by age 80 and found that 29 percent of these women required multiple surgeries [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/5\">",
"     5",
"    </a>",
"    ]. Many other women have mild symptoms, which are managed conservatively with pessaries, pads, or no therapy. Thus, the burden of disease related to pelvic floor disorders is substantial.",
"   </p>",
"   <p>",
"    An area of intense investigation is the effect of pregnancy and childbirth on a woman's risk of developing pelvic floor disorders and whether this risk can be modified by any interventions, such as planned cesarean delivery or avoidance of instrumental vaginal delivery. Some women have requested cesarean delivery for this reason. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/21/344?source=see_link\">",
"     \"Cesarean delivery on maternal request\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The association of pelvic floor disorders (excluding fecal incontinence) with pregnancy and childbirth are reviewed here; information regarding fecal incontinence can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9097?source=see_link\">",
"     \"Fecal incontinence related to pregnancy and vaginal delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ASSOCIATION OF PFD WITH PREGNANCY AND CHILDBIRTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous observational studies have reported that pelvic floor disorders are more prevalent among women who have delivered at least one child [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/6-17\">",
"     6-17",
"    </a>",
"    ]. Examples from some representative studies are listed below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among twins (mean age of 47 years, range 15 to 85 years), parous sisters with at least two births were three times more likely to report fecal incontinence [",
"      <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/10\">",
"       10",
"      </a>",
"      ], and four times more likely to report urinary incontinence than their nulliparous twin sisters [",
"      <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study of over 90,000 women in Sweden found the surgery for pelvic floor disorders was performed in a greater proportion of women with a history of vaginal delivery than those with a history of cesarean delivery: stress urinary incontinence surgery (vaginal delivery: 4.5 percent; cesarean: 1.7 percent) and pelvic organ prolapse repair surgery (vaginal delivery: 8.1 percent; cesarean: 0.7 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study of 27,900 women found that, among premenopausal women, parous women have a higher prevalence of stress urinary incontinence (SUI) and urinary urgency than nulliparous women [",
"      <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/9\">",
"       9",
"      </a>",
"      ]. In contrast, among postmenopausal women, a history of pregnancy and childbirth appears to have little impact on the prevalence of urinary incontinence. Older nulliparous women are as likely to have urinary incontinence as older parous women [",
"      <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/9,19\">",
"       9,19",
"      </a>",
"      ]. It is assumed that the effects of other factors, such as comorbid medical conditions and age-related changes, outweigh the effect of previous pregnancies in these women [",
"      <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Oxford Family Planning study, a prospective cohort study of more than 17,000 women followed for 17 years, found that, compared with nulliparity, the risk of hospital admission for pelvic organ prolapse increased markedly for the first (four-fold) and second birth (eight-fold), and then increased less rapidly for subsequent births (third: 9-fold; fourth: 10-fold) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among postmenopausal women, the Women's Health Initiative observed that a history of at least one delivery was associated with twice the risk of pelvic organ prolapse (uterine prolapse, cystocele, rectocele) compared to nulliparous controls [",
"      <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a survey of United States women, the proportion reporting at least one pelvic floor disorder increased with increasing parity [",
"      <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This and other epidemiologic evidence support an association between pelvic floor disorders and pregnancy and childbirth and suggest that the overall impact of parity is substantial. Among parous women, it has been estimated that 50 percent of incontinence and 75 percent of prolapse can be attributed to pregnancy and childbirth [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/23\">",
"     23",
"    </a>",
"    ]. However, there are many unanswered questions. Most importantly, the available literature cannot distinguish the effects of pregnancy from the effects of childbirth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PREVALENCE OF PFD DURING PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both urinary and fecal incontinence are more common during pregnancy than before pregnancy. Many women experience their first symptoms of incontinence during pregnancy. During pregnancy, urinary incontinence is reported by 7 to 60 percent of pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/20,24-28\">",
"     20,24-28",
"    </a>",
"    ], and fecal incontinence is reported by 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/29\">",
"     29",
"    </a>",
"    ]. As an example, a survey of over 5,000 primiparous women who were continent before pregnancy, 46 percent leaked urine either during or after pregnancy, 7 percent leaked only during pregnancy and 10 percent leaked only after delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/27\">",
"     27",
"    </a>",
"    ]. The prevalence and severity of incontinence increase during the course of pregnancy, reaching a peak in the third trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/30-32\">",
"     30-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognosis for women who develop incontinence during pregnancy is generally favorable. For most women with incontinence during pregnancy, symptoms are likely to resolve after delivery; 70 percent of women with onset of urinary incontinence during pregnancy eventually spontaneously resolve their symptoms postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/24,30,33,34\">",
"     24,30,33,34",
"    </a>",
"    ]. Specifically, within 12 months postpartum, the prevalence drops to 11 to 23 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/24,30,33\">",
"     24,30,33",
"    </a>",
"    ]. Also, among women with persistent incontinence, severity declines in the first year after childbirth, with a substantial reduction in both the frequency of incontinent episodes and other measures of severity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, women with incontinence during pregnancy appear to be at increased risk for persistent postpartum urinary incontinence symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/28,30,35,36\">",
"     28,30,35,36",
"    </a>",
"    ]. A history of incontinence prior to pregnancy significantly increases the chance that postpartum incontinence will persist [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. This is to be expected given that there is no reason that pregnancy and delivery would improve a preexisting condition.",
"   </p>",
"   <p>",
"    There are fewer data about prolapse among pregnant women; however, there is general agreement that Pelvic Organ Prolapse Quantitation (POPQ) stage increases during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. It is not known whether prolapse that arises during or shortly after pregnancy is likely to resolve with time. Further study is needed to investigate the effects of pregnancy and type of delivery on pelvic support disorders. Common conditions unrelated to pregnancy and delivery, such as obesity and chronic pulmonary disease, as well as aging, also affect the risk of developing prolapse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MECHANISM FOR PREGNANCY AND CHILDBIRTH RELATED PFD",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical anatomy of the pelvic floor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pelvic floor is primarily made up of the levator ani and coccygeus muscles (ie, paired puborectalis, pubococcygeus, and iliococcygeus). These muscles consist of two types of fibers: type I (slow twitch fibers), which rely on oxidative metabolism, and type II (fast twitch fibers), which rely on anaerobic glycolytic metabolism. The urethral and anal sphincter muscles are also part of the pelvic floor.",
"   </p>",
"   <p>",
"    The endopelvic connective tissues lie superior to the pelvic floor muscles and connect to the pelvic side walls and sacrum. The urogenital diaphragm, now termed the \"perineal membrane\" (ie, bulbocavernosus, transverse perineal, and ischiocavernosus muscles), lies external and inferior to the pelvic floor.",
"   </p>",
"   <p>",
"    The innervation of this region is from the S2, S3, and S4 segments of the spinal cord, which fuse to form the pudendal nerve. The pudendal nerve innervates the external anal sphincter, whereas the levators, coccygeus muscles, and urogenital diaphragm appear to be innervated by a direct connection of S2, S3, and S4 nerve fibers [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Effect of pregnancy and childbirth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biologic mechanisms explaining how pregnancy and childbirth injure the pelvic floor have not been proven conclusively. Data suggest that pregnancy and delivery contribute to pelvic floor injury due to compression, stretching, or tearing of nerve, muscle, and connective tissue (",
"    <a class=\"graphic graphic_figure graphicRef61738 \" href=\"UTD.htm?1/18/1319\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Neural injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;During labor and vaginal delivery, descent of the fetal head may cause stretching and compression of the pelvic floor and the associated nerves. This process can lead to demyelination and subsequent denervation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/43\">",
"     43",
"    </a>",
"    ]. This mechanism of injury is supported by neurophysiologic tests, including concentric needle EMG and pudendal nerve motor latency, which have demonstrated denervation of the pubovisceral muscles and anal sphincter after 40 to 80 percent of vaginal births [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Risk factors for denervation and pudendal nerve damage include operative delivery, prolonged second stage, and high birth weight [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cohort studies suggest that neuromuscular injury resolves during the first year after delivery for the majority of women [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/44\">",
"     44",
"    </a>",
"    ]. This may account for the spontaneous resolution of incontinence over that same period. However, in some cases, electrophysiologic evidence of denervation injury can be seen five to six years after delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/45,46\">",
"     45,46",
"    </a>",
"    ], and denervation injury may accumulate with increasing parity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/43,47,48\">",
"     43,47,48",
"    </a>",
"    ]. It is not known why some women recover neuromuscular function after childbirth and others demonstrate evidence of permanent damage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Anal sphincter disruption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gross or occult disruption of the anal sphincter is a major risk factor for anal incontinence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9097?source=see_link\">",
"     \"Fecal incontinence related to pregnancy and vaginal delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Injury to the levator ani and coccygeus muscles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic floor muscle strength is decreased after vaginal delivery compared with women who had only cesarean deliveries. As an example, in a prospective cohort study of 666 women followed for 6 to 11 years, pelvic floor muscle strength was lower in women who had a vaginal delivery rather than a cesarean delivery; the lowest strength was in women who had a forceps delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mediolateral episiotomy, which typically involves an intentional incision of the levator ani and coccygeus muscles, is an example of iatrogenic trauma to the pelvic floor during delivery. As expected, mediolateral episiotomy is associated with a substantial decline in pelvic floor strength [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. However, there is no evidence that pelvic floor disorders are increased by mediolateral episiotomy. This was illustrated by a study that evaluated 519 primiparous women three months from delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/51\">",
"     51",
"    </a>",
"    ]. Compared to women with an intact perineum and first- and second-degree spontaneous perineal lacerations, women who had undergone mediolateral episiotomy were no more likely to experience urinary incontinence, anal incontinence, anterior vaginal wall prolapse, apical prolapse, or posterior wall prolapse [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The situation may be different for occult injuries. Forceps delivery, prolonged second stage of labor, and episiotomy are associated with occult injury to the levator ani complex, which can be identified by magnetic resonance imaging or sonography [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/52-55\">",
"     52-55",
"    </a>",
"    ]. The incidence of occult levator trauma among vaginally parous women presenting for treatment of pelvic floor disorders may be as high as 24 percent (95% CI 21-27 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/56\">",
"     56",
"    </a>",
"    ]. Women with such injuries have weaker pelvic floor muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/55\">",
"     55",
"    </a>",
"    ], are more likely to report SUI [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/53\">",
"     53",
"    </a>",
"    ], and are at increased odds of pelvic organ prolapse [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/55\">",
"     55",
"    </a>",
"    ]. These observations suggest that occult injuries to the levator ani muscles during labor and delivery may account for some cases of pelvic floor disorders after childbirth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13992?source=see_link\">",
"     \"Approach to episiotomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/39/15994?source=see_link\">",
"     \"Operative vaginal delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Finite element models have been used to model deformations of the pelvic floor with vaginal delivery. Using this theoretical approach, a model developed by Parente and colleagues predicted that the greatest strain would occur at the bony attachments of the levator ani and pubococcygeus muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/57\">",
"     57",
"    </a>",
"    ], presumably with extension of the fetal head. The degree of deformation predicted would exceed thresholds for injury, especially in the most medial aspects of the levator ani complex. Similar results were obtained with a 3-D computer model of birth [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/58\">",
"     58",
"    </a>",
"    ]. Correlation with anatomic studies of parous women is needed to assess the validity of these simulation models.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CAN OBSTETRICAL CARE BE MODIFIED TO REDUCE PFD?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether obstetrical care can be modified to reduce the long-term risk of pelvic floor disorders is an important area of investigation, given the association between pregnancy, childbirth, and pelvic floor disorders and the impact of these disorders.",
"   </p>",
"   <p>",
"    Unfortunately, the available literature does not distinguish the effects of pregnancy from the effects of childbirth.",
"   </p>",
"   <p>",
"    Finally, the impact of various obstetrical interventions and childbirth experiences on pelvic floor disorders are not known because the available data do not adequately describe obstetrical \"exposures\" across a population (eg, did labor occur and for how long before delivery?, how low did the presenting fetal part descend?, did her symptoms progress or regress and how long was she followed postpartum?).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9030775\">",
"    <span class=\"h2\">",
"     Cesarean delivery before labor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The performance of cesarean delivery to reduce the prevalence of pelvic floor disorders later in life is controversial. &nbsp; The route of delivery appears to be an important risk factor for developing a pelvic floor disorders. A case-control study in which over 15,000 women with pelvic organ prolapse were matched with controls who had a delivery during the same time period found that the odds of an inpatient diagnosis of pelvic organ prolapse were lower in women who had undergone cesarean delivery compared with vaginal delivery (OR 0.18, 95% CI 0.16-0.20) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/59\">",
"     59",
"    </a>",
"    ]. Similarly, a retrospective study of almost 100,000 women found significantly higher risks of urinary incontinence (hazard ratio 2.9; 95% CI 2.4-3.6) and prolapse surgery (hazard ratio 9.2; 95% CI 7.0-12.1) in women who had only vaginal deliveries compared with those who had only cesarean deliveries [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other observational studies have suggested that cesarean delivery is associated with a lower rate of future urinary incontinence and pelvic floor disorders than vaginal delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/1,24,61,62\">",
"     1,24,61,62",
"    </a>",
"    ]. However, the prophylactic benefits of cesarean are limited. As an example, a cohort study of primiparous women found that urinary incontinence was reported by 22.9 percent of 124 participants six months after cesarean before the onset of labor [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/63\">",
"     63",
"    </a>",
"    ]. Less than 1 percent of these 124 participants recalled urinary incontinence prior to childbirth. Thus, cesarean delivery prior to labor did not prevent incident urinary incontinence after delivery in this cohort. Cesarean birth appears to be most effective in reducing stress incontinence and less effective in preventing other pelvic floor disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/64\">",
"     64",
"    </a>",
"    ]. However, observational studies are likely to be confounded by the indications for cesarean birth and by other factors, such as maternal age, obesity, and fetal macrosomia.",
"   </p>",
"   <p>",
"    To date, there have been no randomized trials designed specifically to address the potential value of elective cesarean birth in reducing the risk of pelvic floor disorders. The best available data are derived from a trial of women with term fetuses in breech presentation in which the women were randomly assigned to deliver by planned cesarean or planned vaginal birth [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/65\">",
"     65",
"    </a>",
"    ]. The purpose of this trial was to assess the safest route of delivery of the breech infant. Secondary analysis of data revealed that the rates of urinary and fecal incontinence at two years postpartum were not significantly different in women who assigned to planned cesarean or planned vaginal delivery: urinary incontinence 17.8 and 21.8 percent, respectively, RR 0.81, 95% CI 0.61-1.06 and fecal incontinence 2.4 and 2.2 percent, respectively, RR 1.10, 95% CI 0.47-1.61. Of note, almost 50 percent of women assigned to the planned vaginal delivery group delivered by cesarean.",
"   </p>",
"   <p>",
"    A 2006 National Institutes of Health expert panel concluded that there is only weak evidence to support a preventative role for elective cesarean delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/66\">",
"     66",
"    </a>",
"    ], and that the existing data do not adequately answer the question of whether elective cesarean delivery can reduce the incidence of pelvic floor disorders. Even if a reduction in pelvic floor disorders could be demonstrated, other harms and benefits of elective cesarean delivery need to be weighed against this benefit. One study estimated that seven women would have to deliver all of their children by cesarean birth to prevent one woman from developing pelvic floor disorders later in life [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Changes in labor management",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women who plan vaginal birth, there may be options to minimize the risk of pelvic floor disorders.",
"   </p>",
"   <p>",
"    In the past, it was hypothesized that outlet forceps protected the pelvic floor by controlling delivery of the vertex, thereby allowing less force to be applied to the pelvic musculature. There is no good evidence to support this hypothesis. Based on the studies cited above, avoidance of episiotomy and operative vaginal delivery appear to be the most promising interventions to reduce the risk of damage to the pelvic floor [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. Episiotomy and operative delivery have independent and significant impacts on urinary and anal incontinence after delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/24,61,69\">",
"     24,61,69",
"    </a>",
"    ]. Both of these obstetrical interventions are associated with anal sphincter trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/70,71\">",
"     70,71",
"    </a>",
"    ], a known cause of fecal incontinence. Also, operative delivery has been associated with pudendal neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/45\">",
"     45",
"    </a>",
"    ]. Therefore, reduction of episiotomy and operative delivery rates theoretically could reduce the risk of pelvic floor disorders.",
"   </p>",
"   <p>",
"    However, these conclusions are based on data from observational studies in which the decision to perform an operative delivery or an episiotomy could have been confounded by other factors that influence postpartum incontinence, including cephalopelvic disproportion, maternal race, and the use of other obstetrical interventions. Thus, there is insufficient evidence to establish whether an episiotomy or operative delivery is the cause of postpartum incontinence or simply a marker for a more difficult birth. The risks of performing these procedures should be weighed against the potential benefits in specific clinical situations. Nevertheless, episiotomy rates have been declining given good evidence that does not support routine use of episiotomy. This trend has been associated with a reduction in clinically evident sphincter lacerations [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/72\">",
"     72",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13992?source=see_link\">",
"     \"Approach to episiotomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/39/15994?source=see_link\">",
"     \"Operative vaginal delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The literature also suggests that labor induction,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    use, and epidural anesthesia in labor modestly increase the odds of pelvic floor disorders after vaginal birth [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/61,73,74\">",
"     61,73,74",
"    </a>",
"    ]. However, these data come from observational studies; there are no randomized studies of the impact of these interventions on pelvic floor disorders. Given the multiple factors that influence use of these obstetrical practices, it is plausible that confounders, such as macrosomia, could influence both the likelihood of obstetrical interventions and the later development of pelvic floor disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Prophylactic pelvic floor muscle exercises",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic floor muscle exercises (PFME) performed during pregnancy help to decrease the short-term risk of urinary incontinence in women without prior incontinence, but a long-term benefit has not been established. This was illustrated in a meta-analysis that included data from six randomized trials and found that continent women (most trials included only nulliparous women) who were assigned to perform antenatal PFME compared with those who were not had a significantly decreased risk of urinary incontinence at three to six months postpartum (18 versus 25 percent; risk ratio 0.71, 95% CI 0.54-0.95) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/75\">",
"     75",
"    </a>",
"    ]. Among the few studies that evaluated women six or more months postpartum, no significant effect was seen and the trend was toward a lower rate in urinary incontinence in the women who were not assigned to PFME.",
"   </p>",
"   <p>",
"    In the same meta-analysis, data from seven randomized trials that included a mixed population of women (continent and incontinent; nulliparous and parous) showed that women assigned to antenatal PFME had a significant decrease in the rate of urinary incontinence at up to three months postpartum (risk ratio 0.77, 95% CI 0.59-1.01) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/75\">",
"     75",
"    </a>",
"    ]. This continued as a trend through 12 months postpartum, but did not reach statistical significance. It is important to note the studying of a mixed population of continent and incontinent women results in study use of PFME as both prophylaxis and treatment, so it is difficult to interpret the results.",
"   </p>",
"   <p>",
"    In terms of postpartum PFME, there is increasing evidence that some women sustain injury to the levator ani muscle complex at childbirth [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/76,77\">",
"     76,77",
"    </a>",
"    ].&nbsp;If this is true, PFME may be harmful to some women because an exercise program may be contraindicated in the early phase of injury recovery. This is based on evidence from sports medicine that the preferred early treatment of muscle injury is rest or immobilization, with strength training only after initial healing is complete; however, there are no data regarding this issue following childbirth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34890?source=see_link\">",
"     \"Overview of running injuries of the lower extremity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Limiting parity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstetrical providers may be asked by parous women about the impact of additional deliveries on the risk of pelvic floor disorders. The evidence suggests that the biggest increase in the prevalence of pelvic floor disorders is associated with the first birth [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/7,10,11\">",
"     7,10,11",
"    </a>",
"    ]. As an example, among women over 50 years of age, the odds of uterine prolapse doubles after a first birth and then increases by only 10 percent with each additional birth [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/7\">",
"     7",
"    </a>",
"    ]. There may be a measurable increase in incontinence with additional births after the first [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/7,10,11,78,79\">",
"     7,10,11,78,79",
"    </a>",
"    ], although some studies show no increase with additional births [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/80,81\">",
"     80,81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women considering additional pregnancies can be counseled that there may be an increasing risk of pelvic floor disorders with additional pregnancies. Nevertheless, we believe that considerations other than the risk of pelvic floor disorders will influence decisions regarding family size for the majority of women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;As providers of women's health care, obstetrical care providers should also look beyond obstetrical factors to identify other prevention opportunities. Parity and childbirth are important factors in the development of incontinence and prolapse, but not the only factors. Nulliparous women can experience pelvic floor disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/9,82\">",
"     9,82",
"    </a>",
"    ], and even among parous women, obstetrical history is estimated to account for only 50 percent of incontinence [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other strong risk factors for pelvic floor disorders include age and race, but these factors are not modifiable. To minimize the incidence and impact of pelvic floor disorders, women's health care providers should focus on modifiable risk factors, such as obesity and smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/7,21,83,84\">",
"     7,21,83,84",
"    </a>",
"    ]. Both of these have been repeatedly identified as risk factors for pelvic floor disorders prevalence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severity and represent prevention opportunities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SELECTED MANAGEMENT ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Women with urinary incontinence during and after pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another challenge is determining the best delivery plan for a woman who has developed urinary incontinence during pregnancy. As discussed above, some data suggest that incontinence during pregnancy is a risk factor for persistent incontinence [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/30,35,36,85\">",
"     30,35,36,85",
"    </a>",
"    ]. Therefore, should women with incontinence during pregnancy be considered a high risk group more likely to benefit from elective cesarean birth?",
"   </p>",
"   <p>",
"    There is no evidence that women with incontinence during pregnancy are more likely than women without incontinence during pregnancy to benefit from elective cesarean.",
"   </p>",
"   <p>",
"    In one cohort study, the reduction in risk of postpartum urinary incontinence associated with cesarean birth was greater for women who did not have antepartum urinary incontinence symptoms than for women with incontinence during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/35\">",
"     35",
"    </a>",
"    ]. In that study, cesarean delivery decreased postpartum urinary incontinence by 12 percent and this difference was not affected by antepartum incontinence. Further studies are needed to identify high risk groups of women who may disproportionately benefit from planned cesarean delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Women who have undergone surgical repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typically, surgical treatment of incontinence and prolapse are deferred until childbirth is complete. There is no consensus on management of pregnancy and delivery in women who have undergone a surgical procedure for repair. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43177?source=see_link\">",
"     \"Stress urinary incontinence in women: Choosing a primary surgical procedure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/29/34263?source=see_link\">",
"     \"Delayed surgical management of the disrupted anal sphincter\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Women with a prior anal sphincter laceration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who have a secondary repair of an anal sphincter rupture should be carefully counseled regarding future pregnancy and deliveries. Experts recommend that a woman with persistent fecal incontinence and a poorly functioning anal sphincter be offered a planned cesarean for subsequent deliveries. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9097?source=see_link&amp;anchor=H22#H22\">",
"     \"Fecal incontinence related to pregnancy and vaginal delivery\", section on 'Recurrence with subsequent vaginal delivery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     FUTURE DIRECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;With respect to pregnancy-related prevention opportunities, future research should be directed toward identifying modifiable risk factors, clarifying the mechanisms underlying the association between childbirth and pelvic floor disorders, and identifying subsets of women most likely to benefit from prevention strategies. While elective cesarean is widely perceived to be an effective prevention strategy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/86\">",
"     86",
"    </a>",
"    ], we need more information about the value of this intervention as well as the relative benefits and harms of elective cesarean birth. Given that more than 350,000 inpatient surgeries are performed in the US each year for treatment of pelvic floor disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19753/abstract/87-90\">",
"     87-90",
"    </a>",
"    ], the importance of effective prevention is clear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pregnancy and childbirth appear to be associated with an increased risk of developing pelvic floor disorders. Observational studies have generally been characterized by small numbers of subjects, inadequate attention to potential confounders, poor outcome measures and ascertainment of outcome, and short and incomplete follow-up. This has precluded definitive conclusions regarding the effect of pregnancy and childbirth on the prevalence of these disorders and whether any changes in obstetrical management can reduce the risk. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Association of PFD with pregnancy and childbirth'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Prevalence of PFD during pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pregnancy and delivery likely contribute to pelvic floor injury due to compression, stretching, or tearing of nerve, muscle, and connective tissue. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Mechanism for pregnancy and childbirth related PFD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pelvic floor muscle exercises performed during pregnancy help to decrease the short-term risk of urinary incontinence in women without prior incontinence, but a long-term benefit has not been established. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Prophylactic pelvic floor muscle exercises'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Based on the available evidence, we suggest against performing cesarean delivery to prevent pelvic floor disorders or worsening of existing pelvic floor disorders (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9030775\">",
"       'Cesarean delivery before labor'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Midline episiotomy and operative vaginal delivery increase the risk of anal sphincter tears, which are associated with anal incontinence. This risk should be weighed against the potential benefits of these procedures in specific clinical situations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9097?source=see_link\">",
"       \"Fecal incontinence related to pregnancy and vaginal delivery\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H12\">",
"       'Changes in labor management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/1\">",
"      Lukacz ES, Lawrence JM, Contreras R, et al. Parity, mode of delivery, and pelvic floor disorders. Obstet Gynecol 2006; 107:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/2\">",
"      Varma MG, Brown JS, Creasman JM, et al. Fecal incontinence in females older than aged 40 years: who is at risk? Dis Colon Rectum 2006; 49:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/3\">",
"      Boreham MK, Richter HE, Kenton KS, et al. Anal incontinence in women presenting for gynecologic care: prevalence, risk factors, and impact upon quality of life. Am J Obstet Gynecol 2005; 192:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/4\">",
"      Fultz NH, Burgio K, Diokno AC, et al. Burden of stress urinary incontinence for community-dwelling women. Am J Obstet Gynecol 2003; 189:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/5\">",
"      Olsen AL, Smith VJ, Bergstrom JO, et al. Epidemiology of surgically managed pelvic organ prolapse and urinary incontinence. Obstet Gynecol 1997; 89:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/6\">",
"      O'Boyle AL, Woodman PJ, O'Boyle JD, et al. Pelvic organ support in nulliparous pregnant and nonpregnant women: a case control study. Am J Obstet Gynecol 2002; 187:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/7\">",
"      Hendrix SL, Clark A, Nygaard I, et al. Pelvic organ prolapse in the Women's Health Initiative: gravity and gravidity. Am J Obstet Gynecol 2002; 186:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/8\">",
"      Handa VL, Garrett E, Hendrix S, et al. Progression and remission of pelvic organ prolapse: a longitudinal study of menopausal women. Am J Obstet Gynecol 2004; 190:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/9\">",
"      Rortveit G, Hannestad YS, Daltveit AK, Hunskaar S. Age- and type-dependent effects of parity on urinary incontinence: the Norwegian EPINCONT study. Obstet Gynecol 2001; 98:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/10\">",
"      Abramov Y, Sand PK, Botros SM, et al. Risk factors for female anal incontinence: new insight through the Evanston-Northwestern twin sisters study. Obstet Gynecol 2005; 106:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/11\">",
"      Goldberg RP, Abramov Y, Botros S, et al. Delivery mode is a major environmental determinant of stress urinary incontinence: results of the Evanston-Northwestern Twin Sisters Study. Am J Obstet Gynecol 2005; 193:2149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/12\">",
"      Subak LL, Waetjen LE, van den Eeden S, et al. Cost of pelvic organ prolapse surgery in the United States. Obstet Gynecol 2001; 98:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/13\">",
"      Carley ME, Turner RJ, Scott DE, Alexander JM. Obstetric history in women with surgically corrected adult urinary incontinence or pelvic organ prolapse. J Am Assoc Gynecol Laparosc 1999; 6:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/14\">",
"      Moalli PA, Jones Ivy S, Meyn LA, Zyczynski HM. Risk factors associated with pelvic floor disorders in women undergoing surgical repair. Obstet Gynecol 2003; 101:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/15\">",
"      Chiaffarino F, Chatenoud L, Dindelli M, et al. Reproductive factors, family history, occupation and risk of urogenital prolapse. Eur J Obstet Gynecol Reprod Biol 1999; 82:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/16\">",
"      Rinne KM, Kirkinen PP. What predisposes young women to genital prolapse? Eur J Obstet Gynecol Reprod Biol 1999; 84:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/17\">",
"      MacLennan AH, Taylor AW, Wilson DH, Wilson D. The prevalence of pelvic floor disorders and their relationship to gender, age, parity and mode of delivery. BJOG 2000; 107:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/18\">",
"      Leijonhufvud &Aring;, Lundholm C, Cnattingius S, et al. Risk of surgically managed pelvic floor dysfunction in relation to age at first delivery. Am J Obstet Gynecol 2012; 207:303.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/19\">",
"      Brown JS, Grady D, Ouslander JG, et al. Prevalence of urinary incontinence and associated risk factors in postmenopausal women. Heart &amp; Estrogen/Progestin Replacement Study (HERS) Research Group. Obstet Gynecol 1999; 94:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/20\">",
"      Nygaard I. Urinary incontinence: is cesarean delivery protective? Semin Perinatol 2006; 30:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/21\">",
"      Mant J, Painter R, Vessey M. Epidemiology of genital prolapse: observations from the Oxford Family Planning Association Study. Br J Obstet Gynaecol 1997; 104:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/22\">",
"      Nygaard I, Barber MD, Burgio KL, et al. Prevalence of symptomatic pelvic floor disorders in US women. JAMA 2008; 300:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/23\">",
"      Patel DA, Xu X, Thomason AD, et al. Childbirth and pelvic floor dysfunction: an epidemiologic approach to the assessment of prevention opportunities at delivery. Am J Obstet Gynecol 2006; 195:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/24\">",
"      Burgio KL, Zyczynski H, Locher JL, et al. Urinary incontinence in the 12-month postpartum period. Obstet Gynecol 2003; 102:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/25\">",
"      Viktrup L, Lose G. Lower urinary tract symptoms 5 years after the first delivery. Int Urogynecol J Pelvic Floor Dysfunct 2000; 11:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/26\">",
"      Wesnes SL, Rortveit G, B&oslash; K, Hunskaar S. Urinary incontinence during pregnancy. Obstet Gynecol 2007; 109:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/27\">",
"      Boyles SH, Li H, Mori T, et al. Effect of mode of delivery on the incidence of urinary incontinence in primiparous women. Obstet Gynecol 2009; 113:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/28\">",
"      Solans-Dom&egrave;nech M, S&aacute;nchez E, Espu&ntilde;a-Pons M, Pelvic Floor Research Group (Grup de Recerca del S&ograve;l Pelvi&agrave;; GRESP). Urinary and anal incontinence during pregnancy and postpartum: incidence, severity, and risk factors. Obstet Gynecol 2010; 115:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/29\">",
"      Chaliha C, Kalia V, Stanton SL, et al. Antenatal prediction of postpartum urinary and fecal incontinence. Obstet Gynecol 1999; 94:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/30\">",
"      Viktrup L, Lose G. The risk of stress incontinence 5 years after first delivery. Am J Obstet Gynecol 2001; 185:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/31\">",
"      Thorp JM Jr, Norton PA, Wall LL, et al. Urinary incontinence in pregnancy and the puerperium: a prospective study. Am J Obstet Gynecol 1999; 181:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/32\">",
"      van Brummen HJ, Bruinse HW, van der Bom JG, et al. How do the prevalences of urogenital symptoms change during pregnancy? Neurourol Urodyn 2006; 25:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/33\">",
"      van Brummen HJ, Bruinse HW, van de Pol G, et al. Bothersome lower urinary tract symptoms 1 year after first delivery: prevalence and the effect of childbirth. BJU Int 2006; 98:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/34\">",
"      Mason L, Glenn S, Walton I, Appleton C. The prevalence of stress incontinence during pregnancy and following delivery. Midwifery 1999; 15:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/35\">",
"      Foldspang A, Hvidman L, Mommsen S, Nielsen JB. Risk of postpartum urinary incontinence associated with pregnancy and mode of delivery. Acta Obstet Gynecol Scand 2004; 83:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/36\">",
"      Viktrup L, Lose G, Rolff M, Barfoed K. The symptom of stress incontinence caused by pregnancy or delivery in primiparas. Obstet Gynecol 1992; 79:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/37\">",
"      Farrell SA, Allen VM, Baskett TF. Parturition and urinary incontinence in primiparas. Obstet Gynecol 2001; 97:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/38\">",
"      Stainton MC, Strahle A, Fethney J. Leaking urine prior to pregnancy: a risk factor for postnatal incontinence. Aust N Z J Obstet Gynaecol 2005; 45:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/39\">",
"      O'Boyle AL, O'Boyle JD, Ricks RE, et al. The natural history of pelvic organ support in pregnancy. Int Urogynecol J Pelvic Floor Dysfunct 2003; 14:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/40\">",
"      Sze EH, Sherard GB 3rd, Dolezal JM. Pregnancy, labor, delivery, and pelvic organ prolapse. Obstet Gynecol 2002; 100:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/41\">",
"      O'Boyle AL, O'Boyle JD, Calhoun B, Davis GD. Pelvic organ support in pregnancy and postpartum. Int Urogynecol J Pelvic Floor Dysfunct 2005; 16:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/42\">",
"      Percy JP, Neill ME, Swash M, Parks AG. Electrophysiological study of motor nerve supply of pelvic floor. Lancet 1981; 1:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/43\">",
"      Snooks SJ, Setchell M, Swash M, Henry MM. Injury to innervation of pelvic floor sphincter musculature in childbirth. Lancet 1984; 2:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/44\">",
"      Allen RE, Hosker GL, Smith AR, Warrell DW. Pelvic floor damage and childbirth: a neurophysiological study. Br J Obstet Gynaecol 1990; 97:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/45\">",
"      Snooks SJ, Swash M, Henry MM, Setchell M. Risk factors in childbirth causing damage to the pelvic floor innervation. Int J Colorectal Dis 1986; 1:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/46\">",
"      Snooks SJ, Swash M, Mathers SE, Henry MM. Effect of vaginal delivery on the pelvic floor: a 5-year follow-up. Br J Surg 1990; 77:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/47\">",
"      Gilpin SA, Gosling JA, Smith AR, Warrell DW. The pathogenesis of genitourinary prolapse and stress incontinence of urine. A histological and histochemical study. Br J Obstet Gynaecol 1989; 96:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/48\">",
"      Smith AR, Hosker GL, Warrell DW. The role of partial denervation of the pelvic floor in the aetiology of genitourinary prolapse and stress incontinence of urine. A neurophysiological study. Br J Obstet Gynaecol 1989; 96:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/49\">",
"      Friedman S, Blomquist JL, Nugent JM, et al. Pelvic muscle strength after childbirth. Obstet Gynecol 2012; 120:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/50\">",
"      R&ouml;ckner G, Jonasson A, Olund A. The effect of mediolateral episiotomy at delivery on pelvic floor muscle strength evaluated with vaginal cones. Acta Obstet Gynecol Scand 1991; 70:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/51\">",
"      Sartore A, De Seta F, Maso G, et al. The effects of mediolateral episiotomy on pelvic floor function after vaginal delivery. Obstet Gynecol 2004; 103:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/52\">",
"      Shek KL, Dietz HP. Intrapartum risk factors for levator trauma. BJOG 2010; 117:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/53\">",
"      DeLancey JO, Kearney R, Chou Q, et al. The appearance of levator ani muscle abnormalities in magnetic resonance images after vaginal delivery. Obstet Gynecol 2003; 101:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/54\">",
"      Kearney R, Miller JM, Ashton-Miller JA, DeLancey JO. Obstetric factors associated with levator ani muscle injury after vaginal birth. Obstet Gynecol 2006; 107:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/55\">",
"      DeLancey JO, Morgan DM, Fenner DE, et al. Comparison of levator ani muscle defects and function in women with and without pelvic organ prolapse. Obstet Gynecol 2007; 109:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/56\">",
"      Dietz HP, Simpson JM. Does delayed child-bearing increase the risk of levator injury in labour? Aust N Z J Obstet Gynaecol 2007; 47:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/57\">",
"      Parente MP, Jorge RM, Mascarenhas T, et al. Deformation of the pelvic floor muscles during a vaginal delivery. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/58\">",
"      Lien KC, Mooney B, DeLancey JO, Ashton-Miller JA. Levator ani muscle stretch induced by simulated vaginal birth. Obstet Gynecol 2004; 103:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/59\">",
"      Larsson C, K&auml;llen K, Andolf E. Cesarean section and risk of pelvic organ prolapse: a nested case-control study. Am J Obstet Gynecol 2009; 200:243.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/60\">",
"      Leijonhufvud A, Lundholm C, Cnattingius S, et al. Risks of stress urinary incontinence and pelvic organ prolapse surgery in relation to mode of childbirth. Am J Obstet Gynecol 2011; 204:70.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/61\">",
"      Casey BM, Schaffer JI, Bloom SL, et al. Obstetric antecedents for postpartum pelvic floor dysfunction. Am J Obstet Gynecol 2005; 192:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/62\">",
"      Fritel X, Fauconnier A, Levet C, B&eacute;nifla JL. Stress urinary incontinence 4 years after the first delivery: a retrospective cohort survey. Acta Obstet Gynecol Scand 2004; 83:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/63\">",
"      Borello-France D, Burgio KL, Richter HE, et al. Fecal and urinary incontinence in primiparous women. Obstet Gynecol 2006; 108:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/64\">",
"      Press JZ, Klein MC, Kaczorowski J, et al. Does cesarean section reduce postpartum urinary incontinence? A systematic review. Birth 2007; 34:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/65\">",
"      Hannah ME, Whyte H, Hannah WJ, et al. Maternal outcomes at 2 years after planned cesarean section versus planned vaginal birth for breech presentation at term: the international randomized Term Breech Trial. Am J Obstet Gynecol 2004; 191:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/66\">",
"      National Institutes of Health state-of-the-science conference statement: Cesarean delivery on maternal request March 27-29, 2006. Obstet Gynecol 2006; 107:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/67\">",
"      Handa VL, Blomquist JL, Knoepp LR, et al. Pelvic floor disorders 5-10 years after vaginal or cesarean childbirth. Obstet Gynecol 2011; 118:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/68\">",
"      Handa VL, Blomquist JL, McDermott KC, et al. Pelvic floor disorders after vaginal birth: effect of episiotomy, perineal laceration, and operative birth. Obstet Gynecol 2012; 119:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/69\">",
"      Tegerstedt G, Miedel A, Maehle-Schmidt M, et al. Obstetric risk factors for symptomatic prolapse: a population-based approach. Am J Obstet Gynecol 2006; 194:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/70\">",
"      Kudish B, Blackwell S, Mcneeley SG, et al. Operative vaginal delivery and midline episiotomy: a bad combination for the perineum. Am J Obstet Gynecol 2006; 195:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/71\">",
"      Fitzgerald MP, Weber AM, Howden N, et al. Risk factors for anal sphincter tear during vaginal delivery. Obstet Gynecol 2007; 109:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/72\">",
"      Clemons JL, Towers GD, McClure GB, O'Boyle AL. Decreased anal sphincter lacerations associated with restrictive episiotomy use. Am J Obstet Gynecol 2005; 192:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/73\">",
"      Pregazzi R, Sartore A, Troiano L, et al. Postpartum urinary symptoms: prevalence and risk factors. Eur J Obstet Gynecol Reprod Biol 2002; 103:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/74\">",
"      Thom DH, van den Eeden SK, Brown JS. Evaluation of parturition and other reproductive variables as risk factors for urinary incontinence in later life. Obstet Gynecol 1997; 90:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/75\">",
"      Boyle R, Hay-Smith EJ, Cody JD, M&oslash;rkved S. Pelvic floor muscle training for prevention and treatment of urinary and faecal incontinence in antenatal and postnatal women. Cochrane Database Syst Rev 2012; 10:CD007471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/76\">",
"      Schwertner-Tiepelmann N, Thakar R, Sultan AH, Tunn R. Obstetric levator ani muscle injuries: current status. Ultrasound Obstet Gynecol 2012; 39:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/77\">",
"      Li X, Kruger JA, Nash MP, Nielsen PM. Anisotropic effects of the levator ani muscle during childbirth. Biomech Model Mechanobiol 2011; 10:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/78\">",
"      Handa VL, Harvey L, Fox HE, Kjerulff KH. Parity and route of delivery: does cesarean delivery reduce bladder symptoms later in life? Am J Obstet Gynecol 2004; 191:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/79\">",
"      Grodstein F, Fretts R, Lifford K, et al. Association of age, race, and obstetric history with urinary symptoms among women in the Nurses' Health Study. Am J Obstet Gynecol 2003; 189:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/80\">",
"      Altman D, Ekstr&ouml;m A, Gustafsson C, et al. Risk of urinary incontinence after childbirth: a 10-year prospective cohort study. Obstet Gynecol 2006; 108:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/81\">",
"      Connolly TJ, Litman HJ, Tennstedt SL, et al. The effect of mode of delivery, parity, and birth weight on risk of urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2007; 18:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/82\">",
"      Swift SE. The distribution of pelvic organ support in a population of female subjects seen for routine gynecologic health care. Am J Obstet Gynecol 2000; 183:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/83\">",
"      Hannestad YS, Rortveit G, Daltveit AK, Hunskaar S. Are smoking and other lifestyle factors associated with female urinary incontinence? The Norwegian EPINCONT Study. BJOG 2003; 110:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/84\">",
"      Woodman PJ, Swift SE, O'Boyle AL, et al. Prevalence of severe pelvic organ prolapse in relation to job description and socioeconomic status: a multicenter cross-sectional study. Int Urogynecol J Pelvic Floor Dysfunct 2006; 17:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/85\">",
"      Wesnes SL, Hunskaar S, Bo K, Rortveit G. The effect of urinary incontinence status during pregnancy and delivery mode on incontinence postpartum. A cohort study. BJOG 2009; 116:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/86\">",
"      Wax JR, Cartin A, Pinette MG, Blackstone J. Patient choice cesarean--the Maine experience. Birth 2005; 32:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/87\">",
"      Boyles SH, Weber AM, Meyn L. Procedures for pelvic organ prolapse in the United States, 1979-1997. Am J Obstet Gynecol 2003; 188:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/88\">",
"      Boyles SH, Weber AM, Meyn L. Procedures for urinary incontinence in the United States, 1979-1997. Am J Obstet Gynecol 2003; 189:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/89\">",
"      Brown JS, Waetjen LE, Subak LL, et al. Pelvic organ prolapse surgery in the United States, 1997. Am J Obstet Gynecol 2002; 186:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19753/abstract/90\">",
"      Waetjen LE, Subak LL, Shen H, et al. Stress urinary incontinence surgery in the United States. Obstet Gynecol 2003; 101:671.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8079 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-02B1BD5894-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_18_19753=[""].join("\n");
var outline_f19_18_19753=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ASSOCIATION OF PFD WITH PREGNANCY AND CHILDBIRTH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PREVALENCE OF PFD DURING PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MECHANISM FOR PREGNANCY AND CHILDBIRTH RELATED PFD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical anatomy of the pelvic floor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Effect of pregnancy and childbirth",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Neural injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Anal sphincter disruption",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Injury to the levator ani and coccygeus muscles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CAN OBSTETRICAL CARE BE MODIFIED TO REDUCE PFD?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9030775\">",
"      Cesarean delivery before labor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Changes in labor management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Prophylactic pelvic floor muscle exercises",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Limiting parity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other strategies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SELECTED MANAGEMENT ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Women with urinary incontinence during and after pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Women who have undergone surgical repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Women with a prior anal sphincter laceration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      FUTURE DIRECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/8079\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/8079|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/18/1319\" title=\"figure 1\">",
"      Female pelvic floor childbirth",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13992?source=related_link\">",
"      Approach to episiotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/21/344?source=related_link\">",
"      Cesarean delivery on maternal request",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/29/34263?source=related_link\">",
"      Delayed surgical management of the disrupted anal sphincter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9097?source=related_link\">",
"      Fecal incontinence related to pregnancy and vaginal delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/39/15994?source=related_link\">",
"      Operative vaginal delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34890?source=related_link\">",
"      Overview of running injuries of the lower extremity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43177?source=related_link\">",
"      Stress urinary incontinence in women: Choosing a primary surgical procedure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_18_19754="Anemia in malaria";
var content_f19_18_19754=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Anemia in malaria",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/18/19754/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/18/19754/contributors\">",
"     David J Roberts, MA, MB, D. Phil",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/18/19754/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/18/19754/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/18/19754/contributors\">",
"     Johanna Daily, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/18/19754/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/18/19754/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/18/19754/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/18/19754/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malaria is a global health problem, causing disease on a vast scale. The total burden of disease has been estimated to be 450 million episodes annually and is responsible for 18 percent of all childhood deaths in sub-Saharan Africa, equivalent to 800,000 deaths each year.",
"   </p>",
"   <p>",
"    The majority of malarial infections are associated with some degree of anemia, the severity of which depends upon patient-specific characteristics (eg, age, innate and acquired resistance, comorbid features) as well as parasite-specific characteristics (eg, species, adhesive, and drug-resistance phenotype). Malarial anemia is capable of causing severe morbidity and mortality especially in children and pregnant women infected with Plasmodium falciparum.",
"   </p>",
"   <p>",
"    This topic review will discuss the anemia associated with malarial infection. Protection against malaria afforded by hemoglobinopathies and abnormalities in red cell surface antigens and cytoskeletal proteins is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/23/20858?source=see_link\">",
"     \"Protection against malaria in the hemoglobinopathies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24585?source=see_link\">",
"     \"Protection against malaria by abnormalities in red cell surface antigens and cytoskeletal proteins\"",
"    </a>",
"    .) Other issues related to clinical malaria are discussed separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     The malarial parasite",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four species of the malarial parasite infect man. The severity of hematologic disease is related to the ability of the parasites to invade and grow in different red cell populations as well as the intrinsic growth rate of the parasite.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      P. vivax and P. ovale have a strong preference to infect only young red cells (reticulocytes), thereby limiting parasitemia levels to approximately 1 to 2 percent. Anemia due to hemolysis does occur and may be severe, but there is no peripheral sequestration of parasitized red cells.",
"     </li>",
"     <li>",
"      P. malariae invades red cells of all ages, but parasite multiplication during each cycle is relatively low. Infection results in limited parasitemia (&lt;1 to 2 percent) and mild symptoms.",
"     </li>",
"     <li>",
"      P. falciparum can invade red cells of all ages, including cells as early as orthochromatic erythroblasts [",
"      <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/1\">",
"       1",
"      </a>",
"      ], multiplies 10-fold within each 24 hour cycle, and expresses clonally variant antigens on the surface of infected red cells, which are receptors for ligands on the surface of endothelial cells, red cells, and platelets. These variant antigens enable late blood-stage infected red cells to sequester in post-capillary venules. Parasitemia is often high, occasionally exceeding 50 percent, and the potential for severe anemia, systemic disease, and death is considerable.",
"     </li>",
"     <li>",
"      P. knowlesi was originally described as a malarial infection of macaque monkeys. Morphologically it resembles P. malariae and it appears that it causes significant and sometimes severe human infection, previously misdiagnosed as P. malariae, in Borneo, Malaysia, and in other areas of Southeast Asia. It has even been reported in travelers returning from those locations [",
"      <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/2,3\">",
"       2,3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Prevalence of anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe malarial anemia (SMA) is seen most frequently in areas of very high malarial transmission and most commonly in young children and pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/4\">",
"     4",
"    </a>",
"    ]. The prevalence of anemia, defined as a hematocrit &lt;33 percent, in malarial endemic areas of Africa varies between 31 and 91 percent in children, and between 60 and 80 percent in pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. In a typical study of children living a malarial endemic area in southern Cameroon, among those who were monitored for both asymptomatic and symptomatic malaria, the prevalence of anemia (hemoglobin &lt; 11",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    was the highest in the six-month-old age group (47 percent), 42 percent in children &lt;3 years of age and 21 percent in those 3 to 5 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/7\">",
"     7",
"    </a>",
"    ]. Placental malarial infection was the primary risk factor for anemia in the six-month old children.",
"   </p>",
"   <p>",
"    In epidemiologic studies it is difficult to determine the number of cases of severe anemia attributable to malaria as the WHO definition of SMA is quite strict:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemoglobin concentration &lt;5",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      or hematocrit &lt;15 percent",
"     </li>",
"     <li>",
"      Parasitemia with &gt;10,000",
"      <span class=\"nowrap\">",
"       parasites/microL",
"      </span>",
"      of blood",
"     </li>",
"     <li>",
"      Normocytic blood film (thus excluding thalassemia as well as iron, B12, and folate deficiencies)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In individual cases, it may be difficult to attribute anemia to a single cause, although randomized placebo-controlled trials of malaria chemoprophylaxis and iron supplementation in infants have shown that malaria infection was the main etiologic factor underlying anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Similarly, intermittent anti-malarial treatment in pregnant women can substantially reduce the prevalence of severe maternal anemia.",
"   </p>",
"   <p>",
"    The precise etiology of anemia is often complex in endemic areas since nutritional deficiencies, genetic traits, and intercurrent infection may all contribute to the anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. &nbsp;It seems likely that etiology of SMA in endemic areas is likely to be multifactorial and variable in both time and place. This was illustrated in a case control study of severe anemia in hospitalized children in Malawi, in which severe anemia was associated with the following conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Malarial infection (odds ratio (OR) 2.3; 95% CI 1.6-3.3)",
"     </li>",
"     <li>",
"      HIV infection (OR 2.0; 95% CI 1.0-3.8)",
"     </li>",
"     <li>",
"      Hookworm (OR, 4.8; 95% CI 2.0-12)",
"     </li>",
"     <li>",
"      Bacteremia (OR 5.3; 95% CI 2.6-11)",
"     </li>",
"     <li>",
"      G6PD deficiency (OR 2.4; 95% CI 1.3-4.4)",
"     </li>",
"     <li>",
"      Deficiencies of vitamin A (OR 2.8; 95% CI 1.3-5.8) and vitamin B12 (OR 2.2; 95% CI 1.4-3.6).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In this population, folate deficiency and sickle cell disease were uncommon. Iron deficiency was not prevalent and was negatively associated with bacteremia (OR 0.37; 95% CI 0.22-0.60) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Iron deficiency may be protective against malaria infection; it has been associated with reduced parasitemia, reduced incidence of severe malaria (38 percent decrease), and reduced all-cause mortality (60 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/15\">",
"     15",
"    </a>",
"    ]. In addition, iron supplementation in endemic areas may increase malaria morbidity and mortality.",
"   </p>",
"   <p>",
"    The incidence of malaria and severe malarial anemia has fallen in many parts of sub-Saharan Africa following widespread application of public health measures (eg, impregnated bed nets, indoor residual spraying, intermittent preventive treatment), with concomitant reductions in malaria-specific admission rates, use of blood transfusions, and malaria specific in-patient mortality of 50 percent or more [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/16-18\">",
"     16-18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     FEATURES OF MALARIAL ANEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spectrum of the clinical presentation and severity of P. falciparum infection is broad. In endemic areas many malarial infections present in semi-immune and immune children and adults as an uncomplicated febrile illness. Fever develops with the release of merozoites from ruptured, infected red cells. Anemia, thrombocytopenia, splenomegaly (occasionally massive [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/19\">",
"     19",
"    </a>",
"    ]), hepatomegaly, and jaundice can develop, and splenic rupture can occasionally occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5543?source=see_link\">",
"     \"Clinical manifestations of malaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the clinical setting of SMA is varied and complex. Not only may acute infection present with anemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cerebral malaria, respiratory distress and hypoglycemia, but chronic, repeated malarial infection may also lead to severe anemia. In either case, there may be a background of a low hemoglobin level due to the presence of other factors, as noted above, and malaria itself can predispose to bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Severe malarial anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;New malarial infections are often associated with a sudden drop in hemoglobin concentration associated with increased hemolysis and bone marrow suppression. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Pathogenesis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Non-immune patients may exhibit a number of clinical syndromes including anemia, coma, respiratory distress, and hypoglycemia, and may have a high frequency of concurrent bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Children may present with mild, moderate or even severe anemia with or without other syndromes of severe disease (eg, malaise, fatigue, dyspnea, or respiratory distress as metabolic acidosis supervenes) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/21,23-25\">",
"     21,23-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The age distribution of the syndromes of severe disease is striking, but poorly understood. Children born in endemic areas are largely protected from severe malaria during the first six months of life by the passive transfer of maternal immunoglobulins and by the presence of fetal, rather than adult hemoglobin. Further discussion of how fetal hemoglobin is relatively resistant to digestion of malarial proteases and slows parasite growth can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/23/20858?source=see_link&amp;anchor=H17#H17\">",
"     \"Protection against malaria in the hemoglobinopathies\", section on 'Neonatal red cells and hemoglobin F'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presentation of disease changes from severe anemia in children aged between one and three years in areas of high transmission to cerebral malaria in older children in areas of lower transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/26\">",
"     26",
"    </a>",
"    ]. As transmission intensity declines, severe malaria is most frequently found in older age groups.",
"   </p>",
"   <p>",
"    There has been evidence of an increased incidence of anemia after malarial challenge in vaccine studies in non-human primates and also in field trials of blood stage vaccines [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/27\">",
"     27",
"    </a>",
"    ]. The significance of these findings remains uncertain, but there appears to be an increase in clearance of uninfected red blood cells during blood-stage infection in vaccinated individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Chronic anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia is also present in those with chronic malarial infection. Many children may present with severe anemia and a blood smear negative for malaria parasites, but will respond to antimalarial treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. In an Indian series of children with chronic falciparum malaria, those with moderate to severe anemia and hepatosplenomegaly had a greater degree of hemolysis, neutropenia, atypical lymphocytosis, and thrombocytopenia, but a lower level of parasitemia than patients with acute malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/12\">",
"     12",
"    </a>",
"    ]. Reduced production, increased clearance of cells and hypersplenism may be responsible for the neutropenia and thrombocytopenia seen in such cases. It is now recognized that low levels of parasitemia in otherwise asymptomatic children may be associated with raised levels of hepcidin [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. High hepcidin levels restrict iron absorption and also transfer of iron from bone marrow macrophages to developing red cells during chronic disease or inflammation and in malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/32,33\">",
"     32,33",
"    </a>",
"    ], and may therefore contribute to chronic anemia secondary to malaria infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=see_link\">",
"     \"Anemia of chronic disease (anemia of chronic inflammation)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hematologic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anemia of P. falciparum malaria is typically normocytic and normochromic, with a notable absence of reticulocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/29,34\">",
"     29,34",
"    </a>",
"    ]. Microcytosis and hypochromia may be present due to the very high frequency of thalassemia trait",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    iron deficiency in many, but not all, of the endemic areas [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Blackwater fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;A less common form of anemia in malaria is \"Blackwater Fever\" (BWF) characterized by intravascular hemolysis, the sudden appearance of hemoglobin in the urine, and renal failure, classically associated with irregular use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. Disseminated intravascular coagulation and red cell fragmentation may accompany this presentation.",
"   </p>",
"   <p>",
"    An important clinical point is that BWF is sometimes difficult to relate to malarial infection, because parasitemia can be missed due to synchronous lysis of all infected red cells. Series of cases of BWF in Africa and South-East Asia have shown that sudden hemolysis is associated with malarial infection, glucose-6-phosphate dehydrogenase deficiency, and the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/37,39\">",
"     37,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    BWF virtually disappeared after 1950, when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    superseded",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/40\">",
"     40",
"    </a>",
"    ]. However, in European expatriates living in Africa, BWF has been associated with use of the antimalarial agents halofantrine, quinine, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"     mefloquine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These case series do not attempt to define the pathophysiological process(es) that underlie this syndrome. It appears that oxidative stress may play an important role in some cases. Other mechanism(s) (eg, drug-dependent antibodies) have not been conclusively investigated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Anemia in P. vivax malaria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most work describes the association of P falciparum malaria with anemia, infection with P vivax can, on occasion, cause severe disease, including anemia and severe hemolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. P. vivax malaria has been clearly associated with anemia during pregnancy, along with low birth weight of the children of these infected mothers [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/43\">",
"     43",
"    </a>",
"    ]. Indeed, some studies in rural India suggest that severe disease is associated with P. vivax infection more frequently than with P. falciparum infection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/44\">",
"     44",
"    </a>",
"    ]. Anemia has been associated with increased red cell clearance, reticulocytopenia, and dyserythropoiesis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/45-47\">",
"     45-47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PARASITE LIFE CYCLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;To understand the mechanism of hemolysis in malaria, it is helpful to briefly review the life-cycle of the malarial parasite. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/1/39959?source=see_link\">",
"     \"Pathogenesis of malaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The asexual life cycle begins when sporozoites from the saliva of a female Anopheles mosquito taking a blood meal enter the circulation and invade hepatocytes. After one to two weeks, up to 10,000 merozoites are formed. Following rupture of the hepatocyte, infective merozoites are released into the circulation and invade red cells [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/48\">",
"     48",
"    </a>",
"    ]. Red cell entry occurs via binding of the malarial parasite to specific receptors on the red cell surface, including glycophorin A for P. falciparum and the Duffy blood group antigen for P. vivax [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/12,13,49-51\">",
"     12,13,49-51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24585?source=see_link&amp;anchor=H3#H3\">",
"     \"Protection against malaria by abnormalities in red cell surface antigens and cytoskeletal proteins\", section on 'Red cell surface antigens'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27898?source=see_link&amp;anchor=H45#H45\">",
"     \"A primer of red blood cell antigens and antibodies\", section on 'Duffy blood group system'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once inside the red cell, the parasite makes many modifications to the infected cell [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/52\">",
"     52",
"    </a>",
"    ], ingests and degrades hemoglobin and develops through the stages of rings, trophozoites and schizonts. Mature schizonts burst to release merozoites which invade new red cells.",
"   </p>",
"   <p>",
"    A small proportion of merozoites in red cells transform into male and female gametocytes which are ingested by the mosquito following a subsequent blood meal. Male and female gametes fuse and transform into an o&ouml;cyst which divides asexually into many sporozoites that migrate to the salivary gland of the infected mosquito, from which site they are released during the next blood meal.",
"   </p>",
"   <p>",
"    P. falciparum has additional unique characteristics that help to explain its distinct potential to cause severe or fatal disease. As P. falciparum parasites mature within red cells, they induce the formation of \"knobs\" on the surface of erythrocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. The products of the parasite's VAR gene (Pf-EMP-1) are expressed on these surface projections and bind to receptors on endothelial cells in post-capillary venules [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. The cytoadherence and sequestration of red cells within these small vessels leads to microvascular pathology and obstruction to blood flow.",
"   </p>",
"   <p>",
"    Infected red cells also stick to uninfected red cells and form rosettes that may also obstruct the microcirculation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. Multiple serum components, one of which is IgM, act as bridging molecules for rosette formation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The underlying causes of severe malarial anemia (SMA) in humans may include one or more of the following mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/61\">",
"     61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extravascular clearance",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      intravascular destruction of infected RBCs",
"     </li>",
"     <li>",
"      Clearance of uninfected RBC",
"     </li>",
"     <li>",
"      Activation of the",
"      <span class=\"nowrap\">",
"       monocyte/macrophage",
"      </span>",
"      system (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=see_link&amp;anchor=H29#H29\">",
"       \"Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism\", section on 'Splenomegaly'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Suppression of erythropoiesis along with dyserythropoiesis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Hemolysis of parasitized red cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;During malarial infection there is obvious loss of infected erythrocytes through parasite maturation as well as through recognition by macrophages. The removal of infected erythrocytes in humans with parasitemias of less than 1 percent is unlikely to have a significant impact on the degree of anemia. However, the lysis of uninfected red cells contributes directly to the onset of anemia in individuals suffering from an acute malarial infection, in particular children in whom parasitemias are frequently greater than 10 percent.",
"   </p>",
"   <p>",
"    Mechanisms leading to hemolysis of infected red cells include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormal distribution of membrane phospholipids, such as phosphatidylserine (PS), phosphatidylcholine, and phosphatidyl-ethanolamine [",
"      <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/62\">",
"       62",
"      </a>",
"      ]. PS is confined to the inner half of the membrane bilayer in normal red cells, but is exposed on the outer half in infected cells in conjunction with parasite maturation, although the extent to which this occurs in vivo is unknown. When PS is exposed on the outer half of the membrane bilayer, it can be recognized by macrophages as a signal for attachment and phagocytosis [",
"      <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Red cell membrane damage due to lipid peroxidation induced by heme liberated from digestion of hemoglobin by the parasite [",
"      <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Infected red cells may be opsonized by specific antibodies directed against the variant parasite antigens (Pf-EMP-1) expressed on the surface of the red cell.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The contribution of each of these indirect mechanisms of hemolysis of infected cells in vivo is uncertain. However, all of these effects may be exaggerated by the associated splenic hyperactivity (eg, hypersplenism) described below.",
"   </p>",
"   <p>",
"    During acute P. falciparum malaria, red cells can be detected that contain ring-infected erythrocyte surface antigen (also known as RESA or Pf155) but no intracellular parasite [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/65\">",
"     65",
"    </a>",
"    ]. This could represent an in vivo mechanism, presumably occurring in the spleen, for the removal of intraerythrocytic parasites without red cell destruction. Such a mechanism could explain, at least in part, the disparity between the fall in hematocrit and the decrease in parasite count observed in some hyperparasitemic patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hemolysis of non-infected red cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;During human malarial infection, many uninfected red cells are destroyed in the spleen and possibly the liver; their destruction has been identified as the major contributor to malarial anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/66-68\">",
"     66-68",
"    </a>",
"    ]. Markers of extravascular and intravascular hemolysis were raised in patients with severe malarial anemia (Hb &lt;5",
"    <span class=\"nowrap\">",
"     g/dl)",
"    </span>",
"    compared with children with mild malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/69\">",
"     69",
"    </a>",
"    ]. Both mathematical modeling and clinical observations suggest that 10 uninfected red cells are removed from the circulation for each infected red cell that is removed [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/67\">",
"     67",
"    </a>",
"    ]. Although few direct measurements of red cell survival have been made in human malarial infection, a reduced half-life of normal red cells and increased clearance of heat-treated red cells have been demonstrated in patients with malaria, consistent with these observations [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/66,70,71\">",
"     66,70,71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This reduction in red cell survival persists for some period after clearance of malarial parasitemia, a possible reflection of persistent nonspecific activation of reticuloendothelial function. The activity and the number of macrophages are increased and the spleen is enlarged during human malarial infection; these factors may therefore contribute to the increased removal of uninfected cells [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/64,72-75\">",
"     64,72-75",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Splenic and reticuloendothelial hyperactivity'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The increased clearance of uninfected erythrocytes is due to extrinsic and intrinsic changes to the red cells that enhance their recognition by phagocytes. These changes include some or all of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Uninfected RBCs have reduced deformability leading to enhanced clearance in the spleen. The mechanism responsible for the loss of deformability is not completely understood but may include increased oxidation of membrane components. Such reduction in red cell deformability is strongly associated with mortality, both in adults and children with severe malaria [",
"      <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/76,77\">",
"       76,77",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/41/17046?source=see_link&amp;anchor=H5#H5\">",
"       \"Red blood cell mechanics\", section on 'Membrane deformability and stability'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lipid peroxidation of RBC membranes may be mediated as an indirect effect of pro-inflammatory cytokines associated with acute malaria or as a direct effect of parasite products or parasite-induced lipoperoxides, which have been shown to cause loss of RBC deformability [",
"      <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/64,78-80\">",
"       64,78-80",
"      </a>",
"      ]. Levels of the antioxidant alpha-tocopherol are reduced in the membrane of red cells from children with malaria, consistent with the hypothesis that local antioxidant depletion may contribute to erythrocyte loss [",
"      <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/81\">",
"       81",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The deposition of immunoglobulin and complement on uninfected RBCs may enhance receptor-mediated uptake by macrophages. Early studies have shown that a positive direct antiglobulin (Coombs) test was associated with malarial anemia. The eluted antibodies were specific for parasite-derived antigens rather than host antigens and were likely to arise from immune complexes formed by the combination of parasite antigens with host antibodies [",
"      <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/82,83\">",
"       82,83",
"      </a>",
"      ]. Studies of the surface changes in RBCs of patients with severe malarial anemia have shown that RBCs were more susceptible to phagocytosis. They have also showed increased surface IgG and deficiencies in CR1 and CD55 compared with controls [",
"      <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/84-86\">",
"       84-86",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Parasite products which may be part of the immunoglobulin- antigen complexes deposited on uninfected RBC include the P. falciparum ring surface protein 2 (RSP-2) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/87,88\">",
"       87,88",
"      </a>",
"      ]. RSP-2 is deposited on uninfected RBC and the opsonization of these RSP-2-bearing uninfected RBCs provides a mechanism of removing uninfected RBC.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    High levels of anti-RSP-2 antibodies that facilitate complement- mediated phagocytosis of cells expressing RSP-2 are found in sera from immune adults and children with SMA [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/89\">",
"     89",
"    </a>",
"    ]. This antigen is also present on the surface of erythroblasts in bone marrows of P. falciparum infected patients, suggesting that clearance or damage to circulating or developing erythroid cells by RSP-2 and anti-RSP-2 could contribute to the development of SMA.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cross-reacting IgM and IgG autoantibodies directed against red cells have been described [",
"      <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/90,91\">",
"       90,91",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A progressive reduction in cell surface net negative charge and reduced resistance to linoleic-induced lysis occurs before the appearance of parasites in the blood [",
"      <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/92\">",
"       92",
"      </a>",
"      ]. Reduction of negative charge (Zeta potential) promotes red cell aggregation, increasing the chances of splenic removal.",
"     </li>",
"     <li>",
"      Uninfected red cells from patients with acute P. falciparum malaria have ultrastructural alterations [",
"      <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/93\">",
"       93",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hemolysis may also result from drugs given to treat malaria. These include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"       primaquine",
"      </a>",
"      causing oxidative stress in patients with glucose-6-phosphate deficiency as well as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"       quinine",
"      </a>",
"      which may contribute to hemolysis by as yet undefined mechanisms. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/25/4505?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency\", section on 'Acute hemolytic anemia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relationship and relative contribution of these factors to enhanced removal of uninfected red cells in vivo has not been established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Splenic and reticuloendothelial hyperactivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrastructural studies of the spleen in P. falciparum malaria reveal large numbers of both parasitized and nonparasitized red cells in the cytosol of macrophages, littoral, and reticular cells, congestion and parasitized red cells in splenic sinusoids, and splenic cords containing rosettes of erythrocytes surrounding antigen-presenting cells [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/94\">",
"     94",
"    </a>",
"    ]. These findings suggest both immunologic and nonimmunologic interactions between the spleen and red cells in patients with malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of changes to infected red cells may play a role in the increased splenic filtration of red cells [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/96\">",
"     96",
"    </a>",
"    ]. However, as mentioned above, there is also increased clearance of uninfected cells that persists for some period after the clearance of malarial parasitemia, suggesting that there may be a primary increase in splenic filtration [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This hypothesis was evaluated in a study of the clearance of heat-treated",
"    <sup>",
"     51",
"    </sup>",
"    Cr-labeled autologous red cells in patients with acute P. falciparum malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/66\">",
"     66",
"    </a>",
"    ]. The clearance half-time of infused heat-treated red cells was markedly shortened in the patients with splenomegaly (8.4 versus 63 minutes in controls), but was normal in the patients without splenomegaly who had a lesser degree of anemia. After treatment, the clearance half-times of infused heat-treated red cells in the patients without splenomegaly accelerated to levels comparable to those with splenomegaly. By six weeks after infection, normal clearance rates were restored in most patients. The clinical implications of this phenomenon are uncertain, since heated red cells might have properties different from parasitized native red cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Host genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is enormous variability among individuals in their response to malaria that may reflect host genetic factors. As an example, among West African ethnic groups, similar infection rates, morbidity, and antibody responses are found among the Mossi and Rimaibe in the Northeast of Ouagadougou in Burkina Faso [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/97\">",
"     97",
"    </a>",
"    ]. In contrast, the Fulani, who live together and are exposed to the same hyperendemic transmission of P. falciparum, have less parasitemia, less morbidity, and a higher antibody response. The better outcome in the Fulani could not be explained by differences in the use of malaria protective measures, sociocultural or environmental factors, or genetic factors known to be associated with resistance to malaria.",
"   </p>",
"   <p>",
"    Many genetic traits have been associated with protection from malaria. However, none of these associations has been consistently reported as specific for protection with one syndrome of malaria as opposed to others. For example, in a case-control study of malaria in West African children [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/98,99\">",
"     98,99",
"    </a>",
"    ], a class II HLA haplotype (DRB1*1302-DQB1*0501), common in West Africa but much less frequent in other populations, was associated with protection from SMA due to P. falciparum. This has not been confirmed in other regions and the mechanism of protection has not been determined.",
"   </p>",
"   <p>",
"    Various polymorphisms of the promoter region of the tumor necrosis factor-alpha gene (TNF2 allele) may attenuate or increase the risks for developing complications of malaria, such as cerebral malaria and anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/100-102\">",
"     100-102",
"    </a>",
"    ]. In a study of children living in a malaria-endemic environment, a specific tumor necrosis factor gene single nucleotide polymorphism was associated with an increased risk of iron deficiency and iron deficiency anemia at the end of the malaria season [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     BONE MARROW SUPPRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal response to hemolytic anemia is stimulation of erythropoiesis due to enhanced secretion of erythropoietin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=see_link\">",
"     \"Approach to the diagnosis of hemolytic anemia in the adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, this compensatory mechanism appears to be defective in patients with malaria, since reduced erythrocyte production has been shown to play a crucial role in the genesis of malarial anemia. One or more of the following factors appear to be responsible: a primary decrease in erythroid progenitors, dyserythropoiesis, inappropriately low serum erythropoietin concentrations,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reduced incorporation of iron into red cells secondary to high hepcidin levels. These are discussed further below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Abnormalities of erythroid progenitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe falciparum malaria may have reduced numbers of erythroid burst-forming units (BFU-E) and colony-forming units (CFU-E). The reduction in erythroid progenitor numbers appears to be due, at least in part, to circulating factors capable of inhibiting erythropoiesis. This was illustrated in a study in which serum obtained during parasitemia in complicated cases suppressed BFU-E and CFU-E in cultures of bone marrow obtained both during and after parasitemia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/104\">",
"     104",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20650?source=see_link\">",
"     \"Regulation of erythropoiesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Erythropoietic suppression and dyserythropoiesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The earliest observations of reduced erythropoiesis in acute human malaria were made over 60 years ago when reticulocytopenia was observed in P. vivax and P. falciparum infection, followed by reticulocytosis after parasite clearance had taken place [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/105\">",
"     105",
"    </a>",
"    ]. Later, it was demonstrated that reticulocytopenia in Thai patients with malaria was accompanied by suppression of erythropoiesis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/106\">",
"     106",
"    </a>",
"    ] and was characterized by a defect in erythroid maturation along with increased erythrophagocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bone marrow aspirates taken from Gambian children with acute anemia revealed an increase in cellularity but no significant difference in the total number of erythroblasts when compared with uninfected patients. Children who presented with chronic anemia (parasitaemia &lt;1 percent) had higher degrees of erythroid hyperplasia and dyserythropoiesis than children with acute malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/107,108\">",
"     107,108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dyserythropoiesis or morphologically",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    functionally abnormal production of red cells was demonstrated by the presence of cytoplasmic vacuolization, stippling, fragmentation, intercytoplasmic bridges, nuclear fragmentation and multinuclearity. This coincided with reduced reticulocytosis, indicating functional disruption of bone marrow red cell production [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/107,108\">",
"     107,108",
"    </a>",
"    ]. Signs of dyserythropoiesis have also been seen in patients infected with P. vivax [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a small study of six children with chronic disease, an increased proportion of polychromatic erythroblasts in the G2 phase of division was observed [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/109\">",
"     109",
"    </a>",
"    ]. After treatment of malaria, the reticulocyte count increased in these patients, which pointed to P. falciparum as the cause of dyserythropoiesis and ineffective erythropoiesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Hemozoin and suppression of erythropoiesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemozoin (malarial pigment, beta hematin), a parasite by-product due to incomplete hemoglobin digestion [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/110\">",
"     110",
"    </a>",
"    ], may have a role in the impaired erythroid development through its direct effects on human monocyte function",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    erythroid precursors [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/111-114\">",
"     111-114",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hemozoin reduces human macrophage oxidative burst activity, prevents up-regulation of activation markers [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/115,116\">",
"     115,116",
"    </a>",
"    ], and stimulates the secretion of biologically active endoperoxides from monocytes, such as 15(S)-hydroxyeicosatetraenoic (HETE) and hydroxy-nonenal (HNE) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/117,118\">",
"     117,118",
"    </a>",
"    ]. Hemozoin may therefore affect erythroid growth through oxidation of membrane lipids [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/112\">",
"     112",
"    </a>",
"    ] or other cellular damage leading to cell-cycle arrest",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/114,115\">",
"     114,115",
"    </a>",
"    ]. These endoperoxides may affect erythroid growth through oxidation of membrane lipids [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/112\">",
"     112",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38313?source=see_link&amp;anchor=H39#H39\">",
"     \"Evaluation of the peripheral blood smear\", section on 'Pigmented inclusions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ingestion of hemozoin by macrophages may result in reduced expression of prostaglandin-E2 (PGE(2)); reduced levels of PGE(2) were associated with anemia and reticulocytopenia in children with malaria [",
"      <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/119\">",
"       119",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a clinical study, hemozoin-containing macrophages and plasma hemozoin were associated with anemia and reticulocyte suppression [",
"      <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/113\">",
"       113",
"      </a>",
"      ]. Bone marrow sections from children who died with severe malaria have shown a significant association between the quantity of hemozoin located in erythroid precursors and macrophages and the proportion of abnormal erythroid cells. This effect was shown to be independent of tumor necrosis factor (TNF)-alpha.",
"     </li>",
"     <li>",
"      The presence of pigment-containing monocytes has been shown to be associated with a significantly increased risk for the development of severe malarial anemia (ie, hemoglobin &lt;6",
"      <span class=\"nowrap\">",
"       g/dL)",
"      </span>",
"      in pre-school children from Kenya infected with P. falciparum (OR 4.37; 95% CI 2.39-7.97) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/120\">",
"       120",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Cytokine suppression of erythropoiesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the acute phase of malaria there is a strong inflammatory response, resulting in increases in TNF-alpha and interferon (IFN)-gamma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/121\">",
"     121",
"    </a>",
"    ]. TNF-alpha inhibits all stages of erythropoiesis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/122\">",
"     122",
"    </a>",
"    ] while IFN-gamma, along with TNF-alpha, inhibits erythroid growth and differentiation by up-regulating expression of TRAIL, TWEAK and CD95L in developing erythroblasts [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/123\">",
"     123",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While severe disease in children is associated with elevated levels of pro- and anti-inflammatory cytokines, the severity of anemia seems to be dependent on levels of TNF-alpha relative to its regulator, IL-10. IL-10, a potent anti-inflammatory cytokine, may protect against bone marrow suppression and erythrophagocytic activity induced by TNF-alpha",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mitigate other pro-inflammatory stimuli. Several clinical studies have demonstrated that a low ratio of plasma IL-10 to TNF-alpha is associated with SMA in young children [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/124,125\">",
"     124,125",
"    </a>",
"    ]. In addition, a number of polymorphisms in the human TNF-alpha promoter show greater association with anemia than with cerebral malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many other pro-inflammatory cytokines such as IL-12, IL-18 and migration inhibitory factor (MIF) have also been implicated in the pathogenesis of malarial anemia. In humans, the secretion of IL-12 and IL-18 from macrophages induces production of IFN-alpha from natural killer (NK), B and T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/126\">",
"     126",
"    </a>",
"    ], while MIF is produced by activated T cells and macrophages and inhibits the anti-inflammatory activity of glucocorticoids. The data on serum levels of MIF in patients with malaria are consistent with its role as a hematopoietic suppressor in mice in that MIF concentrations are decreased in those with moderate anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/127\">",
"     127",
"    </a>",
"    ] and are elevated in those with more severe anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/128\">",
"     128",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The association of IL-12 with severe falciparum malaria is less clear. While some studies observe moderate increases in IL-12 and IL-18 in patients with severe anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/126,127\">",
"     126,127",
"    </a>",
"    ], others report decreases in IL-12 in patients with severe anemia (Hb &lt;7.5",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    compared with uncomplicated controls (Hb &gt;10",
"    <span class=\"nowrap\">",
"     g/dL),",
"    </span>",
"    or no significant increases in patients with severe disease compared with uncomplicated malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/128,129\">",
"     128,129",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The glycophosphatidylinositol (GPI) anchor for the merozoite proteins, MSP-1, MSP-2 and MSP-4 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/130\">",
"     130",
"    </a>",
"    ], the parasite product found in plasma during malaria infections, may be implicated in the pro-inflammatory cytokine effects on SMA. GPIs may induce the release of TNF-alpha from human macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/131\">",
"     131",
"    </a>",
"    ], which could contribute to the pathology of SMA. The pro-inflammatory response from human monocytes is through interaction of GPIs with TLR2, and TLR4 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/132\">",
"     132",
"    </a>",
"    ]. Antibodies to GPIs are found in sera of adults from endemic regions in Kenya, but at reduced levels in children who, in general, have more severe disease and anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/133\">",
"     133",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The heme degradation product hemozoin may also be more intimately linked to an innate immune response, and thus pro-inflammatory cytokine release, than previously thought. In humans, some studies have shown that synthetic hemozoin pigment induces expression of TNF-alpha, which has been linked to the ability of hemozoin to induce the metalloproteinase MMP-9 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/134-136\">",
"     134-136",
"    </a>",
"    ]. Data from murine models of malaria have suggested that hemozoin stimulates an innate pro-inflammatory response [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/137\">",
"     137",
"    </a>",
"    ] via a MyD88-dependent TLR9 pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/138\">",
"     138",
"    </a>",
"    ]. It now appears that stimulation of TLR9 may be through DNA associated with hemozoin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Altered iron metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impaired utilization and recycling of iron may contribute to the severity of disease in children presenting with SMA and shares many similarities with the anemia of chronic inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/106\">",
"     106",
"    </a>",
"    ]. The peptide hormone hepcidin has been implicated in mediating the anemia of chronic inflammation by reducing the availability of iron stores for erythropoiesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=see_link&amp;anchor=H5#H5\">",
"     \"Anemia of chronic disease (anemia of chronic inflammation)\", section on 'Hepcidin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hepcidin is regulated by pro-inflammatory mediators such as tumor necrosis factor and IL-6 which are elevated in both murine infections and in patients presenting with severe falciparum malaria, although other parasite-derived and host factors may be involved in stimulating hepcidin production [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/30-32,129,139-141\">",
"     30-32,129,139-141",
"    </a>",
"    ]. Hepcidin levels fall in the most severely ill children as hypoxia inhibits hepcidin production [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/142\">",
"     142",
"    </a>",
"    ]. High hepcidin levels stimulated by blood stage malaria infection are associated with inhibition of liver stage malaria infection in mice [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/143\">",
"     143",
"    </a>",
"    ] and reduced incorporation of iron into red cells in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Evidence from murine malaria suggests that low serum iron caused by elevated hepcidin reduced parasite growth and progression to severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/144\">",
"     144",
"    </a>",
"    ]. These experimental and clinical findings are consistent with a role for iron as a growth factor for malaria parasites and a role for raised hepcidin and reduction in available iron as a protective innate response to malaria infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Erythropoietin",
"    </span>",
"    &nbsp;&mdash;&nbsp;A fall in circulating hemoglobin levels and subsequent tissue hypoxia should normally stimulate elevated levels of erythropoietin (Epo). However, the clinical evidence for appropriately raised levels of Epo in SMA is somewhat contradictory. Studies in adults from Thailand and Sudan have suggested that Epo concentrations, although raised, were inappropriately low for the degree of anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/145,146\">",
"     145,146",
"    </a>",
"    ]. However, several studies of malaria in African children suffering from SMA have shown appropriately raised Epo concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/35,147-149\">",
"     35,147-149",
"    </a>",
"    ]. In fact, Epo levels in SMA are more than threefold higher when compared with anemic children without malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although ineffective or inadequate Epo synthesis may contribute to SMA in some settings, in African children with malaria Epo synthesis is elevated more than expected. It is more likely that a reduced response to Epo, as seen in the anemia of chronic inflammation, and not an inappropriately low level of Epo, is the more significant contribution to pathology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=see_link&amp;anchor=H2#H2\">",
"     \"Anemia of chronic disease (anemia of chronic inflammation)\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1826156\">",
"    <span class=\"h2\">",
"     Deficiencies of folic acid and vitamin B12",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although dietary deficiencies are widespread in malarial endemic regions, the influence of reduced folate levels are not thought to be major contributors to the dyserythropoiesis seen during SMA [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/108\">",
"     108",
"    </a>",
"    ]. The finding of low vitamin B12 levels in malaria suggests that subclinical deficiency of B12 may play a hitherto unrecognized contribution to severe anemia in children in sub-Saharan Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     EFFECT ON PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Falciparum malaria in pregnancy is more likely to be severe and complicated as the placenta contains high levels of parasites. The diagnosis of malaria can be difficult if parasites are concentrated in the placenta and scanty in the blood.",
"   </p>",
"   <p>",
"    Pregnant women may experience a variety of adverse consequences from malarial infection. These include maternal anemia, placental accumulation of parasites via attachment to chondroitin sulfate A in the placental intervillous space [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/150\">",
"     150",
"    </a>",
"    ], low birth weight from prematurity and intrauterine growth retardation, fetal parasite exposure and congenital infection, and increased infant mortality. It has been estimated that 75,000 to 200,000 infant deaths are associated with malarial infection in pregnancy each year [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/151\">",
"     151",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study, high levels of maternal IgG antibodies against a variant surface antigen (VSA) expressed on pregnancy-associated P. falciparum malaria (PAM)-infected red cells protected against low birth weight and maternal anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/18/19754/abstract/152\">",
"     152",
"    </a>",
"    ]. This observation suggests an area of investigation for future therapeutic strategies (eg, VSA-PAM-based vaccination).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of anemia in malaria is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13338?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of severe falciparum malaria\", section on 'Anemia and coagulopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3160148\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malarial anemia is capable of causing severe morbidity and mortality, especially in children and pregnant women. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Overview'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H25\">",
"     'Effect on pregnancy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Clinical presentation",
"      </strong>",
"      &mdash; Anemia, thrombocytopenia, splenomegaly (occasionally massive with or without rupture), hepatomegaly, and jaundice can develop. The anemia is generally normocytic and normochromic, with a striking absence of reticulocytes. Microcytosis and hypochromia may be present due to the very high frequency of thalassemia trait",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      iron deficiency. Infected red cells may be seen on the peripheral blood smear (",
"      <a class=\"graphic graphic_picture graphicRef77517 \" href=\"UTD.htm?6/11/6327\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Features of malarial anemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Pathogenesis",
"      </strong>",
"      &mdash; Malarial anemia is multi-factorial and includes direct destruction of parasitized and non-parasitized red cells, splenic and hepatic sequestration and destruction of red cells, bone marrow suppression, and dyserythropoiesis. Host factors, both genetic and acquired, may also play a part. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Pathogenesis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Bone marrow suppression'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/1\">",
"      Tamez PA, Liu H, Fernandez-Pol S, et al. Stage-specific susceptibility of human erythroblasts to Plasmodium falciparum malaria infection. Blood 2009; 114:3652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/2\">",
"      Singh B, Kim Sung L, Matusop A, et al. A large focus of naturally acquired Plasmodium knowlesi infections in human beings. Lancet 2004; 363:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/3\">",
"      Cox-Singh J, Davis TM, Lee KS, et al. Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. Clin Infect Dis 2008; 46:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/4\">",
"      Greenwood BM. The epidemiology of malaria. Ann Trop Med Parasitol 1997; 91:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/5\">",
"      Menendez C, Fleming AF, Alonso PL. Malaria-related anaemia. Parasitol Today 2000; 16:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/6\">",
"      Schellenberg D, Schellenberg JR, Mushi A, et al. The silent burden of anaemia in Tanzanian children: a community-based study. Bull World Health Organ 2003; 81:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/7\">",
"      Cornet M, Le Hesran JY, Fievet N, et al. Prevalence of and risk factors for anemia in young children in southern Cameroon. Am J Trop Med Hyg 1998; 58:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/8\">",
"      Menendez C, Kahigwa E, Hirt R, et al. Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants. Lancet 1997; 350:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/9\">",
"      Schellenberg D, Menendez C, Kahigwa E, et al. Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. Lancet 2001; 357:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/10\">",
"      Weatherall DJ, Abdalla S, Pippard MJ. The anaemia of Plasmodium falciparum malaria. Ciba Found Symp 1983; 94:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/11\">",
"      Phillips RE, Pasvol G. Anaemia of Plasmodium falciparum malaria. Baillieres Clin Haematol 1992; 5:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/12\">",
"      Sen R, Tewari AD, Sehgal PK, et al. Clinico-haematological profile in acute and chronic Plasmodium falciparum malaria in children. J Commun Dis 1994; 26:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/13\">",
"      Lamikanra AA, Brown D, Potocnik A, et al. Malarial anemia: of mice and men. Blood 2007; 110:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/14\">",
"      Calis JC, Phiri KS, Faragher EB, et al. Severe anemia in Malawian children. N Engl J Med 2008; 358:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/15\">",
"      Gwamaka M, Kurtis JD, Sorensen BE, et al. Iron deficiency protects against severe Plasmodium falciparum malaria and death in young children. Clin Infect Dis 2012; 54:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/16\">",
"      Ceesay SJ, Casals-Pascual C, Erskine J, et al. Changes in malaria indices between 1999 and 2007 in The Gambia: a retrospective analysis. Lancet 2008; 372:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/17\">",
"      Steketee RW, Campbell CC. Impact of national malaria control scale-up programmes in Africa: magnitude and attribution of effects. Malar J 2010; 9:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/18\">",
"      Pedro R, Akech S, Fegan G, Maitland K. Changing trends in blood transfusion in children and neonates admitted in Kilifi District Hospital, Kenya. Malar J 2010; 9:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/19\">",
"      Bedu-Addo G, Bates I. Causes of massive tropical splenomegaly in Ghana. Lancet 2002; 360:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/20\">",
"      Scott JA, Berkley JA, Mwangi I, et al. Relation between falciparum malaria and bacteraemia in Kenyan children: a population-based, case-control study and a longitudinal study. Lancet 2011; 378:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/21\">",
"      Marsh K, Forster D, Waruiru C, et al. Indicators of life-threatening malaria in African children. N Engl J Med 1995; 332:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/22\">",
"      Berkley J, Mwarumba S, Bramham K, et al. Bacteraemia complicating severe malaria in children. Trans R Soc Trop Med Hyg 1999; 93:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/23\">",
"      Krishna S, Waller DW, ter Kuile F, et al. Lactic acidosis and hypoglycaemia in children with severe malaria: pathophysiological and prognostic significance. Trans R Soc Trop Med Hyg 1994; 88:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/24\">",
"      English M, Muambi B, Mithwani S, Marsh K. Lactic acidosis and oxygen debt in African children with severe anaemia. QJM 1997; 90:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/25\">",
"      English M. Life-threatening severe malarial anaemia. Trans R Soc Trop Med Hyg 2000; 94:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/26\">",
"      Snow RW, Omumbo JA, Lowe B, et al. Relation between severe malaria morbidity in children and level of Plasmodium falciparum transmission in Africa. Lancet 1997; 349:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/27\">",
"      Ellis RD, Fay MP, Sagara I, et al. Anaemia in a phase 2 study of a blood stage falciparum malaria vaccine. Malar J 2011; 10:13.",
"     </a>",
"    </li>",
"    <li>",
"     Warrell DA, Molyneux ME, Beales PF. Severe and complicated malaria. In: World Health Organization Division of Control of Tropical Diseases, Royal Society of Tropical Medicine and Hygiene, London 1990.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/29\">",
"      Roberts DJ, Casals-Pascual C, Weatherall DJ. The clinical and pathophysiological features of malarial anaemia. Curr Top Microbiol Immunol 2005; 295:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/30\">",
"      Howard CT, McKakpo US, Quakyi IA, et al. Relationship of hepcidin with parasitemia and anemia among patients with uncomplicated Plasmodium falciparum malaria in Ghana. Am J Trop Med Hyg 2007; 77:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/31\">",
"      de Mast Q, Nadjm B, Reyburn H, et al. Assessment of urinary concentrations of hepcidin provides novel insight into disturbances in iron homeostasis during malarial infection. J Infect Dis 2009; 199:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/32\">",
"      de Mast Q, van Dongen-Lases EC, Swinkels DW, et al. Mild increases in serum hepcidin and interleukin-6 concentrations impair iron incorporation in haemoglobin during an experimental human malaria infection. Br J Haematol 2009; 145:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/33\">",
"      Prentice AM, Doherty CP, Abrams SA, et al. Hepcidin is the major predictor of erythrocyte iron incorporation in anemic African children. Blood 2012; 119:1922.",
"     </a>",
"    </li>",
"    <li>",
"     Abdalla SH, Pasvol G. Malaria: A Hematological Perspective, Imperial College Press, London 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/35\">",
"      Newton CR, Warn PA, Winstanley PA, et al. Severe anaemia in children living in a malaria endemic area of Kenya. Trop Med Int Health 1997; 2:165.",
"     </a>",
"    </li>",
"    <li>",
"     Stephens, JW. Blackwater Fever, University of Liverpool Press, Liverpool, UK 1937.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/37\">",
"      Tran TH, Day NP, Ly VC, et al. Blackwater fever in southern Vietnam: a prospective descriptive study of 50 cases. Clin Infect Dis 1996; 23:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/38\">",
"      Naqvi R, Ahmad E, Akhtar F, et al. Predictors of outcome in malarial renal failure. Ren Fail 1996; 18:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/39\">",
"      Delacollette C, Taelman H, Wery M. An etiologic study of hemoglobinuria and blackwater fever in the Kivu Mountains, Zaire. Ann Soc Belg Med Trop 1995; 75:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/40\">",
"      Bruneel F, Gachot B, Wolff M, et al. Resurgence of blackwater fever in long-term European expatriates in Africa: report of 21 cases and review. Clin Infect Dis 2001; 32:1133.",
"     </a>",
"    </li>",
"    <li>",
"     Tjitra E, Warikar N, Ebsworth EP, et al. Major Burden of P. vivax infection in Papua, Indonesia; A Region with High levels of Chloroquine Resistance. In: XVIe International Congress for Tropical Medicine and Malaria, Queguiner P, Saliou P (Eds), Marseille 2005. p.315.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/42\">",
"      Rodr&iacute;guez-Morales AJ, S&aacute;nchez E, Vargas M, et al. Anemia and thrombocytopenia in children with Plasmodium vivax malaria. J Trop Pediatr 2006; 52:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/43\">",
"      Nosten F, McGready R, Simpson JA, et al. Effects of Plasmodium vivax malaria in pregnancy. Lancet 1999; 354:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/44\">",
"      Kochar DK, Tanwar GS, Khatri PC, et al. Clinical features of children hospitalized with malaria--a study from Bikaner, northwest India. Am J Trop Med Hyg 2010; 83:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/45\">",
"      Jootar S, Chaisiripoomkere W, Pholvicha P, et al. Suppression of erythroid progenitor cells during malarial infection in Thai adults caused by serum inhibitor. Clin Lab Haematol 1993; 15:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/46\">",
"      Douglas NM, Anstey NM, Buffet PA, et al. The anaemia of Plasmodium vivax malaria. Malar J 2012; 11:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/47\">",
"      Panichakul T, Payuhakrit W, Panburana P, et al. Suppression of erythroid development in vitro by Plasmodium vivax. Malar J 2012; 11:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/48\">",
"      Zuccala ES, Baum J. Cytoskeletal and membrane remodelling during malaria parasite invasion of the human erythrocyte. Br J Haematol 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/49\">",
"      Sim BK, Chitnis CE, Wasniowska K, et al. Receptor and ligand domains for invasion of erythrocytes by Plasmodium falciparum. Science 1994; 264:1941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/50\">",
"      Chitnis CE, Chaudhuri A, Horuk R, et al. The domain on the Duffy blood group antigen for binding Plasmodium vivax and P. knowlesi malarial parasites to erythrocytes. J Exp Med 1996; 184:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/51\">",
"      Chitnis CE, Miller LH. Identification of the erythrocyte binding domains of Plasmodium vivax and Plasmodium knowlesi proteins involved in erythrocyte invasion. J Exp Med 1994; 180:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/52\">",
"      Moxon CA, Grau GE, Craig AG. Malaria: modification of the red blood cell and consequences in the human host. Br J Haematol 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/53\">",
"      Raventos-Suarez C, Kaul DK, Macaluso F, Nagel RL. Membrane knobs are required for the microcirculatory obstruction induced by Plasmodium falciparum-infected erythrocytes. Proc Natl Acad Sci U S A 1985; 82:3829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/54\">",
"      Newbold C, Craig A, Kyes S, et al. Cytoadherence, pathogenesis and the infected red cell surface in Plasmodium falciparum. Int J Parasitol 1999; 29:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/55\">",
"      Baruch DI, Pasloske BL, Singh HB, et al. Cloning the P. falciparum gene encoding PfEMP1, a malarial variant antigen and adherence receptor on the surface of parasitized human erythrocytes. Cell 1995; 82:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/56\">",
"      Smith JD, Chitnis CE, Craig AG, et al. Switches in expression of Plasmodium falciparum var genes correlate with changes in antigenic and cytoadherent phenotypes of infected erythrocytes. Cell 1995; 82:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/57\">",
"      Su XZ, Heatwole VM, Wertheimer SP, et al. The large diverse gene family var encodes proteins involved in cytoadherence and antigenic variation of Plasmodium falciparum-infected erythrocytes. Cell 1995; 82:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/58\">",
"      Kaul DK, Roth EF Jr, Nagel RL, et al. Rosetting of Plasmodium falciparum-infected red blood cells with uninfected red blood cells enhances microvascular obstruction under flow conditions. Blood 1991; 78:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/59\">",
"      Rowe JA, Moulds JM, Newbold CI, Miller LH. P. falciparum rosetting mediated by a parasite-variant erythrocyte membrane protein and complement-receptor 1. Nature 1997; 388:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/60\">",
"      Somner EA, Black J, Pasvol G. Multiple human serum components act as bridging molecules in rosette formation by Plasmodium falciparum-infected erythrocytes. Blood 2000; 95:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/61\">",
"      Boele van Hensbroek M, Calis JC, Phiri KS, et al. Pathophysiological mechanisms of severe anaemia in Malawian children. PLoS One 2010; 5:e12589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/62\">",
"      Schwartz RS, Olson JA, Raventos-Suarez C, et al. Altered plasma membrane phospholipid organization in Plasmodium falciparum-infected human erythrocytes. Blood 1987; 69:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/63\">",
"      Allen TM, Williamson P, Schlegel RA. Phosphatidylserine as a determinant of reticuloendothelial recognition of liposome models of the erythrocyte surface. Proc Natl Acad Sci U S A 1988; 85:8067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/64\">",
"      Mohan K, Dubey ML, Ganguly NK, Mahajan RC. Plasmodium falciparum: role of activated blood monocytes in erythrocyte membrane damage and red cell loss during malaria. Exp Parasitol 1995; 80:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/65\">",
"      Angus BJ, Chotivanich K, Udomsangpetch R, White NJ. In vivo removal of malaria parasites from red blood cells without their destruction in acute falciparum malaria. Blood 1997; 90:2037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/66\">",
"      Looareesuwan S, Ho M, Wattanagoon Y, et al. Dynamic alteration in splenic function during acute falciparum malaria. N Engl J Med 1987; 317:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/67\">",
"      Jakeman GN, Saul A, Hogarth WL, Collins WE. Anaemia of acute malaria infections in non-immune patients primarily results from destruction of uninfected erythrocytes. Parasitology 1999; 119 ( Pt 2):127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/68\">",
"      Price RN, Simpson JA, Nosten F, et al. Factors contributing to anemia after uncomplicated falciparum malaria. Am J Trop Med Hyg 2001; 65:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/69\">",
"      Fendel R, Brandts C, Rudat A, et al. Hemolysis is associated with low reticulocyte production index and predicts blood transfusion in severe malarial anemia. PLoS One 2010; 5:e10038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/70\">",
"      Looareesuwan S, Merry AH, Phillips RE, et al. Reduced erythrocyte survival following clearance of malarial parasitaemia in Thai patients. Br J Haematol 1987; 67:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/71\">",
"      Looareesuwan S, Davis TM, Pukrittayakamee S, et al. Erythrocyte survival in severe falciparum malaria. Acta Trop 1991; 48:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/72\">",
"      Brown AE, Webster HK, Teja-Isavadharm P, Keeratithakul D. Macrophage activation in falciparum malaria as measured by neopterin and interferon-gamma. Clin Exp Immunol 1990; 82:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/73\">",
"      Ladhani S, Lowe B, Cole AO, et al. Changes in white blood cells and platelets in children with falciparum malaria: relationship to disease outcome. Br J Haematol 2002; 119:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/74\">",
"      Evans KJ, Hansen DS, van Rooijen N, et al. Severe malarial anemia of low parasite burden in rodent models results from accelerated clearance of uninfected erythrocytes. Blood 2006; 107:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/75\">",
"      Jenkins NE, Chakravorty SJ, Urban BC, et al. The effect of Plasmodium falciparum infection on expression of monocyte surface molecules. Trans R Soc Trop Med Hyg 2006; 100:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/76\">",
"      Dondorp AM, Angus BJ, Hardeman MR, et al. Prognostic significance of reduced red blood cell deformability in severe falciparum malaria. Am J Trop Med Hyg 1997; 57:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/77\">",
"      Dondorp AM, Nyanoti M, Kager PA, et al. The role of reduced red cell deformability in the pathogenesis of severe falciparum malaria and its restoration by blood transfusion. Trans R Soc Trop Med Hyg 2002; 96:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/78\">",
"      Dondorp AM, Omodeo-Sal&egrave; F, Chotivanich K, et al. Oxidative stress and rheology in severe malaria. Redox Rep 2003; 8:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/79\">",
"      Omodeo-Sal&egrave; F, Motti A, Dondorp A, et al. Destabilisation and subsequent lysis of human erythrocytes induced by Plasmodium falciparum haem products. Eur J Haematol 2005; 74:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/80\">",
"      Uyoga S, Skorokhod OA, Opiyo M, et al. Transfer of 4-hydroxynonenal from parasitized to non-parasitized erythrocytes in rosettes. Proposed role in severe malaria anemia. Br J Haematol 2012; 157:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/81\">",
"      Griffiths MJ, Ndungu F, Baird KL, et al. Oxidative stress and erythrocyte damage in Kenyan children with severe Plasmodium falciparum malaria. Br J Haematol 2001; 113:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/82\">",
"      Facer CA, Bray RS, Brown J. Direct Coombs antiglobulin reactions in Gambian children with Plasmodium falciparum malaria. I. Incidence and class specificity. Clin Exp Immunol 1979; 35:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/83\">",
"      Facer CA. Direct Coombs antiglobulin reactions in Gambian children with Plasmodium falciparum malaria. II. Specificity of erythrocyte-bound IgG. Clin Exp Immunol 1980; 39:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/84\">",
"      Waitumbi JN, Opollo MO, Muga RO, et al. Red cell surface changes and erythrophagocytosis in children with severe plasmodium falciparum anemia. Blood 2000; 95:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/85\">",
"      Owuor BO, Odhiambo CO, Otieno WO, et al. Reduced immune complex binding capacity and increased complement susceptibility of red cells from children with severe malaria-associated anemia. Mol Med 2008; 14:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/86\">",
"      Gwamaka M, Fried M, Domingo G, Duffy PE. Early and extensive CD55 loss from red blood cells supports a causal role in malarial anaemia. Malar J 2011; 10:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/87\">",
"      Pouvelle B, Buffet PA, L&eacute;polard C, et al. Cytoadhesion of Plasmodium falciparum ring-stage-infected erythrocytes. Nat Med 2000; 6:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/88\">",
"      Douki JB, Sterkers Y, L&eacute;polard C, et al. Adhesion of normal and Plasmodium falciparum ring-infected erythrocytes to endothelial cells and the placenta involves the rhoptry-derived ring surface protein-2. Blood 2003; 101:5025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/89\">",
"      Layez C, Nogueira P, Combes V, et al. Plasmodium falciparum rhoptry protein RSP2 triggers destruction of the erythroid lineage. Blood 2005; 106:3632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/90\">",
"      Rosenberg EB, Strickland GT, Yang SL, Whalen GE. IgM antibodies to red cells and autoimmune anemia in patients with malaria. Am J Trop Med Hyg 1973; 22:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/91\">",
"      Lustig HJ, Nussenzweig V, Nussenzweig RS. Erythrocyte membrane-associated immunoglobulins during malaria infection of mice. J Immunol 1977; 119:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/92\">",
"      Sabolovic D, Bouanga JC, Danis M, et al. Alterations of uninfected red blood cells in malaria. Parasitol Res 1994; 80:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/93\">",
"      el-Shoura SM. Falciparum malaria in naturally infected human patients: ultrastructural alterations of non-parasitized red blood cells during anaemia. Appl Parasitol 1993; 34:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/94\">",
"      Pongponratn E, Riganti M, Bunnag D, Harinasuta T. Spleen in falciparum malaria: ultrastructural study. Southeast Asian J Trop Med Public Health 1987; 18:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/95\">",
"      Buffet PA, Safeukui I, Deplaine G, et al. The pathogenesis of Plasmodium falciparum malaria in humans: insights from splenic physiology. Blood 2011; 117:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/96\">",
"      Safeukui I, Correas JM, Brousse V, et al. Retention of Plasmodium falciparum ring-infected erythrocytes in the slow, open microcirculation of the human spleen. Blood 2008; 112:2520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/97\">",
"      Modiano D, Petrarca V, Sirima BS, et al. Different response to Plasmodium falciparum malaria in west African sympatric ethnic groups. Proc Natl Acad Sci U S A 1996; 93:13206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/98\">",
"      Hill AV, Allsopp CE, Kwiatkowski D, et al. Common west African HLA antigens are associated with protection from severe malaria. Nature 1991; 352:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/99\">",
"      Hill AV, Elvin J, Willis AC, et al. Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature 1992; 360:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/100\">",
"      McGuire W, Hill AV, Allsopp CE, et al. Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature 1994; 371:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/101\">",
"      McGuire W, Knight JC, Hill AV, et al. Severe malarial anemia and cerebral malaria are associated with different tumor necrosis factor promoter alleles. J Infect Dis 1999; 179:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/102\">",
"      Rihet P, Traor&eacute; Y, Abel L, et al. Malaria in humans: Plasmodium falciparum blood infection levels are linked to chromosome 5q31-q33. Am J Hum Genet 1998; 63:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/103\">",
"      Atkinson SH, Rockett KA, Morgan G, et al. Tumor necrosis factor SNP haplotypes are associated with iron deficiency anemia in West African children. Blood 2008; 112:4276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/104\">",
"      Abdalla SH, Wickramasinghe SN. A study of erythroid progenitor cells in the bone marrow of Gambian children with falciparum malaria. Clin Lab Haematol 1988; 10:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/105\">",
"      Vryonis G. Observations on the parasitization of erythrocytes by Plasmodium vivax, with special reference to reticulocytes. American Journal of Hygiene 1939; 30:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/106\">",
"      Phillips RE, Looareesuwan S, Warrell DA, et al. The importance of anaemia in cerebral and uncomplicated falciparum malaria: role of complications, dyserythropoiesis and iron sequestration. Q J Med 1986; 58:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/107\">",
"      Abdalla S, Weatherall DJ, Wickramasinghe SN, Hughes M. The anaemia of P. falciparum malaria. Br J Haematol 1980; 46:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/108\">",
"      Abdalla SH. Hematopoiesis in human malaria. Blood Cells 1990; 16:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/109\">",
"      Wickramasinghe SN, Abdalla S, Weatherall DJ. Cell cycle distribution of erythroblasts in P. falciparum malaria. Scand J Haematol 1982; 29:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/110\">",
"      Pagola S, Stephens PW, Bohle DS, et al. The structure of malaria pigment beta-haematin. Nature 2000; 404:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/111\">",
"      Skorokhod OA, Caione L, Marrocco T, et al. Inhibition of erythropoiesis in malaria anemia: role of hemozoin and hemozoin-generated 4-hydroxynonenal. Blood 2010; 116:4328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/112\">",
"      Giribaldi G, Ulliers D, Schwarzer E, et al. Hemozoin- and 4-hydroxynonenal-mediated inhibition of erythropoiesis. Possible role in malarial dyserythropoiesis and anemia. Haematologica 2004; 89:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/113\">",
"      Casals-Pascual C, Kai O, Cheung JO, et al. Suppression of erythropoiesis in malarial anemia is associated with hemozoin in vitro and in vivo. Blood 2006; 108:2569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/114\">",
"      Lamikanra AA, Theron M, Kooij TW, Roberts DJ. Hemozoin (malarial pigment) directly promotes apoptosis of erythroid precursors. PLoS One 2009; 4:e8446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/115\">",
"      Schwarzer E, Turrini F, Ulliers D, et al. Impairment of macrophage functions after ingestion of Plasmodium falciparum-infected erythrocytes or isolated malarial pigment. J Exp Med 1992; 176:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/116\">",
"      Schwarzer E, Alessio M, Ulliers D, Arese P. Phagocytosis of the malarial pigment, hemozoin, impairs expression of major histocompatibility complex class II antigen, CD54, and CD11c in human monocytes. Infect Immun 1998; 66:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/117\">",
"      Schwarzer E, Ludwig P, Valente E, Arese P. 15(S)-hydroxyeicosatetraenoic acid (15-HETE), a product of arachidonic acid peroxidation, is an active component of hemozoin toxicity to monocytes. Parassitologia 1999; 41:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/118\">",
"      Schwarzer E, Kuhn H, Valente E, Arese P. Malaria-parasitized erythrocytes and hemozoin nonenzymatically generate large amounts of hydroxy fatty acids that inhibit monocyte functions. Blood 2003; 101:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/119\">",
"      Anyona SB, Kempaiah P, Raballah E, et al. Reduced systemic bicyclo-prostaglandin-E2 and cyclooxygenase-2 gene expression are associated with inefficient erythropoiesis and enhanced uptake of monocytic hemozoin in children with severe malarial anemia. Am J Hematol 2012; 87:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/120\">",
"      Novelli EM, Hittner JB, Davenport GC, et al. Clinical predictors of severe malarial anaemia in a holoendemic Plasmodium falciparum transmission area. Br J Haematol 2010; 149:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/121\">",
"      Kwiatkowski D, Hill AV, Sambou I, et al. TNF concentration in fatal cerebral, non-fatal cerebral, and uncomplicated Plasmodium falciparum malaria. Lancet 1990; 336:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/122\">",
"      Dufour C, Corcione A, Svahn J, et al. TNF-alpha and IFN-gamma are overexpressed in the bone marrow of Fanconi anemia patients and TNF-alpha suppresses erythropoiesis in vitro. Blood 2003; 102:2053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/123\">",
"      Felli N, Pedini F, Zeuner A, et al. Multiple members of the TNF superfamily contribute to IFN-gamma-mediated inhibition of erythropoiesis. J Immunol 2005; 175:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/124\">",
"      Kurtzhals JA, Adabayeri V, Goka BQ, et al. Low plasma concentrations of interleukin 10 in severe malarial anaemia compared with cerebral and uncomplicated malaria. Lancet 1998; 351:1768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/125\">",
"      Othoro C, Lal AA, Nahlen B, et al. A low interleukin-10 tumor necrosis factor-alpha ratio is associated with malaria anemia in children residing in a holoendemic malaria region in western Kenya. J Infect Dis 1999; 179:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/126\">",
"      Malaguarnera L, Pignatelli S, Musumeci M, et al. Plasma levels of interleukin-18 and interleukin-12 in Plasmodium falciparum malaria. Parasite Immunol 2002; 24:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/127\">",
"      Awandare GA, Hittner JB, Kremsner PG, et al. Decreased circulating macrophage migration inhibitory factor (MIF) protein and blood mononuclear cell MIF transcripts in children with Plasmodium falciparum malaria. Clin Immunol 2006; 119:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/128\">",
"      Chaiyaroj SC, Rutta AS, Muenthaisong K, et al. Reduced levels of transforming growth factor-beta1, interleukin-12 and increased migration inhibitory factor are associated with severe malaria. Acta Trop 2004; 89:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/129\">",
"      Lyke KE, Burges R, Cissoko Y, et al. Serum levels of the proinflammatory cytokines interleukin-1 beta (IL-1beta), IL-6, IL-8, IL-10, tumor necrosis factor alpha, and IL-12(p70) in Malian children with severe Plasmodium falciparum malaria and matched uncomplicated malaria or healthy controls. Infect Immun 2004; 72:5630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/130\">",
"      Miller LH, Roberts T, Shahabuddin M, McCutchan TF. Analysis of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1). Mol Biochem Parasitol 1993; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/131\">",
"      Schofield L, Hackett F. Signal transduction in host cells by a glycosylphosphatidylinositol toxin of malaria parasites. J Exp Med 1993; 177:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/132\">",
"      Krishnegowda G, Hajjar AM, Zhu J, et al. Induction of proinflammatory responses in macrophages by the glycosylphosphatidylinositols of Plasmodium falciparum: cell signaling receptors, glycosylphosphatidylinositol (GPI) structural requirement, and regulation of GPI activity. J Biol Chem 2005; 280:8606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/133\">",
"      Naik RS, Branch OH, Woods AS, et al. Glycosylphosphatidylinositol anchors of Plasmodium falciparum: molecular characterization and naturally elicited antibody response that may provide immunity to malaria pathogenesis. J Exp Med 2000; 192:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/134\">",
"      Pichyangkul S, Saengkrai P, Webster HK. Plasmodium falciparum pigment induces monocytes to release high levels of tumor necrosis factor-alpha and interleukin-1 beta. Am J Trop Med Hyg 1994; 51:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/135\">",
"      Sherry BA, Alava G, Tracey KJ, et al. Malaria-specific metabolite hemozoin mediates the release of several potent endogenous pyrogens (TNF, MIP-1 alpha, and MIP-1 beta) in vitro, and altered thermoregulation in vivo. J Inflamm 1995; 45:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/136\">",
"      Prato M, Giribaldi G, Polimeni M, et al. Phagocytosis of hemozoin enhances matrix metalloproteinase-9 activity and TNF-alpha production in human monocytes: role of matrix metalloproteinases in the pathogenesis of falciparum malaria. J Immunol 2005; 175:6436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/137\">",
"      Jaramillo M, Plante I, Ouellet N, et al. Hemozoin-inducible proinflammatory events in vivo: potential role in malaria infection. J Immunol 2004; 172:3101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/138\">",
"      Coban C, Ishii KJ, Kawai T, et al. Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin. J Exp Med 2005; 201:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/139\">",
"      Langhorne J, Quin SJ, Sanni LA. Mouse models of blood-stage malaria infections: immune responses and cytokines involved in protection and pathology. Chem Immunol 2002; 80:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/140\">",
"      Armitage AE, Pinches R, Eddowes LA, et al. Plasmodium falciparum infected erythrocytes induce hepcidin (HAMP) mRNA synthesis by peripheral blood mononuclear cells. Br J Haematol 2009; 147:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/141\">",
"      de Mast Q, Syafruddin D, Keijmel S, et al. Increased serum hepcidin and alterations in blood iron parameters associated with asymptomatic P. falciparum and P. vivax malaria. Haematologica 2010; 95:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/142\">",
"      Casals-Pascual C, Huang H, Lakhal-Littleton S, et al. Hepcidin demonstrates a biphasic association with anemia in acute Plasmodium falciparum malaria. Haematologica 2012; 97:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/143\">",
"      Portugal S, Carret C, Recker M, et al. Host-mediated regulation of superinfection in malaria. Nat Med 2011; 17:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/144\">",
"      Wang HZ, He YX, Yang CJ, et al. Hepcidin is regulated during blood-stage malaria and plays a protective role in malaria infection. J Immunol 2011; 187:6410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/145\">",
"      Burgmann H, Looareesuwan S, Kapiotis S, et al. Serum levels of erythropoietin in acute Plasmodium falciparum malaria. Am J Trop Med Hyg 1996; 54:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/146\">",
"      el Hassan AM, Saeed AM, Fandrey J, Jelkmann W. Decreased erythropoietin response in Plasmodium falciparum malaria-associated anaemia. Eur J Haematol 1997; 59:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/147\">",
"      Kurtzhals JA, Rodrigues O, Addae M, et al. Reversible suppression of bone marrow response to erythropoietin in Plasmodium falciparum malaria. Br J Haematol 1997; 97:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/148\">",
"      Nussenblatt V, Mukasa G, Metzger A, et al. Anemia and interleukin-10, tumor necrosis factor alpha, and erythropoietin levels among children with acute, uncomplicated Plasmodium falciparum malaria. Clin Diagn Lab Immunol 2001; 8:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/149\">",
"      Verhoef H, West CE, Kraaijenhagen R, et al. Malarial anemia leads to adequately increased erythropoiesis in asymptomatic Kenyan children. Blood 2002; 100:3489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/150\">",
"      Ricke CH, Staalsoe T, Koram K, et al. Plasma antibodies from malaria-exposed pregnant women recognize variant surface antigens on Plasmodium falciparum-infected erythrocytes in a parity-dependent manner and block parasite adhesion to chondroitin sulfate A. J Immunol 2000; 165:3309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/151\">",
"      Steketee RW, Nahlen BL, Parise ME, Menendez C. The burden of malaria in pregnancy in malaria-endemic areas. Am J Trop Med Hyg 2001; 64:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/18/19754/abstract/152\">",
"      Staalsoe T, Shulman CE, Bulmer JN, et al. Variant surface antigen-specific IgG and protection against clinical consequences of pregnancy-associated Plasmodium falciparum malaria. Lancet 2004; 363:283.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7112 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.16.9.173-D52E307D49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_18_19754=[""].join("\n");
var outline_f19_18_19754=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3160148\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      The malarial parasite",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Prevalence of anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      FEATURES OF MALARIAL ANEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Severe malarial anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Chronic anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hematologic features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Blackwater fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Anemia in P. vivax malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PARASITE LIFE CYCLE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Hemolysis of parasitized red cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hemolysis of non-infected red cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Splenic and reticuloendothelial hyperactivity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Host genetic factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      BONE MARROW SUPPRESSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Abnormalities of erythroid progenitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Erythropoietic suppression and dyserythropoiesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Hemozoin and suppression of erythropoiesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Cytokine suppression of erythropoiesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Altered iron metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Erythropoietin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1826156\">",
"      Deficiencies of folic acid and vitamin B12",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      EFFECT ON PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3160148\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7112\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7112|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/11/6327\" title=\"picture 1\">",
"      Malaria trophozoites",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27898?source=related_link\">",
"      A primer of red blood cell antigens and antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=related_link\">",
"      Anemia of chronic disease (anemia of chronic inflammation)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=related_link\">",
"      Approach to the diagnosis of hemolytic anemia in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/25/4505?source=related_link\">",
"      Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5543?source=related_link\">",
"      Clinical manifestations of malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38313?source=related_link\">",
"      Evaluation of the peripheral blood smear",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=related_link\">",
"      Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/1/39959?source=related_link\">",
"      Pathogenesis of malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24585?source=related_link\">",
"      Protection against malaria by abnormalities in red cell surface antigens and cytoskeletal proteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/23/20858?source=related_link\">",
"      Protection against malaria in the hemoglobinopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/41/17046?source=related_link\">",
"      Red blood cell mechanics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20650?source=related_link\">",
"      Regulation of erythropoiesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13338?source=related_link\">",
"      Treatment of severe falciparum malaria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_18_19755="Materials for OFCs";
var content_f19_18_19755=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F64516&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F64516&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Examples of materials for creating food challenge substances",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Common allergens",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Peanut flour, peanut butter",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Powdered egg white",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Powdered/fresh milk",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Soy milk, soy flour",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Wheat breads, flour",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Useful carrier agents",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Proprietary formulas (hydrolyzed casein, amino acid)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Baby foods (squash, carrot, potato)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Apple sauce",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Corn meal, instant oats, instant mashed potatoes",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Juices",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_18_19755=[""].join("\n");
var outline_f19_18_19755=null;
var title_f19_18_19756="Probability bleeding varices";
var content_f19_18_19756=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F65361&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F65361&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Probability of bleeding from esophageal varices",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Red wale markings",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Child class A",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Child class B",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Child class C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        F1",
"       </td>",
"       <td class=\"subtitle2\">",
"        F2",
"       </td>",
"       <td class=\"subtitle2\">",
"        F3",
"       </td>",
"       <td class=\"subtitle2\">",
"        F1",
"       </td>",
"       <td class=\"subtitle2\">",
"        F2",
"       </td>",
"       <td class=\"subtitle2\">",
"        F3",
"       </td>",
"       <td class=\"subtitle2\">",
"        F1",
"       </td>",
"       <td class=\"subtitle2\">",
"        F2",
"       </td>",
"       <td class=\"subtitle2\">",
"        F3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        42",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        54",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        42",
"       </td>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        64",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        52",
"       </td>",
"       <td>",
"        44",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        76",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Estimations are based upon",
"    <strong>",
"     one-year percentage",
"    </strong>",
"    probability of bleeding.",
"    <br/>",
"    F1, F2, F3 refer to size of the varix.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: deFranchis R, N Engl J Med 1988; 319:983.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_18_19756=[""].join("\n");
var outline_f19_18_19756=null;
var title_f19_18_19757="FTT diet feeding history";
var content_f19_18_19757=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55626&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55626&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Important aspects of the feeding history in the evaluation of the child (&lt;2 years of age) with failure to thrive",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        General aspects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        When does the child eat? (Are there regular and appropriately spaced feeding intervals?)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        How much juice (or other sweetened beverages such as soda) does the child drink per day?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Does the family follow a special diet (eg, vegetarian, \"heart healthy\")? What advice has been followed thus far?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        When did the child begin solid foods? How were they introduced? How were they tolerated?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Does the child spit up or vomit in relation to feeding?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Are there any stooling patterns associated with feeding?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Does the infant tire with feeding? (May indicate cardiac or pulmonary disorder.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Breast-fed infants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        How often does the infant nurse? (Should be at least eight times per day between zero to four months; five times per day between four and eight months; and on demand thereafter.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        How long does the infant nurse?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Is feeding providing adequate stimulation of milk production?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Can the mother hear the infant swallow?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Does the baby have a strong suck? (A weak suck may indicate neurologic disorder.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Does the mother feel the sensation of let-down (a warm, tingly feeling as the milk begins to flow from the breast when the infant cries)?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Is the mother stressed or fatigued? (These may result in low milk production.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Formula-fed infants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        How much formula does the child ingest? How often? (Daily intake should be approximately 16 to 32 oz at 0 to 4 months, 24 to 40 oz at 4 to 6 months, 24 to 32 oz at 6 to 8 months, 16 to 32 oz at 8 to 10 months, and 16 to 24 oz at 10 to 12 months.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        How is the formula mixed?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Does the caregiver add anything (eg, infant cereal, baby foods) to the bottle?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Does the caretaker hold the bottle during feedings, or prop the bottle in the infant's mouth?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Feeding environment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Who feeds the child? If the child is fed by multiple caretakers, do they have consistent feeding styles?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Where does the child eat (eg, in a high chair, on a caretaker's lap)?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Does the child usually eat alone or with others?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Are there mealtime distractions (eg, television)?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Feeding behavior/interactions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        How does the caretaker know when the child is hungry?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        How does the caretaker know when the child is not hungry?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Does the caretaker say or do anything when the child eats well?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Does the caretaker say or do anything when the child eats poorly?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Does the child refuse food?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Do the caretaker and the child have struggles over feeding?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Does the child have strong likes and dislikes? If so, can/does the caretaker feed the child accordingly?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Does the child feed differently with different people?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Does the child make a mess when he or she eats? If so, is this difficult for the caretaker?",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Zenel JA Jr. Failure to thrive: A general pediatrician's perspective. Pediatr Rev 1997; 18:371.",
"      </li>",
"      <li>",
"       Bithoney WG, Dubowitz H, Egan H. Failure to thrive/growth deficiency. Pediatr Rev 1992; 13:453.",
"      </li>",
"      <li>",
"       Gahagan S, Holmes R. A stepwise approach to evaluation of undernutrition and failure to thrive. Pediatr Clin North Am 1998; 45:169.",
"      </li>",
"      <li>",
"       Frank D, Silva M, Needlman R. Failure to thrive: Mystery, myth and method. Contemp Pediatr 1993; 10:114.",
"      </li>",
"      <li>",
"       Frank DA, Zeisel SH. Failure to thrive. Pediatr Clin North Am 1988; 35:1187.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_18_19757=[""].join("\n");
var outline_f19_18_19757=null;
var title_f19_18_19758="Mirena IUD";
var content_f19_18_19758=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F81587&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F81587&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mirena&reg; IUD",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Berlex Laboratories. Copyright &copy; Berlex Laboratories.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_18_19758=[""].join("\n");
var outline_f19_18_19758=null;
var title_f19_18_19759="HSG with traction";
var content_f19_18_19759=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79936&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79936&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Hysterosalpingogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 220px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Hysterosalpingogram (HSG) showing an irregular uterine cavity interpreted by the radiologist as showing multiple submucous myomas. (B) Repeat HSG of the same patient shown in A, but with the cervix pulled down. Now a septate uterus is obvious, not submucous myomas.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Baramki, TA. Hysterosalpingography. Fertil Steril 2005; 83:1595. Copyright &copy; 2005 Elsevier Science, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_18_19759=[""].join("\n");
var outline_f19_18_19759=null;
